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ABSTRACT OF THE DISSERTATION
A recombinant virus and reporter mouse system for the study of chronic chikungunya
virus pathogenesis
by
Alissa Roxanne Young
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2018
Professor Deborah J. Lenschow, Chair
Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during acute disease
causes fever as well as severe joint and muscle pain.

Chronic joint and muscle pain

persists in a significant subset of patients, yet we still have a poor understanding of what
drives this chronic disease. While replicating virus has not been detected in the joints of
patients with chronic arthritis or in various animal models at chronic time points, persistent
viral RNA can be detected for months after acute infection.
To identify the cells that could be contributing to chronic CHIKV pathogenesis, we
developed recombinant viruses that express Cre recombinase (CHIKV-3ʹ-Cre and
CHIKV-5ʹ-Cre). These viruses replicated in cell types targeted by CHIKV, including
myoblasts and fibroblasts, and they induced acute arthritis in a murine model of CHIKV
arthritis. Importantly, they also induced chronic disease, including persistent viral RNA
and chronic myositis and synovitis similar to wild-type (WT) virus. CHIKV-3ʹ-Cre infection
of tdTomato reporter mice resulted in a population of tdTomato+ cells that persisted for at
least 112 days. The majority of these cells localized to the dermis and muscle, and
xiv

immunofluorescence profiling revealed that these tdTomato+ cells were dermal and
muscle fibroblasts and myofibers. Treatment with an antibody against Mxra8, a host
receptor for CHIKV, reduced the levels of viral RNA and the total number of tdTomato+
cells in the chronic phase, with a preferential reduction in fibroblasts. Anti-Mxra8
treatment demonstrated a correlation between chronic viral RNA levels and the number
of surviving tdTomato+ cells, thus suggesting that viral RNA can be found within these
persistent tdTomato+ cells. This CHIKV-3ʹ-Cre and tdTomato reporter mouse system
demonstrates that cells can survive CHIKV infection in vivo and represents a powerful
tool to study the chronic pathogenesis of CHIKV infection.
In the process of optimizing this reporter system, we observed noticeable effects
on pathogenesis depending on viral inoculum. Increasing the dose of CHIKV (WT, 5ʹ-Cre,
and 3ʹ-Cre) was associated with an earlier peak of swelling and infectious titers in the
ipsilateral ankle, earlier resolution of swelling, and faster clearance of infectious virus in
the ipsilateral ankle and distal sites. This accelerated clearance phenotype could explain
why levels of persistent viral RNA tended to be lower in the ipsilateral ankle with
increasing initial inoculum.
Ultimately, our CHIKV-Cre system could be applied to many aspects of studying
chronic CHIKV pathogenesis. For example, single cell or nucleus RNA-seq could help
determine whether persistent viral RNA is concentrated in tdTomato+ cells, the nature of
this persistent viral RNA, and whether the host transcriptome of tdTomato+ cells is altered.
Electron microscopy could help determine the subcellular location of persistent viral RNA
within tdTomato+ cells. CHIKV-Cre infection of Diphtheria toxin receptor (DTR) mice could
allow for depletion of DTR+ cells and exploration of how these cells contribute to chronic
xv

pathogenesis. Overall, our CHIKV-Cre and tdTomato reporter mouse system marks
myofibers and fibroblasts as cells that may harbor viral components and likely contribute
to chronic CHIKV pathogenesis. Further characterization of these cells will no doubt aid
in our understanding and development of potential treatments for this debilitating
infection.

xvi

Chapter 1:
Introduction

1

1.1 Chikungunya Virus
Chikungunya virus (CHIKV) is a re-emerging arthropod-borne virus (“arbovirus”) that
causes polyarthritis and myalgia. Chronic joint and muscle pain persists in a significant subset
of patients for months to years after the initial infection, but chronic pathogenesis of the virus is
still poorly understood. CHIKV is endemic throughout tropical regions, including Africa, Asia,
islands in the Indian and Pacific Oceans, and Central and South America. The World Health
Organization (WHO) classifies CHIKV as a neglected tropical disease, and perhaps as a
consequence no vaccines or treatments are currently approved for CHIKV.

1.1.1 Evolution and Epidemiology
CHIKV is a reemerging pathogen originally identified in Tanzania in 1952 [1–3]. The name
“chikungunya” derives from the local Makonde tongue and translates into “that which bends up,”
an apt description for the characteristic joint “pain [that] was frightening in its severity” [1,4]. The
prolonged arthritis of Chikungunya fever (CHIKF) was concomitant with rash and leucopenia;
despite its significant morbidity, this early CHIKF exhibited no known mortality [1]. Subsequent
studies implicated CHIKV as an arbovirus transmitted by Aedes genus mosquitos [3]. Ultimately,
CHIKF was recognized to be endemic throughout Africa, consisting of the two distinct West
African and East/Central/South African (ECSA) lineages [5]; phylogenetic analyses estimate its
emergence as a human virus within the last 500 years [6]. A third, Asian lineage likely diverged
from the ECSA phylogroup in the middle of the twentieth century [6] and caused its first recognized
outbreaks in Thailand in 1958 and India in 1963 [7] (Figure 1.1A). Throughout the latter half of
the twentieth century, these three lineages caused scattered outbreaks, often with decades
spanning cases [6,8]. During this time, CHIKV followed a sylvatic transmission cycle, which
comprises cycling between wild animals and vectors, with occasional outbreaks in humans.
Known animal reservoirs of CHIKV include monkeys, rodents, bats, and birds [6,9].
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Up until the 2000s, CHIKV was considered a self-limiting, tropical virus; however, within
the past 15 years CHIKV has reemerged with increased virulence and range, resulting in urban
transmission cycles without the need for animal host intermediates. In 2004, an ECSA-derived
strain of CHIKV initiated an epidemic in Kenya with over 13,000 cases [10]. By 2005, the virus
spread to La Réunion Island, where it infected over 200,000 people [8,11]. The Réunion epidemic
included the first reports of increased pathogenicity, including neurological symptoms, intrapartum
transmission, and approximately 250 deaths [12–14]. The Réunion strain was surprisingly spread
by Aedes albopictus, a particularly bloodthirsty mosquito with a much larger spread compared to
the previous vector, A. aegypti [9,15,16]. Genetic analyses revealed that an A226V mutation in
the E1 protein caused this increased A. albopictus transmission [17]. Owing in part to this vector
shift, CHIKV subsequently spread throughout the Eastern Hemisphere, establishing endemic
conditions in tropical regions including India and the South Pacific, infecting millions and killing
thousands, and even causing isolated outbreaks in Europe [16,18,19]. This ECSA-derived strain
is thus dubbed the Indian Ocean Lineage (IOL) (Figure 1.1B).
In 2013, autochthonous (local) CHIKV transmission was reported in the Western
Hemisphere, and nearly 2 million suspected CHIKV cases have since been reported in the
Caribbean, Central America, and South America [18,20–22]. However, it is likely that the current
CHIKV epidemic in the Americas represents a reintroduction of the virus as presumed Dengue
epidemics in the American tropics during the 1800s closely resemble CHIKV symptomology [23].
Since 2014, thousands of travel-acquired cases of CHIKV have been reported in the United States
[24]. Locally transmitted CHIKV cases have also been reported in Florida (12 cases in 2014) and
in Texas (1 case in 2015), but no local cases have been reported within the past three years [25].
The Western Hemisphere CHIKV strains are most closely related to the Asian, not IOL, lineage,
which initiated a separate, East Asian epidemic in 2006 [18,26,27]. As such, the Western
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Hemisphere CHIKV strains have not been reported to contain the E1 A226V substitution. Overall,
CHIKV is a relevant, reemerging virus inciting epidemics around the globe.

1.1.2 Virus Structure and Replication
CHIKV is a positive-sense RNA virus belonging to the Togaviridae family and alphavirus
genus [5]. While the related New World alphaviruses are associated with encephalitis (e.g.
Eastern, Western, and Venezuelan Equine Encephalitis viruses), the Old World alphaviruses,
which include CHIKV, often cause musculoskeletal disease and arthralgia (e.g. CHIKV, Ross
River virus, Sindbis virus, Semliki Forest virus, O'nyong’nyong virus, Mayaro virus) [28]. CHIKV
is currently the most prevalent and widespread of these arthritogenic alphaviruses [29]. As is
characteristic of alphaviruses, CHIKV is a relatively small and simple virus. It consists of an 11.8
kilobase, single-stranded RNA genome. The genome is encapsulated within an icosahedral
nucleocapsid which is enclosed within a 60-70 nm spherical envelope with proteinaceous spikes
[9,28] (Figure 1.2A).
The unipartite, positive-sense genome closely resembles host messenger RNA with a 5ʹ
cap and 3ʹ polyadenylated tail. The genome sequentially comprises a 5ʹ un-translated region
(UTR), a 5ʹ open reading frame (ORF) encoding 4 nonstructural proteins, a subgenomic promoter,
a 3ʹ ORF encoding five proteins, and a 3ʹ UTR (Figure 1.2B). The 5ʹ and 3ʹ UTRs contain
promoters necessary for genome replication and other regulatory elements [9,28,30]. The 3ʹ UTR
is highly variable in length amongst alphaviruses and appears to be involved with vector
competence [31,32]. Many of the functions of the nine viral proteins and specific replication events
have not been directly studied in CHIKV, due to it being a Biosafety Level 3 (BSL3) virus, and are
thus extrapolated from studies of related alphaviruses such as Sindbis virus and Semliki Forest
virus.
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The 5ʹ ORF encodes four non-structural proteins (nsP1-4), which are involved in viral
genome replication. The nsP1 protein is involved in 5ʹ capping newly synthesized viral RNA,
initiating negative strand synthesis, and anchoring viral replication complexes to the host
membrane. The nsP2 protein has helicase, ATPase, and protease activities. The nsP3 protein is
an ADP-ribose-1-phosphate phosphatase and has an RNA-binding motif. The nsP4 protein is the
virus’ RNA-dependent RNA polymerase (RdRp) [28,33,34].
The 3ʹ ORF comprises three structural genes (CP, E1 and E2) and two smaller cleavage
products (E3 and 6K). The capsid protein (CP) forms the nucleocapsid around the genomic RNA.
CP contains an RNA-binding domain and a protease domain [35]. E1 and E2 are glycosylated,
associate in a heterodimer, and form trimeric spikes on the envelope. E1 associates with the viral
envelope and capsid, and it functions as a Type II fusion protein during endosomal entry. E2 binds
to host cell receptors [28,36,37]. Mxra8 has recently been reported to be a host receptor for
CHIKV and other arthritogenic alphaviruses; however, it is likely that CHIKV also uses other host
receptors as Mxra8 blockade did not entirely abrogate infection [38]. The E3 and 6K proteins are
cleavage products during viral replication. E3 and 6K contain signal peptide sequences and may
direct E2 and E1, respectively, to the secretory pathway before being cleaved by host proteases
[39]. E3 may help shield the fusion peptide of E1 during viral budding [40]. The 61-amino acid 6K
protein may also be involved with viral budding and formation of ion channels [28,37,41].
Replication of CHIKV within target cells appears to be characteristic of alphaviruses
(Figure 1.3A-B). E2 binds to a host receptor on the cell surface [28,42]. CHIKV infection appears
to be dependent on membrane cholesterol, which is suggestive of lipid raft involvement [43,44].
Incidentally, the A229V mutation characteristic of the IOL strain increases dependence on
cholesterol [43]; how this enhances replication in A. albopictus remains unclear. Receptor binding
triggers clathrin-mediated endocytosis [45]. CHIKV infectivity is dependent on endosomal
acidification, indicating a pH-dependent activation of the E1 fusion protein. Additionally, CHIKV
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replication depends only on early endosomes, indicating that the virus escapes into the cytoplasm
prior to endosomal maturation [36,43].
Once released into the cytoplasm, CP associates with the ribosome, which may assist in
uncoating of the nucleocapsid [28]. Early during replication, the 5ʹ ORF is directly translated into
the P123 polyprotein (Figure 1.3A). During approximately 10% of the translation events,
suppression of termination occurs at the opal stop codon between nsP3 and nsP4,
and readthrough results in production of the P1234 polyprotein [46]. nsP2 proteolytically
processes the P123 or P1234 polyproteins into the four non-structural proteins [28,33].
Genome replication cannot occur until after the nsP2 cleavage step as the RdRp (nsP4)
is not carried in the capsid and must be translated by host machinery [33]. The P123/nsP4
complex catalyzes replication of the negative strand from the positive genome. The negativesense RNA strand predominates early in infection, and it serves as a template for a full-length
positive-sense genome, which is preferentially catalyzed by the short-lived nsP1/P23/nsP4
complex. Full processing of P23 into nsP2 and nsP3 results in the mature nsP1/nsP2/nsP3/nsP4
complex, which preferentially drives production of the 3ʹ subgenomic 26S RNA [46]. The 26S
fragment accumulates later during infection, and it serves as a template for the structural
polyprotein driven by the powerful subgenomic promoter [28,33,36]. This subgenomic RNA
replication strategy utilized by members of the Togaviridae family thus ensures that structural
proteins are produced at a higher amount than non-structural proteins, which are only needed at
lower catalytic amounts.
Translation of the subgenomic RNA results in production of the structural polyprotein. As
CP emerges from the ribosome, it autocatalyzes its release from the growing polyprotein using
its protease domain. The E3-E2-6K-E1 polyprotein is subsequently translated, but 10-18% of the
time ribosomal frameshifting in the 6K RNA results in production of the E3-E2-TF (transframe)
polyprotein [47]. TF retains the ion-channel properties of 6K, and disrupting TF production
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attenuates alphavirus production; however, its exact role is unclear [48]. The structural
polyproteins are cleaved into E3-E2, 6K, TF, and E1 by host signal peptidase enzymes.
During viral replication in mammalian cells, the viral RNAs are sequestered into various
vesicular bodies derived from host membrane (Figure 1.3B). These membranous bodies likely
shield double-stranded RNA (dsRNA) intermediates from full detection by host pattern recognition
receptors (PRRs). Early in infection, the negative sense genomes are found within spherule
extrusions of the cell membrane, with the non-structural proteins associated with the neck of the
spherules [49]. Internalization of the spherules and association with lysosomes produces the first
iteration of cytopathic vacuoles (CPV-I), where production of full-length genomes and subgenomic
RNAs continues [40]. Later during infection, a second type of virally-induced large cytopathic
vacuoles is formed, termed CPV-II. CPV-II are derived from the trans-Golgi network and comprise
a large vesicle containing helical tubular formations of the envelope glycoproteins; the vesicles
are dotted with non-enveloped nucleocapsids. The role of the CPV-II is unclear, but they may
facilitate virion assembly [40,50].
Virion assembly occurs in the cytoplasm and commences with the C protein forming a
nucleocapsid around genomic RNA; the capsid displays icosahedral symmetry (T=4) and
contains 240 CP capsomers [28,51]. Budding occurs through the plasma membrane which has
become inundated by the E1 and E2 viral glycoproteins. In order to be infective, E2 must be
processed by a host furin protease in order to remove E3. Budding results in an enveloped virion
coated by 80 trimers of E1-E2 dimer spikes [28]. The replication cycle begins anew when a virion
binds a new cell. Ultimately, CHIKV replication produces cytopathic effects and can be lytic [52].

1.1.3 Tropism and Acute Pathogenesis
As an arbovirus, CHIKV depends on replication within a mosquito vector. The Aedes
receptor for CHIKV has not yet been identified, but it is known to replicate within the mosquito

7

midgut and transit into the salivary glands [9,17]. CHIKV can be transmitted to humans in the
saliva of an infected, biting mosquito; factors in Aedes saliva have been shown to enhance the
pathogenesis of other arboviruses such as Dengue virus [53]. The initial infection is followed by
a noninfectious, incubation period of 3 to 7 days [11,13,42]. The virus appears to be highly
transmissible, especially on geographically constrained islands; for instance 75% of the
population of Lamu Island and 30% of La Réunion Island were infected during outbreaks in 2004
and 2006, respectively [10,28]. An estimated 75-95% of people who are infected with CHIKV
become symptomatic [11,54].
It is thought that CHIKV can propagate within stromal cells, including fibroblasts,
surrounding the site of injection [55,56]. In vitro, mouse embryonic fibroblasts (MEFs) and other
primary fibroblasts can be thus used as a model cell for CHIKV infection [54,57]. Within hours,
CHIKV spreads from the connective tissue around the bite site into the microvasculature and
lymph vessels [29,57]. From there, the virus spreads into the liver, lymph nodes, and spleen
(Figure 1.4); viral replication in these sites ultimately leads to viremia and initiation of symptoms
such as fever [29]. High levels of viremia last for several days, with titers in infected humans
reported to be as high as 108 to 109 viral RNA copies per milliliter [42,58]. The transmission cycle
begins anew when an uninfected Aedes mosquito takes a blood meal from a viremic individual. It
has not been demonstrated whether the blood titers result from free virus, blood cells infected
with virus, or a combination of both. Nonetheless, there are some indications that infected
hematopoietic cells can be found in the blood.
For instance, one study assayed viral growth in a barrage of cell lines and reported that
CHIKV can replicate in macrophages but not monocytes or dendritic cells [42]. However, another
study reported that in human blood samples from acute CHIKV patients up to 7% of CD14+
monocytes and 3% of CD303+ plasmacytoid dendritic cells harbored CHIKV antigen [59]. The
overall viral load in the blood also correlated with the percentage of infected monocytes,
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suggesting that infected monocytes could serve to shuttle virus through the blood during viremia.
The study also demonstrated that live CHIKV but not heat-inactivated CHIKV could infect
monocytes isolated from peripheral blood mononuclear cells (PBMCs) [59]. Growth in
hematopoietic cells such as macrophages and monocytes could prove to be a critical step in
CHIKV pathogenesis. Infected monocytes could spread CHIKV to sequestered organs such as
the brain and muscle; infected macrophages may also contribute to chronic infection and
potentially inflammasome activation [56,59]. In vitro, CHIKV can infect RAW 264.7 cells (an
immortalized mouse macrophage cell line), which results in secretion of TNF-α, IL-6 and GM-CSF
[60]. No studies have reported substantive CHIKV growth in lymphocytes.
During this short-lived viremia, CHIKV spreads to many regions of the body, including the
joints, muscles, and brain. Like other alphaviruses, CHIKV displays a propensity to infect multiple
tissue types. CHIKV can productively replicate in epithelial cells, endothelial cells, fibroblasts, and
osteoblasts [29,42]. In addition to epithelial and connective tissues, CHIKV also grows to high
titers in neurons and muscle satellite cells [52,55,61]. Specific strains can grow in additional tissue
types. For instance, one study demonstrated that a virulent IOL CHIKV strain isolated in 2006
from the La Réunion Island outbreak (LR2006-OPY1) can infiltrate and grow within skeletal
muscle fibers while a pre-epidemic strain cannot [57]. It is unclear how CHIKV can transit the
insulating barriers surrounding muscle and other targets such as the brain.
Infection of these target tissues triggers a vigorous inflammatory response. Within the
joints, infection of synoviocytes leads to expression of chemokines and inflammatory cytokines,
including IL-6, MCP-1, and IL-1β [29,54,62]. This is followed by a massive influx of immune cells,
including macrophages, monocytes, natural killer (NK) cells, and T cells into the synovial cavity
[54,63,64]. This substantial immune infiltrate results in painful distention of the joint capsule,
leading to CHIKF’s characteristic arthralgia and arthritis [29]. The infiltrating immune cells may
also become overactive and cause tissue damage through secretion of metalloproteinases
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[29,54]. In addition to inflamed joints, CHIKV can also cause muscle, tendon, and brain damage
[64,65]. The exact mechanism of this pathology is unclear but likely involves a combination of
host and virus factors. Not only is CHIKV infection itself lytic, but it can also induce apoptosis
[52,60] and results in the secretion of many potentially toxic pro-inflammatory cytokines [9,63,65].
Acute CHIKV symptoms can in large part be attributed to a hyper-responsive innate immune
system.

1.1.4 Prophylactics and Therapeutics
No licensed anti-virals or vaccines are currently available for acute or chronic CHIKV
disease. Current therapeutics include supportive measures such as maintaining patient water and
electrolyte levels, as well as non-specific drugs including analgesics, antipyretics, and nonsteroidal anti-inflammatory drugs [16,56,64]. Public health efforts also aim to decrease
transmission with vector elimination and mosquito netting [22].
A variety of studies have identified compounds with antiviral activity against CHIKV in vitro
or in vivo. For instance, drugs against other microorganisms have demonstrated in vitro efficacy
against CHIKV infection [11,66,67]. Examples of repurposed antivirals include Favipiravir, arbidol,
ribavirin, and interferon-α, but their actual in vivo or clinical effectiveness remains untested [68–
70]. A recent in vitro loss-of-function screen identified several pro-viral host factors with preexisting small-molecule inhibitors available, some of which showed in vivo efficacy alone or in
combination [71]. Additional in vivo studies have demonstrated the efficacy of monoclonal
antibodies against CHIKV, alone or in combination with immunomodulatory agents such as
CTLA4-Ig [72–75].
Multiple vaccine candidates have been produced, but none are currently approved for
human use [76]. Three vaccine candidates have completed Phase I and II clinical trials with
varying results. The first CHIKV vaccine candidate tested involved a lab-attenuated CHIKV strain
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derived from the Asian lineage [77] (Figure 1.1A); this vaccine proved to be immunogenic in
Phase I and II clinical trial. However, a small percentage of participants developed transient
arthritis, so this candidate has not been pursued further [76,77]. A second candidate involves a
recombinant live-attenuated measles virus (MV) that expresses virus-like particles (VLPs)
containing CP, E3, E2, 6K, and E1 proteins from the La Réunion ECSA CHIKV strain [78]. A
recent Phase II trial of the MV-CHIKV vaccine reported good safety, tolerability, and
immunogenicity, with CHIKV-neutralizing antibodies detectable in all MV-CHIK treatment groups
[79]. A third CHIKV vaccine candidate (VRC-CHKVLP059-00-VP) also involves VLPs, but in this
case the vaccine itself comprises VLPs containing CP, E1, and C2 proteins from the 37997 West
African CHIKV strain; Phase I results using this vaccine were promising [80]. The Phase II trial
was scheduled to end in October 2018, but the results of this trial have not yet been reported.
Additional vaccine candidates are in the pre-clinical pipeline having showed efficacy in
animal models of CHIKV infection. One CHIKV vaccine candidate involves a chimeric virus
combining the non-structural proteins of Eilat virus (an insect-specific alphavirus) with CP, E1,
and E2 structural proteins from CHIKV-99659, a human isolate from the British Virgin Islands.
This vaccine demonstrated immunogenicity in mice and non-human primate models [81]. Another
potential vaccine involves a La Réunion CHIKV strain attenuated with site-directed mutations in
the nuclear localization sequence (NLS) of CP. This vaccine demonstrated efficacy against both
CHIKV and Ross River virus (RRV) in mice [82].
The majority of the clinical testing for these antivirals and vaccines rely on readouts from
acute disease, such as early viral titers, or later titers of neutralizing antibodies. It is unclear how
these therapeutics and prophylactics would impact chronic CHIKV disease; presumably, a
reduction in acute disease would also result in a reduction of chronic disease. A better
understanding of the intricacies of both acute and chronic CHIKV pathogenesis could ultimately
lead to better treatments for this debilitating disease.
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1.2 Chronic CHIKV Pathogenesis
Following acute CHIKV infection, an estimated 10-60% of patients report symptoms that
can persist for 6 weeks to 6 years after the initial infection. The most common symptoms include
arthritis, arthralgia, alopecia, and depression. Risk factors for these persistent symptoms include
female sex, old age, and prolonged or more severe acute disease. A handful of studies of human
or animal samples have reported detection of CHIKV antigen or RNA within joint and muscle
tissues, often associated with macrophages and endothelial cells; however, detection of viral
components in tissues at chronic time points is rare, especially in human samples. Hypotheses
to explain the chronic manifestations of CHIKV infection include persistent viral RNA causing
inflammation, a low level of actively replicating virus, or viral induction of autoimmunity. The
chronic pathogenesis of CHIKV infection remains poorly understood, thus necessitating the
development of better tools and model systems.

1.2.1 Chronic Clinical Manifestations
As discussed previously, acute CHIKV is associated with one to two weeks of
musculoskeletal symptoms, including fever, rash, headache, asthenia, and joint and muscle pain
often so severe that upright gait is too painful; neurological symptoms are also sometimes
reported during acute infection [83]. Following acute CHIKV infection, the fever and rash resolve,
and virus is no longer detectable by RT-PCR in the serum [84]. However, a significant subset of
patients continues to report persistent symptoms.
The most common chronic symptoms reported by patients are persistent arthralgia (joint
pain or stiffness), arthritis (joint swelling), or more general rheumatic musculoskeletal pain
(RMSP) in distal joints such as the ankles and wrists, typically with a bilateral and symmetrical
manifestation. The prevalence of these symptoms depends on the study, with ~50-60% on the
high end and ~10-20% on the low end. For example, one study of 250 CHIKV patients following
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the 2007 Italian outbreak reported that 72.3% of patients described persistent arthralgia 4 to 5
months post infection and 60.8% at 12 to 13 months; the prevalence of persistent arthralgia at 12
to 13 months was as high as 73.8% in patients who had pre-existing joint pain prior to CHIKV
infection [85]. In another study of 437 CHIKV patients in South India 15 months following a 2007
epidemic, 57% reported post-viral polyarthralgia [86]. A similar study identified 1195 CHIKV
patients 18 months following a 2009 outbreak in rural India and found that 48.6% had persistent
RSMP [87].
Other studies report lower prevalence of chronic arthralgia symptoms, such as 12.5% (2
out of 16) of German patients 6 months after travel to endemic Asian areas in 2006 [88], or 10%
(3 out of 30) of patients 3 months after acute infection in a 2008 Singapore outbreak [89]. A study
of 403 adult CHIKV patients in South India in 2006 reported persistent arthralgia in 16% of patients
3 to 6 months following infection, 12.7% between 6 and 12 months, and 7% beyond 1 year [90].
The majority of other studies report percentages falling somewhere in the middle of these
extremes [91–93]. For example, the TELECHIK survey, which was a 2-year follow-up of the acute
SEROCHIK survey for the 2006 La Réunion Island outbreak, found that 42.8% of 515 CHIKV+
patients still reported chronic RMSP [94]; however, a reanalysis of the TELECHIK survey reported
that 81.9% of 422 CHIKV+ patients experienced chronic RMSP [95]. Meta-analyses of chronic
CHIKV studies have reported an average of approximately 40% of CHIKV patients developing
chronic symptoms [96,97]. Including studies with only 1 year or more follow-ups, the overall
CHIKV chronic symptom rate was 21% [97].
Many factors likely influenced the wide range of reported prevalence in these studies,
including the specific epidemic and CHIKV strain, as well as specific study design and inclusion
criteria. For example, studies associated with the 2006 La Réunion Island epidemic [94,95,98] or
outbreaks in India [86,87] tended to be associated with a higher prevalence of chronic CHIKV
symptoms. A meta-analysis of 38 chronic CHIKV studies found a similar trend, with ECSA-

13

diverged CHIKV strains (e.g., La Réunion Island, India, France) inciting a higher average
prevalence of chronic symptoms than recent Caribbean strains or South African ECSA strains
from the 1980s [96]. Of note, retrospective studies tended to have a higher percentage of patients
reporting persistent arthralgia compared to prospective studies [97], which suggests at least some
degree of memory and reporting bias.
Not only did patients report joint-associated pain or swelling, but joint damage could
sometimes be detected through radiographic changes. For example, one study examined 21
CHIKV patients two years following the 2006 La Réunion Island outbreak and identified 5 patients
with bone erosions and 12 patients with joint space narrowing in the hands and or feet [99].
Another study also from La Réunion Island identified bone lesions by radiography in 50% of
the patients diagnosed with chronic inflammatory rheumatism following CHIKV infection [100].
However, a third study found no evidence of structural damage by radiography in the 437 CHIKV+
patients examined [86].

1.2.2 Non-Rheumatic Chronic Symptoms
In addition to joint-associated symptoms, other commonly reported chronic CHIKV
symptoms include alopecia, depression, sleep disorders, and overall loss in the quality of life
(QOL) [96,97]. Two studies reported alopecia prevalence of 10-30% [85,101], while one study
reported no change in the prevalence of hair loss [94]. Rates of depression following CHIKV
infection ranged from 13 to 54% [92,98,101–103]; however, one case reported a low depression
prevalence of 6.3% (3 of 47) [104]. Overall, the quality of life for CHIKV patients was reduced,
often for several years. For example, a study of French gendarmes (military police) following the
2006 La Réunion Island epidemic found a significant negative impact on completing daily
activities (such as showering, making bed) and a higher consumption of healthcare 30 months
after infection [98]. In a 6-year follow-up of these gendarmes, the QOL scores had not
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significantly improved from the 30-month survey [103]. Another study in rural India reported that
a fifth to a quarter of patients reported moderate or severe difficulty in completing simple
physical tasks such as arising and walking [87]. Additional studies using the standardized Short
Form questionnaires (SF-36 and SF-12) described a significant QOL reduction in the physical
and or mental health domains [101,105].

1.2.3 Chronic Biomarkers
Multiple studies have attempted to identify predictive markers for CHIKV-induced chronic
arthralgia. Older age (>35-45 year old) individuals, females, and people who experienced
prolonged or severe acute disease appear to be most at risk for development of chronic
symptoms [54,85,90,91,102,106]. One group found an increased likelihood of chronic CHIKV in
patients with high acute serum concentration of C-reactive protein (CRP) [54]. Another group
indicated elevated acute IL-6 and GM-CSF as predictors, but found no association with acute
disease severity, viremia, or CRP levels [89]. One study reported an association of chronic
arthralgia with CHIKV-RNA detection beyond 7 days of symptom onset [107]. A study in rural
Southern India identified vegetarianism as the strongest determinant of chronic CHIKV
development [87]. While these studies agree that chronic CHIKV pathogenesis is characterized
by a chronic inflammatory state, they do not arrive at consistent markers, and the biomarkers
themselves are not indicative of an exact disease mechanism.

1.2.4 Congenital CHIKV
In addition to symptoms in infected adults, long-term complications can also arise from
congenital CHIKV, acquired by neonates through vertical transmission from infected mothers,
likely via intrapartum transmission (during childbirth). In the infants who survived the acute
CHIKV infection during the La Réunion Island epidemic, many neurological manifestations
occurred, included encephalopathy, intracranial hemorrhage, cerebral palsy, ataxia, and
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blindness [108]. Further follow-up of these congenital CHIKV cases at 2 years of age revealed
continued neurodevelopmental deficits [109]. One study of pregnant CHIKV-infected women in
Thailand found no vertical transmission of CHIKV to neonates [110], which could indicate that
perinatal transmission is strain-specific. These studies highlight that neurological symptoms
dominant during neonatal infection, likely due to increased accessibility to the infant brain,
compared to adults where rheumatic symptoms predominate with neurological manifestations
only rarely reported.

1.2.5 Hypotheses for Chronic Pathogenesis
Hypotheses to explain chronic CHIKV pathogenesis abound, including the induction of
autoimmunity, the persistence of ultralow levels of replicating virus, and the activation of
inflammatory responses against residual viral RNA. The role of autoimmunity in chronic CHIKV
pathogenesis is unclear. A small subset of chronic CHIKV patients test positive for antinuclear
antibodies (ANA); however, their pre-CHIKV status is unknown [24,102,111]. Viral infections are
also known to transiently induce ANA, so the relevance of this observation to the development of
chronic arthritis is unclear. Furthermore, these same studies have not detected other known
autoantibodies, including anti-dsDNA, anti-endomysium, anti-Sm, anti-Jo-1, or anti-cyclic
citrullinated peptide antibodies (ACCP), or rheumatoid factor [24,102,111]. It has been proposed
that CHIKV patients could harbor unknown autoantibodies through molecular mimicry [112]. As it
stands, proving or disproving the involvement of autoimmunity in chronic CHIKV pathogenesis
remains challenging.
There is evidence that CHIKV antigen may persist in tissues chronically. CHIKV antigen
was detected in the synovial macrophages of one patient 18 months after infection [54], as well
as in a human muscle specimen at least three months after acute infection [61]. Cells positive for
CHIKV antigen can also be detected in persistently-infected macaques [56] or wild-type mice
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[113]. Recombinant CHIKV expressing firefly luciferase also produce detectable luminescence
during the chronic stage of disease, suggesting that the virus could be undergoing low levels of
replication [114–116]. However, these and other studies have not demonstrated that the virus
itself is replication proficient. One study reported the detection of infectious CHIKV by TCID50
assay at 44 dpi in the spleen, liver, and muscle tissue of IV-inoculated macaques, but not the joint
tissue [56]. To our knowledge, infectious virus has not been isolated from the joint tissue of chronic
patient or wild-type animal samples [117,118]. Therefore, while it is impossible to completely
dismiss autoimmunity and low-level viral replication as the driving force behind chronic disease,
the data supporting these hypotheses has not been definitively seen in various human or animal
studies.
A prevailing hypothesis for chronic CHIKV pathogenesis is that non-infectious CHIKV RNA
remains in infected tissues, and its dsRNA intermediates act as a proinflammatory patternassociated molecular patterns (PAMPs) [119]. Chronic CHIKV RNA can consistently be detected
through qPCR in animal models, including the joints and spleen of mice and the spleen, lymph
nodes, and liver of macaques, despite the fact that infectious virus is cleared much sooner
[56,120]. Detection of chronic CHIKV RNA in human samples has been less consistent. One study
reported the presence of CHIKV E1 and nsP2 RNAs in a human synovial fluid sample, but others
have failed to detect chronic CHIKV RNA in patient serum or synovial fluid [54,118]. Such negative
results could reflect the difficulty in obtaining more invasive patient samples such as joint, muscle,
or spleen biopsies, as can be readily obtained in animal models.
Of note, administering viral or synthetic dsRNA or IFN-α by itself can even induce arthritis
in mice through activation of IL-1R signaling, and IFNAR-/- mice are protected from these effects
[121,122]. Therefore, administration of a viral PAMP alone or the downstream effector (type I IFN)
can be sufficient to cause arthritic disease, even in the absence of an actively replicating virus.

17

1.3 Tools to Study Chikungunya Virus Infection
While clinical data provides some insight into the acute and chronic pathogenesis of
CHIKV, the exact mechanisms of disease can only truly be dissected with in vivo models of
infection. Fortunately, the past 10 to 15 years has seen vast advancements in CHIKV animal
models. Furthermore, the cloning of CHIKV has allowed for the production of recombinant viruses
that can be manipulated with the insertion of reporter genes or mutations, rather than relying on
immutable and heterogenous clinical isolates.

1.3.1 Animal Models
Mice and nonhuman primates have both been used as models of CHIKV infection [123].
Mouse models include neonatal mice, immunocompromised mice, and WT mice that develop
arthritis and myositis. Infection of neonatal mice results in lethality, often with neurological
symptoms, which parallels neonatal human infection; decreasing the age of infection from 12 to
9 to 6-day-old pups subsequently increases mortality [124]. Knockout neonatal mice have been
used to explore the involvement of specific interferon-stimulated genes (ISGs) during CHIKV
infection [125]. Immunocompromised adult mice also develop severe CHIKV disease that can
result in lethality. For example, mice that lack the type I IFN receptor (IFNAR-/-) or type I IFN
regulatory factors (IRF3/7-/-) exhibit 100% mortality 3 to 8 days after infection [124,126,127]. As
such, these mice are useful in the testing of neutralizing CHIKV antibodies [75]. However, due to
the high levels of lethality, neither neonatal nor immunocompromised mice are useful for the study
of chronic CHIKV pathogenesis.
The arthritis mouse model allows for study of both acute and chronic CHIKV pathogenesis.
This model comprises inoculating immunocompetent adolescent (3-4 weeks old) mice with CHIKV
subcutaneously into the rear footpad, mimicking a mosquito bite. This model recapitulates many
acute aspects of human disease including viral replication in the joint and muscle tissues,
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tenosynovitis and myositis, viremia, and dissemination to distal joint and lymphoid tissues
[64,66,128]. Inoculation of mice into the footpad results in a biphasic swelling pattern in the
ipsilateral foot, with the first swelling peak corresponding to cell lysis, local proinflammatory
cytokine production, edema, and monocyte infiltration. The second peak is associated with an
influx of inflammatory infiltrates, including B and T lymphocytes [64,66,128]. This model also
recapitulates aspects of chronic CHIKV disease. CHIKV RNA persists in the joints for several
months after infection, and there are signs of chronic myositis and synovitis [117,120]. However,
the arthritis model is not without its limitations, including lack of bilateral symmetrical joint
involvement [129].
Nonhuman primate models have also been used to study aspects of CHIKV pathogenesis.
Rhesus macaques have been used since the 1960s for CHIKV virulence studies [130], and in
more recent years studies of CHIKV pathogenesis and transmission or testing of vaccines and
antivirals have also utilized Rhesus macaques [131–134]. Cynomolgus macaques have also been
used to study CHIKV pathogenesis. For instance, one study used cynomolgus macaques to
identify cell types that harbor CHIKV antigen at chronic time points [56]. While nonhuman primate
models more closely recapitulate human disease and are typically required prior to clinical testing
in humans, they do not offer the flexibility and specificity of mouse models, as non-WT animals
are typically not used.

1.3.2 Recombinant Viruses
While clinical isolates were used for much of the early research on CHIKV, recombinant
CHIKV constructs allow for increased manipulation of the virus. Reporter genes can be inserted
into the CHIKV genome through introduction of a second subgenomic promoter, either in between
the structural and non-structural genes (5ʹ) or at the end of the genome (3ʹ). Previous studies
have introduced fluorescent proteins such as GFP or mCherry into these locations, resulting in
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viruses with tissue fluorescence only during active viral replication. These reports demonstrate
that 5ʹ clones (e.g. CHIKV-5ʹ-GFP) have lower recombinant protein expression but higher stability
than the 3ʹ variants (e.g. CHIKV-3ʹ-GFP); these viruses are also somewhat attenuated compared
to WT CHIKV [135,136]. Firefly luciferase has also been successfully introduced into CHIKV
clones [114–116]. Other groups have also reported success with introducing reporter genes into
the nsP3 gene [137].
While fluorescent or luminescent viruses are useful for the study of acute CHIKV
pathogenesis, fluorescent protein expression is typically transient, and luminescent output is often
only resolvable on the tissue level; thus, such strategies are less helpful for the detailed study of
chronic CHIKV pathogenesis. In order to study the chronic pathogenesis of other viruses, some
groups have utilized recombinant viruses expressing Cre recombinase, which can indelibly mark
infected cells in reporter cells or mice. This Cre-virus approach has been previously used to
explore the chronic pathogenesis of influenza virus [138,139] and HSV-1 [140,141], but it has not
yet been attempted with any alphaviruses, to our knowledge. As such, this dissertation concerns
optimization and characterization of two CHIKV-Cre viruses, which we use to investigate the
chronic pathogenesis of CHIKV.
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1.4 Figures

Figure 1.1: Evolution and epidemiology of CHIKV
(A) Phylogenetic map displaying the three CHIKV phylogroups: ECSA, Asian, and African;
adapted from [142]. (B) World map showing the countries and territories where CHIKV cases
have been reported as of May 29, 2018. The map does not include countries or territories where
only travel-acquired cases have been reported; figure was adapted from [143].
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Figure 2.2: CHIKV virion and genome structure
(A) CHIKV virion structure; adapted from [144]. (B) CHIKV genome; adapted from [28].
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Figure 3.3: Replication cycle of CHIKV in mammalian cells
(A) CHIKV genome replication and transcription; adapted from [144]. (B) CHIKV replication in
mammalian cells; adapted from [40].
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Figure 4.4: Acute and chronic pathogenesis of CHIKV
Acute CHIKV symptoms are associated with disseminated viral replication in a variety of tissues.
It is hypothesized that chronic CHIKV disease is due to persistence of virus, inflammatory
cytokines, and joint damage; adapted from [40].
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Chapter 2:
A Recombinant Chikungunya Virus Reporter System
This chapter contains data from a manuscript in preparation for submission:
Alissa R. Young, Marissa C. Locke, Lindsey E. Cook, Bradley E. Hiller, Rong Zhang,
Matthew L. Hedberg, Kristen J. Monte, Deborah J. Veis, Michael S. Diamond, and
Deborah J. Lenschow. A recombinant chikungunya virus reporter system defines
dermal and muscle fibroblasts and skeletal myofibers as targets during the chronic
phase of infection. In preparation to submit to PLoS Pathogens (2019).
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2.1 Abstract
Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during acute disease
causes fever as well as severe joint and muscle pain. Chronic joint and muscle pain persists in
a significant subset of patients for months to years after the initial infection, yet we still have a
poor understanding of what drives this chronic disease. While replicating virus has not been
detected in the joints of patients with chronic arthritis or in various animal models at chronic time
points, persistent viral RNA can be detected for months after acute infection. To identify the cells
that might contribute to chronic CHIKV pathogenesis, we developed a recombinant virus that
expresses Cre recombinase (CHIKV-3ʹ-Cre). This virus replicated in cell types targeted by CHIKV,
including myoblasts and fibroblasts, and it induced acute arthritis in a murine model of CHIKV
arthritis. Importantly, it also induced chronic disease, including persistent viral RNA and chronic
myositis and synovitis similar to wild-type (WT) virus. CHIKV-3ʹ-Cre infection of tdTomato reporter
mice resulted in a population of tdTomato+ cells that persisted for at least 112 days. The majority
of these cells localized to the dermis and muscle, and immunofluorescence profiling revealed that
these tdTomato+ cells were dermal and muscle fibroblasts and myofibers. Treatment with an
antibody against Mxra8, a host receptor for CHIKV, reduced the levels of viral RNA and the total
number of tdTomato+ cells in the chronic phase, with a preferential reduction in fibroblasts. AntiMxra8 treatment demonstrated a correlation between chronic viral RNA levels and the number of
tdTomato+ cells, thus suggesting that viral RNA can be found within these persistent tdTomato+
cells. This CHIKV-3ʹ-Cre and tdTomato reporter mouse system demonstrates that cells can
survive CHIKV infection in vivo and represents a powerful tool to study the chronic pathogenesis
of CHIKV infection.
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2.2 Introduction
Chikungunya virus (CHIKV) is a globally re-emerging arbovirus originally identified in
Tanzania in 1952 [1–3]; phylogenetic analyses estimate its original emergence as a human virus
within the last 500 years [6]. Up until the 2000s, CHIKV was considered a self-limiting, tropical
virus of minimal concern; however, within the last 15 years, CHIKV has reemerged with increased
virulence and range. In 2004, an East/Central/South African (ECSA) lineage [5] of CHIKV initiated
an epidemic in Kenya with over 13,000 cases, the first large epidemic in decades [10]. By 2005,
the virus spread to La Réunion Island off the east coast of Madagascar, where it infected over
200,000 people [8,11]. The La Réunion epidemic included the first reports of increased
pathogenicity, including neurological symptoms, intrapartum transmission, and approximately 250
deaths [12–14]. The virus subsequently spread throughout the Eastern Hemisphere, establishing
endemic conditions in tropical regions including India and the South Pacific, and even causing
isolated outbreaks in Europe [18]. In 2013, an Asian lineage strain of CHIKV spread to the
Americas and has caused nearly 2 million suspected cases in the Caribbean, Central, and South
America [18,20–22].
An estimated 75-95% of people who acquire CHIKV by a mosquito bite [9,15,16]
experience an acute disease characterized by fever, rash, arthralgias, and myalgias that last for
approximately one to two weeks [11,29,54]. Follow-up studies have reported that between 30%
to 60% of CHIKV infected patients develop chronic joint and muscle pain that lasts for months to
years after the acute infection [96,118,145]. Whereas CHIKV disease is rarely fatal, the acute and
chronic viral arthritis has a high morbidity. For instance the 2005 outbreak on La Réunion Island
resulted in an estimated loss of 55,000 DALYs (disability-adjusted life years) or healthy years lost
to illness [145], and the CHIKV epidemic in the Americas is predicted to cause an estimated one
million cases of chronic CHIKV symptoms [146]. Furthermore, there are no approved vaccines or
therapeutics for CHIKV, and over-the-counter medications provide little relief [67]. Despite its high
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prevalence in patients and significant morbidity, the mechanism of chronic CHIKV pathogenesis
is poorly understood.
Overall, chronic CHIKV disease is characterized by elevated inflammatory markers and
immune activation. A number of pro-inflammatory cytokines are elevated in the serum during
chronic CHIKV disease, including IL-1β, IL-6, and G-CSF [62,147–149]. Chronic CHIKV patients
also have higher levels of activated CD8+ T cells and NK cells, resembling seronegative
Rheumatoid arthritis [24]. Mouse models of CHIKV infection have highlighted the importance of
adaptive immunity in determining CHIKV clearance or persistence; mature B cells and a
productive antibody response appear to be especially critical, as RAG1-/- and μMT mice (both of
which lack mature B cells) fail to clear infectious CHIKV [115,117,120,150,151]. Multiple studies
have attempted to identify predictive markers for CHIKV-induced chronic arthralgia
[54,89,97,107,152]. While these studies agree that chronic CHIKV pathogenesis is characterized
by a chronic inflammatory state, they do not define consistent biomarkers or disease mechanisms.
Hypotheses to explain chronic CHIKV pathogenesis abound, including the induction of
autoimmunity, the persistence of ultralow levels of replicating virus, and activation of inflammatory
responses against residual viral RNA. There is evidence that CHIKV antigen may persist in
tissues chronically. CHIKV antigen was detected in the synovial macrophages of one patient 18
months after infection [54], as well as in a human muscle specimen at least three months after
acute infection [61]. Cells positive for CHIKV antigen can also be detected in persistently-infected
macaques [56] or wild-type mice [113]. Recombinant CHIKV expressing firefly luciferase also
produce detectable luminescence during the chronic stage of disease [114–116]. However, these
and other studies have not demonstrated that the virus itself is replication proficient, and to our
knowledge, infectious virus has not been isolated from the joint tissue of chronic patient or wildtype animal samples [117,118]. Therefore, while it is impossible to completely dismiss

28

autoimmunity and low-level viral replication as the driving force behind chronic disease, the data
supporting these hypotheses has not been consistently seen in various human or animal studies.
A prevailing hypothesis for chronic CHIKV pathogenesis is that non-infectious CHIKV RNA
remains in infected tissues, and its dsRNA intermediates act as a proinflammatory patternassociated molecular patterns (PAMPs) [119]. Chronic CHIKV RNA can consistently be detected
through qPCR in animal models, including the joints and spleen of mice and the spleen, lymph
nodes, and liver of macaques, despite the fact that infectious virus appears to be cleared much
sooner [56,120]. Detection of chronic CHIKV RNA in human samples has been less consistent.
One study reported the presence of CHIKV E1 and nsP2 RNAs in a human synovial fluid sample,
but others have failed to detect chronic CHIKV RNA in patient serum or synovial fluid [54,118].
Such negative results could reflect the difficulty in obtaining more invasive patient samples such
as joint, muscle, or spleen biopsies, as can be readily obtained in animal models.
Despite the presence of chronic RNA is these various models, the cells that potentially
harbor the viral RNA are unknown. Histological detection tools such as immunohistochemistry
(IHC) are only rarely able to detect CHIKV antigen-positive cells in wild-type mice, likely owing to
the insensitivity of these techniques [113]. Moreover, studies using RNA in situ hybridization (ISH)
for detection of CHIKV RNA have not been published beyond acute time points in mice. Much
remains to be explored surrounding chronic CHIKV pathogenesis, including the identification of
cells that survive infection and potentially harbor viral RNA, the state of the viral RNA that persists,
and why the immune response cannot clear this persistent RNA.
To begin to address these questions, we have established a model that allows for the
permanent marking of cells that are infected by CHIKV. We engineered a recombinant CHIKV
clone that expresses Cre recombinase, as has been done previously for influenza virus [138,139]
and HSV-1 [140,141]. We demonstrate that this CHIKV-Cre virus infects and replicates in cell
types targeted by CHIKV including myoblasts and fibroblasts and induces acute arthritis in mice.
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Importantly, this virus was also able to establish chronic disease including the persistence of viral
RNA for weeks after acute infection. Combining this Cre expressing virus with reporter mice we
were able to visualize and identify the surviving marked cells in the chronic phase that were likely
infected in the acute phase. This system represents a powerful tool to study how cells that survive
infection by CHIKV contribute to chronic disease pathogenesis of this debilitating virus.

2.3 Results
2.3.1 Generation and in vitro characterization of CHIKV-3ʹ-Cre
To identify cells that survive CHIKV infection, we generated a recombinant chikungunya
virus using the La Réunion clone, LR2006 OPY1, (denoted CHIKV-WT) and engineered it to
express the bacteriophage Cre recombinase gene under control of a second subgenomic
promoter. Two versions of the Cre recombinase virus were generated: in one version the second
subgenomic promoter and Cre recombinase was introduced between the non-structural and
structural genes (denoted CHIKV-5ʹ-Cre), and in the other version the subgenomic promoter and
Cre recombinase were inserted downstream of the structural genes (denoted CHIKV-3ʹ-Cre)
(Figure S2.1A).
For these studies, we used reporter mice harboring a fluorescent protein (tdTomato)
driven by a constitutive Rosa promoter interrupted with a stop cassette. Infection of these mice
with our recombinant viruses should result in the expression of Cre recombinase, which can bind
to the LoxP sites, excise the stop cassette, and promote constitutive expression of the fluorescent
protein. Thus, the fluorescent reporter will be expressed in all cells where Cre recombinase was
expressed, even when viral replication is abrogated (Figure 2.1A). This system can help
determine whether individual cells can survive the initial CHIKV infection.
To characterize the system, we tested the ability of CHIKV-3ʹ-Cre to function in reporter
cells in culture. Murine embryonic fibroblasts (MEFs) from tdTomato reporter mice were isolated
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and infected with either CHIKV-WT or CHIKV-3ʹ-Cre. Two days post infection (dpi), a population
of tdTomato+ cells was detected following CHIKV-3ʹ-Cre infection, whereas no tdTomato+ cells
were identified during infection with media (mock) or CHIKV-WT (Figure 2.1B-C). Infection with
CHIKV-5ʹ-Cre also induced reporter expression, although in a lower number of cells than CHIKV3ʹ-Cre, and this difference was seen across several multiplicities of infection (MOIs) (Figure
S2.1B).
To determine if viral replication was required to activate the reporter, we pretreated cells
with IFN-β and then infected them with CHIVK-3ʹ-Cre.

Pretreatment with IFN-b prevented

expression of the tdTomato reporter by CHIKV-3ʹ-Cre, demonstrating that viral replication and
protein expression are required (Figure 2.1C). As another control, cell debris from BHK-21 cells
infected with CHIKV-3ʹ-Cre was tested for its ability to activate reporter cells; non-virion
components in the cell debris from lysed cells, such as Cre protein, could be taken up by
uninfected cells and lead to aberrant reporter expression. Cell debris itself resulted in many
tdTomato+ cells; however, UV-inactivation of infectious virus in this cell debris inhibited activation
of the tdTomato reporter (Figure 2.1C). Similar results were also seen with CHIKV-5ʹ-Cre (Figure
S2.1C). Taken together, these results suggest that active viral replication and expression of Cre
recombinase in the infected cell is necessary for activation of tdTomato expression.
We next assessed the ability of CHIKV-3ʹ-Cre to replicate in fibroblasts and muscle cells,
two cell types that are targeted during acute CHIKV infection [29,42,54,55,57,58,66]. C2C12
myoblasts or MEFs from C57BL/6 mice were inoculated with CHIKV-WT or CHIKV-3ʹ-Cre at an
MOI of 1, and viral replication was assessed at various time points post infection.

In C2C12

myoblasts, CHIKV-3ʹ-Cre replicated to similar levels and with similar kinetics as CHIKV-WT
(Figure 2.1D). CHIKV-3ʹ-Cre also replicated in MEFs, although it was attenuated compared to
CHIKV-WT (Figure 2.1E). Similar results were seen when C2C12 cells or MEFs were infected at
an MOI of 0.05 or with CHIKV-5ʹ-Cre (Figure S2.1D-E). Therefore, the CHIKV-3ʹ-Cre virus retains
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its ability to replicate in key target cells during infection, though with some attenuation in
fibroblasts.

2.3.2 CHIKV-3ʹ-Cre induces acute arthritis
A mouse model of CHIKV infection has been shown to recapitulate several aspects of
human infection [64,66,129]. Acute infection is characterized by footpad swelling that resolves
within 10-14 dpi and by replication of the virus within the infected footpad and ankle as well as
dissemination to other tissue sites including the contralateral ankle, wrists, quadriceps muscle,
spleen, and serum. In addition, during acute disease, edema and immune cell infiltration into the
joint and muscle is observed. We therefore next evaluated the ability of CHIKV-3ʹ-Cre to induce
acute clinical disease.
C57BL/6 mice were inoculated with either CHIKV-WT or CHIKV-3ʹ-Cre into the footpad
and analyzed for swelling, viral replication, and histopathology. Injection of each virus into the
hind paw resulted in a biphasic pattern of acute ipsilateral footpad swelling with peaks seen at 3
and 6 dpi and with resolution of the swelling by 10-14 dpi (Figure 2.2A). Although the initial
swelling peak at 2-3 dpi, thought to be driven by edema and monocyte infiltration [128], was
reduced in CHIKV-3ʹ-Cre infection, the latter and more pronounced swelling peak at 6 dpi, thought
to be driven by the infiltration of monocytes and CD4+ T cells [115,128], was equivalent between
the two viruses (Figure 2.2A). Similar results were also seen with CHIKV-5ʹ-Cre (Figure S2.2A
Fig). The resolution of swelling was similar between both viruses.
We next measured viral titers in the ipsilateral ankle of the infected mice. High viral loads
were detected in both the CHIKV-WT and CHIKV-3ʹ-Cre infected mice at 1, 3, and 5 dpi, although
CHIKV-3ʹ-Cre was mildly attenuated with ~10-fold lower viral loads compared to CHIKV-WT.
Infectious virus from either CHIKV-WT and CHIKV-3ʹ-Cre was undetectable by 10-14 dpi (Figure
2.2B). Again, similar results were seen with CHIKV-5ʹ-Cre (Figure S2.2B Fig). Infection with
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CHIKV-WT also resulted in viremia and dissemination to and replication in distal tissues such as
the ipsilateral quadriceps muscle, contralateral ankle, and spleen. Whereas viral replication of
both CHIKV-3ʹ-Cre and CHIKV-5ʹ-Cre was detected at these distal sites, they were attenuated
compared to CHIKV-WT (Figure S2.2C-F).
We also utilized RNA in-situ hybridization (ISH) to detect viral RNA in various tissue
compartments. RNA ISH was performed on the ipsilateral foot and ankle two days after mock
infection or infection with CHIKV-WT or CHIKV-3ʹ-Cre. CHIKV E1 RNA could be detected for both
viruses in several tissue compartments, including skeletal muscle, skin, and synovium (Figure
S2.3A). However, the ISH staining for CHIKV-3ʹ-Cre was often less intense than CHIKV-WT, likely
a reflection of its attenuation. Notwithstanding these differences, CHIKV-3ʹ-Cre had a similar
tissue tropism to CHIKV-WT.
CHIKV infection results in moderate to severe arthritis that can be detected at acute and
subacute time points in animal models [117,120]. This is characterized by edema and swelling
within the skin and subcutaneous tissue and cellular infiltrates into the joint space, muscle, and
tenosynovial tissues. Specimens comprising the ipsilateral foot and ankle were harvested seven
days after mock-infection or infection with either CHIKV-WT or CHIKV-3ʹ-Cre, and H&E sections
were scored for overall inflammation (Figure 2.2C-D).
Histopathologic examination and analysis revealed significant edema, especially in the
dermis and hypodermis, and inflammation with tissue damage in the footpad, skeletal muscle,
and tenosynovial joint tissues was evident in mice infected by either virus compared to mockinfected animals (Figure 2.2D). Based on histological analysis, the overall severity of the
inflammatory response in the joint space, muscle, and tenosynovial soft tissues was
indistinguishable between CHIKV-WT and CHIKV-3ʹ-Cre at 7 dpi (Figure 2.2C). Similar results
were seen with CHIKV-5ʹ-Cre at 7 dpi (Figure S2.3B-C). Thus, CHIKV-3ʹ-Cre retains the
pathogenic potential to induce acute musculoskeletal disease.
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2.3.3 CHIKV-3ʹ-Cre induces chronic disease
Chronic CHIKV arthritis is characterized by persistent myositis and chronic synovial
inflammation and proliferation with mild histological features. In addition, persistent viral RNA can
be detected in these tissues in mice long after acute disease, despite the absence of detectable
replicating virus [117,120]. Therefore, we next evaluated if the CHIKV-3ʹ-Cre virus could establish
chronic disease.
Ipsilateral foot and ankle joints were harvested twenty-eight days after inoculation with
media (mock-infection), CHIKV-WT, or CHIKV-3ʹ-Cre. Histopathological examination and analysis
showed patchy areas of chronic inflammatory infiltrates within the muscle, with some evidence of
synovial proliferation within the joints, consistent with a remote/resolving arthritis, in both the
CHIKV-WT and CHIVK-3ʹ-Cre infected but not mock-infected mice (Figure 2.3A). However,
compared to the specimens harvested at 7 dpi (Figure 2.2C-D), there was markedly less
histologic evidence of inflammation and tissue damage in the specimens harvested at 28 dpi.
Mild inflammation was not identified in any of the mock-infected joints, and it was only
histologically identified in a subset of CHIKV-WT or CHIKV-3ʹ-Cre chronically infected specimens;
however, the difference did not achieve statistical significance at the cohort level (Figure 2.3B).
Similar results were observed for CHIKV-5ʹ-Cre (Figure S2.4A-B). These results are consistent
with the comparatively mild histologic findings previously described in CHIKV-associated chronic
arthritis and highlight the importance of diagnostic techniques with greater sensitivity than
histopathology.
We next evaluated if viral RNA persisted in tissues after infection with the CHIKV-3ʹ-Cre
virus. Samples harvested at 28 dpi were analyzed for the presence of CHIKV viral E1 RNA by
real-time quantitative PCR (RT-qPCR). CHIKV RNA was detected in the ipsilateral ankles of mice
infected with either CHIKV-WT or CHIKV-3ʹ-Cre, although at this time point the level of viral RNA
were slightly decreased (~3.5-fold) in the CHIKV-3ʹ-Cre infected mice compared to CHIKV-WT
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(Figure 2.3C). As expected, mock infection or infection with UV-inactivated CHIKV-3ʹ-Cre did not
result in a positive signal for viral RNA (Figure 2.3C).
An analysis of the kinetics of CHIKV viral RNA in the ankles of infected mice revealed that
both CHIKV-WT and CHIKV-3ʹ-Cre established peak levels of viral RNA during acute disease, 17 dpi (Figure 2.3D). Persistent levels of chronic viral RNA were detected through 112 dpi (16
weeks), and both viruses established similar levels of persistent viral RNA at these late time points
(Figure 2.3D). Again, similar results were observed for CHIKV-5ʹ-Cre (Figure S2.4C). While RNA
ISH could identify cells during acute infection (Figure S2.3A), it was not sensitive enough to
identify RNA positive cells in the chronic phase (data not shown).
At peak productive infection, engagement of the subgenomic promoter produces a
subgenomic RNA segment containing the structural genes [28,33,36]. As such, this results in
more copies of structural genes, such as E1, being produced than copies of non-structural genes,
such as nsP1, during active replication. Consistent with this description and as seen previously
[120], during the first 7 days of infection the ratio of E1 to nsP1 RNA copies was greater than 1
for both CHIKV-WT and CHIKV-3ʹ-Cre indicating viral replication was occurring (Figure 2.3E).
However, after 7 dpi the ratio of E1 to nsP1 was approximately 1, and the viral RNA levels
decreased with a similar time course for both viruses. Similar results were observed for CHIKV5ʹ-Cre (Figure S2.4D). These results indicate that the subgenomic promoter is only active during
the first week of acute infection, as supported by infectious virus only being detected during the
same time course (Figure 2.2B). Thus, persistent RNA detected after 7 dpi is likely non-replicative
and non-infectious.
These results indicate that CHIKV-3ʹ-Cre retains its pathogenic potential and can induce
both acute and chronic disease. Despite displaying slight attenuation during acute infection,
CHIKV-3ʹ-Cre can establish chronic disease including persistent viral RNA and histological
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damage. Such data justifies its utilization as a tool to identify the cells that can survive CHIKV
infection and may contribute to chronic arthritis pathogenesis.

2.3.4 CHIKV-3ʹ-Cre marks dermal and muscle fibroblasts and myofibers
Previous reports have indicated that CHIKV is highly cytopathic and induces cell death in
the majority of cells that it infects [52,60].

Yet, persistent viral RNA can be detected long past

acute infection. To test whether cells could survive CHIKV infection, tdTomato reporter mice were
inoculated with media (mock), CHIKV-WT, or CHIKV-3ʹ-Cre and analyzed for the presence of
tdTomato+ cells at time points in the chronic phase. Notably, tdTomato+ cells were observed in
the ipsilateral foot 28 dpi with CHIKV-3ʹ-Cre, but not in C57BL/6 or reporter mice that were mockinfected or infected with CHIKV-WT or UV-inactivated CHIKV-3ʹ-Cre (Figure 2.4A-B, Figure
S2.5A). Infection with CHIKV-5ʹ-Cre infection also resulted in tdTomato+ cells in the ipsilateral
foot, but to a much lower level than CHIKV-3ʹ-Cre (Figure S2.5B-D). tdTomato+ cells were
detected up to at least 112 days (16 weeks) after infection with CHIKV-3ʹ-Cre (Figure 2.4C).
Closer examination of ipsilateral feet infected with CHIKV-3ʹ-Cre revealed that the majority
of tdTomato+ cells appeared to be concentrated in the skeletal muscle and in the dermal layer of
the skin (Figure 2.4A). In the muscle, the tdTomato+ cells appeared to be a mixture of long, multinucleated myofibers and small, uni-nucleated non-myofiber cells (Figure 2.4A). A high amount
of tdTomato+ cells were also observed in the dermis of the skin. Other connective tissues such as
bone, synovium, and tendons contained rarer populations of tdTomato+ cells (Figure S2.5E).
To define the identity of the tdTomato+ cells, we performed co-staining with a variety of
cell specific markers. Since the majority of the tdTomato+ cells were localized to the muscle and
the dermis we focused our analysis on these two areas. In the muscle, the long multi-nucleated,
striated cells that histologically were consistent with striated muscle fibers co-stained with
sarcomeric alpha actinin (SAA), a microfilament protein that attaches actin filaments to the Z-
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discs in myofibers and exhibits a striated pattern (Figure 2.5A), confirming that these tdTomato+
cells are skeletal muscle cells.
Within the muscle we also observed a subset of tdTomato+ cells that were small, uninucleated, and negative for SAA staining. CHIKV is known to infected fibroblasts and the
morphology of these cells was consistent with fibroblasts. Although there is no specific marker
for fibroblasts, these tdTomato+ cells co-stained for vimentin, an intermediate filament that is
highly expressed in fibroblasts. In the dermis of the skin, many of the tdTomato+ cells also costained strongly with vimentin (Figure 2.5A). Some of the tdTomato+ cells in the skin or muscle
also co-stained with CD44, CD29, or CD105, additional fibroblast markers (Figure 2.5A, Figure
S2.6).
As these mesenchymal markers can be expressed in other cell types, sections also were
stained with CD31 (endothelial cell marker), CD45 (hematopoietic cell marker), or smooth muscle
actin (SMA, myofibroblast and smooth muscle marker). tdTomato+ cells in the skin and muscle
did not strongly co-stain with these markers, suggesting that these tdTomato+ fibroblast-like cells
are not immune cells, endothelial cells, or smooth muscle cells (Figure 2.5B). A small subset of
tdTomato+ cells in the skin also co-stained with beta III tubulin (Figure S2.6). These cells could
be part of nerve fibers [153] or fibroblasts with stem cell characteristics that can become
neuroectodermal cells [154,155]. Co-staining demonstrates that many of the tdTomato+ cells
appear to be myofibers and dermal and muscle fibroblasts.

2.3.5 Anti-Mxra8 treatment preferentially reduces fibroblasts
Mxra8 is a cell adhesion molecule that was described as an entry receptor for multiple
arthritogenic alphaviruses. Treatment with anti-Mxra8 monoclonal antibodies (mAbs) reduced
CHIKV infection and foot swelling at 3 dpi during acute disease [38]. We assessed the impact of
Mxra8 blockade on the establishment of chronic disease and the persistence of infected cells
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after acute infection. tdTomato reporter mice were treated with either isotype control antibody or
with anti-Mxra8 mAbs 12 hours prior to infection and then at 4, 8, 12, 16, 20, and 24 dpi. Mice
treated with anti-Mxra8 mAbs showed a significant reduction (73% decrease) in persistent viral
RNA detected in the ipsilateral ankle 28 dpi compared to the isotype control mAb treated mice
as judged by RT-qPCR (Figure 2.6A).
Consistent with this data, the anti-Mxra8 treated mice had significantly reduced numbers
(75% decrease) of tdTomato+ cells in the ipsilateral ankle 28 days after infection as compared to
the isotype control (Figure 2.6B-C). Quantification of cell co-staining demonstrated that the
most significant reductions with anti-Mxra8 treatment were observed in CD29+ fibroblasts in the
muscle and skin (Figure 2.6D), with an 89% and 78% decrease, respectively. Anti-Mxra8
treatment also reduced the number of tdTomato+ SAA+ myofibers by 57%, thus to a lesser
extent than fibroblasts (Figure 2.6E). As such, anti-Mxra8 treatment perturbed the distribution of
tdTomato+ cell types in the muscle, with a higher percentage of remaining tdTomato+ cells
staining for SAA than for CD29 in the muscle (Figure 2.6F). Anti-Mxra8 treatment thus reduced
the amount of persistent viral RNA and overall numbers and distribution of tdTomato+ cells in
musculoskeletal tissues during the chronic phase.

2.4 Discussion
CHIKV causes a debilitating acute disease that results in chronic arthralgias and myalgias
in a significant subset of patients. The mechanism of this chronic CHIKV pathogenesis is unclear
but may be related to persistent viral RNA in musculoskeletal tissues. To begin to identify the cells
that contribute to chronic pathogenesis, we created a recombinant CHIKV that expresses Cre
recombinase and permanently marks infected cells in reporter mice. Using this tool, we provide
evidence that a subset of cells infected with CHIKV can survive infection.

38

Previous reports have used immunofluorescence microscopy, immunohistochemistry, or
RNA quantification tools to detect CHIKV antigen or RNA in animal and patient cells at time points
in the chronic phase of disease [54,56,61,113]. However, CHIKV antigen-positive cells are
reported to be rare in these samples from the subacute or convalescent phase, likely owing to the
insensitivity of these techniques. Our reporter virus system constitutively marks cells that were
once productively infected as opposed to those which acquired antigen by passive engulfment.
We constructed two variants of the CHIKV-Cre construct, inserting the Cre recombinase
gene into the CHIKV genome through introduction of a second subgenomic promoter, either in
between the structural and non-structural genes (CHIKV-5ʹ-Cre) or at the 3ʹ end of the genome
(CHIKV-3ʹ-Cre). As has been reported previously with CHIKV-GFP clones [135,136], the
introduction of Cre recombinase resulted in mild attenuation of both viruses. However, the CHIKVCre viruses retained sufficient virulence to infect targets of CHIKV replication (fibroblasts and
myoblasts) and induce acute swelling and histopathology that was comparable to CHIKV-WT.
The CHIKV-Cre viruses also established chronic disease resulting in persistence of viral RNA,
chronic myositis, and synovial inflammation. From our more detailed studies, we used the CHIKV3ʹ-Cre rather than CHIKV-5ʹ-Cre, as certain aspects of CHIKV-3ʹ-Cre infection more closely
resembled CHIKV-WT infection. For example, the ratio of E1:nsP1 in the first seven days of
infection was more similar between CHIKV-3ʹ-Cre and CHIKV-WT than with CHIKV-5ʹ-Cre. This
difference is likely because the E1 gene is under the replicative direction of the subgenomic
promoters; the internal genomic structure of CHIKV-3ʹ-Cre is identical to CHIKV-WT in contrast
to CHIKV-5ʹ-Cre.
Using CHIKV-Cre viruses and tdTomato reporter mice, we also show that, like viral RNA,
tdTomato+ cells can be detected in the ankle for at least 112 days (16 weeks) after infection. One
limitation of our CHIKV-Cre reporter mouse system is that it cannot distinguish when during
infection a cell is marked. We favor the hypothesis that cells are infected during the first week of
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infection, survive acute infection without lysing, and persist for the lifetime of the cell. The
infectious viral titers and E1:nsP1 ratios support this idea that CHIKV is only actively replicating
during the acute phase of infection. Another scenario is that some tdTomato+ cells may arise as
daughter cells from mitotic replication of directly infected tdTomato+ cells; while these daughter
cells were not themselves infected, they may still retain viral RNA or an altered transcriptome. A
third hypothesis is that tdTomato+ cells arise throughout acute and chronic time points via
undetectable levels of replicating virus. It is also a possibility that all three scenarios occur in our
reporter mice, perhaps at different levels in various cell types.
Using our CHIKV-3ʹ-Cre and tdTomato reporter mouse system, we sought to identify the
cell types targeted by CHIKV that persist into the chronic phase. In the acute phase, CHIKV has
been shown to acutely infect a vast array of cell types, including fibroblasts, synoviocytes,
macrophages, skeletal muscle fibers, satellite cells, osteoblasts, endothelium, keratinocytes, and
neurons [29,42,55,61]. In vitro infections with many of these cell types exhibit high levels of
cytopathic effects and cell death [52,60]. Immunofluorescence analysis using our reporter mice
shows that the persistent tdTomato+ cells are predominantly a mixture of SAA+ skeletal myofibers
and vimentin+ CD44+ CD29+ CD105+ cells that are likely mesenchymal cells such as fibroblasts,
both of which are cell types reported be permissive to CHIKV infection [57,156].
Not all cells known to be infected by CHIKV in the acute phase were apparent in our
analysis in the chronic phase. Few cells in the synovial membrane were tdTomato+, even though
mild synovial inflammation was present at chronic time points as has been previously reported
[117,120]. During the acute stage of infection, we could detect staining for viral RNA in the
synovium; however, the synovial staining was much less pronounced than in the muscle or skin
for both CHIKV-WT and CHIKV-3ʹ-Cre. These results may indicate that synovial cells are not
infected in large numbers in vivo, or more likely, given synovial fibroblasts’ permissiveness to
CHIKV infection in vitro, many synovial cells are infected but do not survive acute, lytic infection.
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These results could explain why previous efforts to detect viral components in patient samples at
chronic time points have generally been unsuccessful as they have focused on synovial fluid
analysis and occasionally synovial tissue, but rarely skin or muscle samples.
In addition to a paucity of tdTomato+ synovial cells, few tdTomato+ cells were associated
with the bone or other connective tissues like tendons and ligaments. A small number of
tdTomato+ cells were sometimes found associated with the periosteum, which could represent a
population of fibroblasts or osteoblasts. Previous reports have suggested that acute infection of
osteoblasts can perturb osteoclast function and can lead to chronic histological damage
[157,158], which is not precluded by our results as the osteoblasts may accomplish such
outcomes while still succumbing to lytic infection.
Additional cell types that have been linked to chronic pathogenesis were not detected in
our mice with CHIKV-3ʹ-Cre. Endothelial cells or macrophages reportedly contain CHIKV antigens
during chronic infection in humans, macaques, or mice [54,56,113]. Some reports have also
suggested that hematopoietic cells such as monocytes or macrophages can be directly infected
by CHIKV [42,59]. However, the vast majority of tdTomato+ cells were CD31- and CD45-, which
is consistent with previous reports examining acute CHIKV staining in skin samples [58]. Although
further study is warranted, these cell types may not survive CHIKV infection, they may be poorly
infected by CHIKV (not enough to induce sufficient Cre recombinase), or they may not be
productively infected and instead phagocytose viral antigen from adjacent infected cells.
We also explored how Mxra8 blockade affected the tropism of CHIKV in the chronic stage
of pathogenesis. Mxra8 was recently discovered as a host entry receptor for several arthritogenic
alphaviruses including CHIKV, and its blockade reduced acute viral load both in vitro and in vivo
[38]. In our reporter mice, anti-Mxra8 treatment reduced the viral RNA burden in musculoskeletal
tissue in the chronic phase. Other CHIKV treatments, such as mAbs against viral envelope
proteins, have been successful at reducing acute viral loads but have not significantly affected
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persistence of viral RNA levels [159]. Such results suggest that targeting viral entry early in
infection could be key to alleviating both acute and chronic symptoms of disease.
In addition to decreasing chronic RNA levels by 73%, anti-Mxra8 treatment also reduced
the total number of tdTomato+ by 75%, thus correlating the level of chronic viral RNA and the
number of persistent tdTomato+ cells in the chronic phase. Such correlative results suggest that
persistent viral RNA might be contained within the tdTomato+ cells. However, current RNA ISH
techniques are not sensitive enough to directly visualize CHIKV RNA within tdTomato+ cells at
this stage. Immunofluorescence analysis revealed that anti-Mxra8 treatment resulted in a
significant reduction of CD29+ tdTomato+ fibroblast-like cells in the dermis and skeletal muscle.
Anti-Mxra8 treatment also impacted the abundance of tdTomato+ SAA+ myofibers, although to a
lesser extent than fibroblasts, suggesting that another host receptor may exist on myofibers for
CHIKV-LR, the strain used for the present studies. Such results underline the fact that CHIKV
likely utilizes multiple host entry receptors in addition to Mxra8, making potential treatments even
more difficult to target.
Indeed, Mxra8 was shown to be a stronger determinant of CHIKV infection of Asian than
ECSA strains [38], such as the La Réunion strain used for this study. Thus, it could be informative
to repeat these studies with other CHIKV lineage strains that express Cre recombinase. Other
strains or viruses may persist in distinct populations of tdTomato+ cells and or demonstrate
differential susceptibility to treatments such as anti-Mxra8 treatment. The CHIKV-3ʹ-Cre and
tdTomato model thus also represents a method of testing anti-viral treatments for their efficacy at
chronic timepoints, supplemented with viral RNA analysis.
A significant unanswered question in CHIKV disease pathogenesis is the mechanistic
driving force of symptoms during the chronic phase. Replicating virus has not been detected at
chronic time points, yet chronic inflammation is clearly present in tissue, serum, and synovial
samples, both histologically and transcriptionally [37,160,161]. While chronic viral RNA can be
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detected, to date it has been difficult to identify the cells harboring this RNA. Our model provides
insight into these questions by identifying the cell types that have been productively infected by
CHIKV and are present in the chronic phase. A limitation of the model is that we cannot be certain
at what stage a given tdTomato+ cell became infected with CHIKV. Ultimately, by combining
reporter gene expression with flow cytometric cell sorting and single cell RNA sequencing
analysis, we may be able to determine the transcriptional programs and inflammatory states of
these marked cells in the acute and chronic phase of CHIKV disease.
In conclusion, our CHIKV-3ʹ-Cre and tdTomato system provides further evidence for key
musculoskeletal cells as targets of CHIKV infection in the acute and chronic stages of disease.
How exactly these cells contribute to pathogenesis remains to be elucidated. Uncovering the
mechanisms for long-term pathogenesis could aid in the development of treatments and
preventative measures for this incapacitating virally-induced chronic arthritis.

2.5 Materials and Methods
2.5.1 Viruses
The wild-type strain of chikungunya virus (denoted CHIKV-WT) used for these studies
is LR2006 OPY1, an ECSA strain of CHIKV isolated from the La Réunion Island outbreak [135].
This strain has been characterized by many groups and used extensively by our lab
[17,56,57,64,66]. Plasmids for CHIKV-5ʹ-GFP and CHIKV-3ʹ-GFP were obtained from Stephen
Higgs (Kansas State University), and the Cre recombinase gene, with a nuclear localization signal
(NLS) sequence, was substituted for GFP in both viruses [135,136]. To produce the CHIKV-5ʹCre plasmid, Cre was PCR amplified from a Cre-containing plasmid with a forward primer (FW,
containing an AscI restriction enzyme recognition site and homology to the 5ʹ end of the Cre gene)
and a reverse primer (RV, containing a PmeI site and homology to the 3ʹ end of the Cre gene).
This amplicon was inserted into a CHIKV-5ʹ-GFP plasmid linearized with AscI and PmeI. To
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produce the CHIKV-3ʹ-Cre plasmid, Cre was PCR amplified from the CHIKV-5ʹ-Cre plasmid using
AscI-Cre FW and BsmBI-Cre RV primers. The 3ʹ UTR was also PCR amplified from the CHIKV3ʹ-GFP virus using BsmBI-3ʹUTR FW and NotI-3ʹUTR RV primers. Both PCR fragments were
simultaneously inserted into a CHIKV-3ʹ-GFP plasmid linearized with AscI and NotI. The infectious
clone plasmids for CHIKV-WT, CHIKV-3ʹ-Cre, and CHIKV-5ʹ-Cre were sequenced, and they
exhibited 100% identity with reference and predicted sequences.
To produce recombinant viral stocks, the infectious clone plasmids were linearized with
NotI, and RNA was produced using a SP6 in vitro RNA transcription kit (Agilent, Promega,
BioLabs). The RNA was transfected into baby hamster kidney 21 cells (BHK-21 cells) using
Lipofectamine 2000 (Invitrogen) and CD1 media without antibiotics. After 48 hours, the
supernatant was collected, centrifuged at 150-300 g to clear cell debris, aliquoted, and stored at
-80°C. Titers of the viral stocks were regularly assessed by plaque assay as previously described
[125]. All cell and animal work with live CHIKV was performed in a BSL3 facility and followed strict
guidelines established by the Environmental Health and Safety committee at Washington
University School of Medicine.

2.5.2 Mice
The following strains of mice were obtained from the Jackson Laboratory: C57BL/6 (JAX
Stock No: 000664; C57BL/6J) and tdTomato reporter mice (JAX Stock No: 007914; B6.CgGt(ROSA)26Sortm14(CAG-tdTomato)Hze/J). Mice were bred and maintained as congenic colonies at
Washington University School of Medicine animal facilities in accordance with all federal and
University guidelines. C57BL/6 mice were primarily used for viral titer and viral RNA analysis,
whereas the tdTomato reporter mice were used for histological analysis. For all experiments, mice
were weight- and sex-matched prior to infection; both sexes were used. For mouse studies, the
principles of good laboratory animal care were adhered to in strict accordance with NIH
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recommendations [162]. All animal protocols were approved by the Animal Studies Committee at
Washington University. Every effort was made to minimize animal suffering.

2.5.3 Cells and Media
Murine embryonic fibroblasts (MEFs) were generated from C57BL/6 and tdTomato
reporter mice, and they were grown at 37°C and 5% CO2 in CD10 media: Dulbecco’s modified
Eagle medium (DMEM) (Corning) supplemented with 10% fetal bovine serum (FBS) (Biowest),
1% penicillin-streptomycin (P/S; Corning), 1% L-glutamine (Glu; Corning), 1% non-essential
amino acids (NEAA; Corning), and 1% HEPES (Corning). For some experiments CD1 media
(CD10 media with only 1% FBS) was used. MEFs were used prior to passage number 5 for
these studies. The C2C12 myoblast cell line was obtained from ATCC (ATCC CRL1772) and
cultured using the same conditions as the MEFs.

2.5.4 Viral Growth Curves
MEFs and C2C12 myoblasts were grown as described above. For viral growth curves,
MEFs were plated at 2 x 104 cells/well and C2C12s at 1 x 104 cells/well in 96-well tissue culturetreated plates and allowed to adhere overnight. Cells were rinsed with CD1 media: DMEM
containing 1% FBS, 1% P/S, 1% Glu, 1% NEAA, and 1% HEPES. Diluted virus was then added
at the indicated multiplicity of infection (MOI) and allowed to adhere for 1 hour. The input virus
was then removed, the cells were washed once with CD1, and fresh CD1 media was added. At
each time point, a plate was frozen at -80°C and underwent three freeze-thaw cycles before
titers were determined on BHK-21 cells by plaque assay.

2.5.5 In Vitro Coverslip Studies
tdTomato reporter MEFs were plated onto collagen type I-treated 22mm glass coverslips
(Corning) at 4 x 105 cells/well in 6-well tissue culture-treated plates in CD10. If indicated, cells
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were also concurrently pre-treated with ~100 U IFN-b, and all cells were allowed to adhere to
the coverslips overnight. Cells were infected with virus at the indicated MOI, as described
above. After 48 hours, the supernatant was removed, and the cells were fixed to the coverslips
with 4% paraformaldehyde (PFA) for at least 10 minutes. Coverslips were stored in the wells
with phosphate-buffered solution (PBS) at 4°C until further processing.
Alternatively, the MEFs were treated with lysed cell debris (CD). Briefly, BHK-21 cells
were plated at 5 x 105 in tissue culture-treated plates in CD10 and allowed to adhere overnight.
The cells were infected with CHIKV-3ʹ-Cre at an MOI of 10, and the supernatant was removed
at 24 hours p.i. Large cellular debris was cleared from these supernatants by centrifugation at
150-300 g, leaving behind virus and cellular lysate (including virus-produced Cre protein).
Aliquots of this CD were stored at -80°C. In some instances, virus in these samples was UVinactivated using a Stratagene Stratalinker 1800 with two sessions at 500 mJ.
Coverslips were prepared for microscopy as follows. Coverslips were permeabilized for
10 min at room temperature (RT, ~23°C) with 0.2% Triton-X in PBST (PBS + 0.1% Tween20),
washed with PBST, stained with DAPI (100 µg/mL in PBST) for 10 min at RT, washed with
PBST, mounted onto a glass slide using ProLong Gold (Invitrogen), and allowed to cure
protected from light at RT overnight. Coverslips were imaged using a Nikon Spinning Disk
Confocal Microscope, maintained at the Washington University Center for Cellular Imaging
(WUCCI). For illustration purposes, cells were imaged at 4x or 10x with a single capture using
the DAPI and RFP channels. For quantification purposes, four random locations were selected
on each coverslip, and a 4x4 stitched image of 16 adjacent 4x images (15% overlap) was
produced from each location. Image files were processed and automatically quantified for cell
number and tdTomato+ cell count using ImageJ. The nuclei or cells were automatically
quantified using the Quantify Particles function, with the size being a minimum of 500 pixels2.
The DAPI+ nucleus count represents the total number of cells per field, and the RFP+ cell count
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represents the total number of tdTomato+ cells per field. The % of tdTomato+ cells was
calculated by dividing the total number of tdTomato+ cells per field by the total number of cells
per field for each image.

2.5.6 Viral Burden Studies in Animals
Four-week old C57BL/6 mice sedated with ketamine were injected subcutaneously with
106 plaque-forming units (PFU) of virus diluted in 10-30 µL of CD1 without P/S into the left
(ipsilateral) footpad, between the second and third digits. Swelling of the infected foot was
monitored daily using digital calipers, by measuring both height and width. For infectious virus
and viral RNA samples, mice were sedated and sacrificed with ketamine at the indicated time
point, blood samples were taken by cutting of the inferior vena cava or abdominal aorta, and 510 mL PBS was perfused into heart. Various tissues (spleen, ipsilateral and contralateral ankles
with toes removed and skin included, and ipsilateral quadriceps muscles) were harvested into
homogenization bead tubes and stored at -80°C. For infectious virus samples, the bead tubes
contained 600 µL PBS, were weighed prior to and after addition of tissue sample, and were
stored on ice until transferred to -80°C; infectious virus titer was determined by plaque assay.
For viral RNA samples, the bead tubes contained no PBS and were snap frozen in liquid
nitrogen before being transferred to -80°C; viral RNA levels were determined using RT-qPCR,
as described below. Alternatively, viral RNA levels could be measured from infectious virus
samples by isolating RNA from tissue homogenates after 25 µL was removed for a plaque
assay. Blood samples were allowed to coagulate at RT, samples were spun down at 9,000 g for
5-10 minutes, and serum was removed into a fresh tube and stored at -80°C.
For Mxra8 mAb studies, tdTomato reporter mice were infected with CHIKV-3ʹ-Cre as
described above. The mice were injected intraperitoneally with 250 ug of Armenian hamster
isotype control (Bio X Cell # BE0260) or Armenian hamster anti-Mxra-8 mAbs diluted in PBS
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[38] (125 ug each of 1G11.E6 and 7F1.D8) at 12 hours prior to infection and at 4, 8, 12, 16, 20,
and 24 dpi. Samples were harvested for RNA or histology as described above. RT-qPCR
analysis, frozen section slides and quantification, and immunofluorescence was performed as
described herein.

2.5.7 Quantitative Real-Time PCR
RNA was isolated from Trizol-tissue homogenates using the standard Trziol-chloroform
extraction protocol and or an RNAeasy mini-prep kit (Qiagen). Isolated RNA was resuspended
in UltraPure H2O (Ambion) and stored at 4°C overnight or -80°C for long-term storage. Viral
standards were produced by producing RNA from the infectious clone plasmids as described
above. The copy number of the standard was determined by quantifying the sample and
calculating the copy number using the known ssRNA genome length. A 1:10 dilution series of
the standard was prepared ranging from ~101 copies to ~109 copies. RT-qPCR was performed
on a Bio-Rad CFX machine using the TaqMan™ RNA-to-CT™ 1-Step Kit (Applied
BiosystemsTM) with a 25 µL total reaction volume per well, 2 uL of RNA sample, and the
indicated amount of Taqman primers and probe from Integrated DNA Technologies: E1 FW (5ʹTCG ACG CGC CCT CTT TAA -3ʹ), E1 probe (5ʹ- /56-FAM/ ACC AGC CTG/ ZEN/ CAC CCA
TTC CTC AGA C/ 3IABkFQ/ -3ʹ), E1 RV (5ʹ- ATC GAA TGC ACC GCA CAC T -3ʹ), nsP1 FW
(5ʹ- AAA GGG CAA ACT CAG CTT CAC -3ʹ), nsP1 probe (5ʹ-/ 56-FAM/ CGC TGT GAT/ ZEN/
ACA GTG GTT TCG TGT G/ 3IABkFQ/ -3ʹ), and nsP1 RV (5ʹ- GCC TGG GCT CAT CGT TAT
TC -3ʹ). To quantify the Cre copy number, pre-made Enterobacteria phage P1 cyclization
recombinase FAM Taqman copy number primers/probe were used (ThermoFischer
Mr00635245_cn), and 1.25 µL of the 20x working stock was used per 25 µL reaction. The
following PCR cycling protocol was used: 30 minutes at 48°, 10 min at 95°, and 40 cycles of 15
sec at 95° and 1 min at 60°C. RNA copy number was determined for each sample using the
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matching RNA standard, and the copy number was normalized to the total µg of RNA for each
sample (determined by NanoDrop).

2.5.8 Histology Studies
Four-week old tdTomato mice were infected as described above. For histology samples,
mice were sedated with ketamine and sacrificed at the indicated time point, and 5-10 mL 4% PFA
was perfused into heart. Various tissues (spleen, ipsilateral and contralateral feet/ankles) were
harvested and fixed in 4% PFA. After 48 h of immersion fixation, tissues were washed with PBS
and transferred to BSL2 facilities for further processing. Tissues containing bone (e.g., whole
foot/ankle samples) were decalcified in 14% acid-free EDTA (VWR) for 14 days. For frozen
section processing, decalcified tissues and soft tissues (e.g., spleen) were equilibrated overnight
in 30% sucrose in PBS and then frozen in optimal cutting temperature (OCT) compound (Tissue
Tek). Samples were then cut with a cryostat at 10 µm for spleens or 30 µm for foot/ankle samples
onto SuperFrost Plus slides (Fisher). Slides were stored at -20°C until further processing.
Frozen section slides were prepared for microscopy by fixing with cold acetone,
permeabilizing with 0.2% Triton-X in PBST, washing with PBST, and mounting with a No. 1-1/2
glass coverslip (VWR) using Vectashield containing DAPI (Vector Laboratories H-1200). Slides
were imaged using a Nikon Spinning Disk Confocal Microscope, maintained at the WUCCI. Whole
tiled images of the foot and ankle were prepared using the 4x objective and the DAPI, GFP, and
RFP channels using large-image capture and 15% overlap. Alternatively, frozen section slides
were processed and imaged using immunofluorescence, as described below.
Image files were processed using ImageJ. The total number or tissue-specific number of
tdTomato+ cells was quantified by eye using manual cell counters in ImageJ or Photoshop;
counters were blinded to sample identity. The total area of each foot/ankle or tissue was measured
using ImageJ, and each count of total tdTomato+ cells was normalized to respective area.
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Tissues were prepared as described above. For paraffin section processing, decalcified
tissues were dehydrated using washes of 30% ethanol (EtOH), 50% EtOH, and 70% EtOH.
Samples were submitted to the Musculoskeletal Research Center for paraffin embedding,
sectioning, and H&E staining. Histopathologic examination and analysis was performed by a
pathologist blinded to intervention groups. The presence of acute and/or chronic inflammation
within the skeletal muscle, synovial tissues, and joint space was noted. The overall severity of
inflammation was scored as follows: 0 for none, 1 for mild, 2 for moderate, and 3 for severe.
Representative images were taken using the Zeiss Axio Imager Z2 Fluorescence Microscope with
ApoTome 2, managed at the WUCCI.

2.5.9 Immunofluorescence
To process for immunofluorescence, frozen section slides were first fixed with cold
acetone. If indicated for the specific antibody, the samples underwent antigen retrieval using
antigen unmasking solution (H3300; Vector Laboratories), which was incubated overnight in a
60°C water bath, protected from light. Samples were then permeabilized with 0.2% Triton-X in
PBST (PBS + 0.1% Tween 20) and then washed with PBST. Samples were blocked for 1-2 h with
TSA blocking reagent (Perkin Elmer FP1012). Samples were then incubated overnight at 4°C in
primary antibody diluted 1:100 in 3% normal goat serum (NGS, Equitech-Bio, Inc.) and 3% bovine
serum albumin (BSA, Sigma) in PBST. After two washes with PBST, samples were incubated for
1-2 h at RT in secondary antibody diluted 1:500 in 1% BSA PBST. Samples were washed once
with PBST, stained with DAPI (100 µg/mL in PBST) for 10 min at RT, washed once with PBST,
and a glass coverslip was mounted with ProLong Gold and slides were allowed to cure protected
from light at RT overnight. Slides were imaged using a Nikon Spinning Disk Confocal Microscope
or a Nikon A1Rsi Confocal Microscope, both maintained at the WUCCI. For illustration purposes,
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cells were imaged at 20x or 100x with a single capture using the DAPI, GFP, RFP, and or AF647
channels.
The following primary antibodies were used for these studies with antigen retrieval: antivimentin (Abcam, clone EPR3776); anti-beta III tubulin (Abcam, clone EP1569Y); anti-CD45
(Abcam, polyclonal ab10558); anti-CD44 (Abcam, clone EPR18668); anti-CD29 (eBioscience,
clone KMI6). The following antibodies did not require antigen retrieval: anti-CD31 (BD
Biosciences, clone MEC 13.3); anti-SAA (Abcam, clone EA-53); anti-105 (eBioscience, clone
MJ7/18).

2.5.10 RNA In-Situ Hybridization
Paraffin sections were processed using the provided RNAscope reagents and protocols
from Advanced Cell Diagnostics. Slides were first prepared as directed for indicated in formalinfixed paraffin-embedded (FFPE) sample (ACD Document Number 322452). The prepared
samples were then exposed to RNAscope® Probe- V-CHIKV-sp (ACD) or negative control probe
(ACD). The probed samples were then detected following the RNAscope® 2.5 HD Detection
Reagent – BROWN protocol (ACD Document Number 322310), with the only modification being
that slides were washed via pipetting the wash buffer onto the slides instead of submerging the
slides into wash buffer. Representative images were taken using the Zeiss Axio Imager Z2
Fluorescence Microscope with ApoTome 2, managed at the WUCCI.

2.5.11 Statistical Analysis
All data were analyzed using the Prism software, version 7 (GraphPad), as detailed in the
figure captions. The following statistical tests were used: unpaired t test, Mann-Whitney test,
ordinary one-way analysis of variance (ANOVA), ordinary two-way ANOVA, and two-way
repeated-measures ANOVA. The following post-tests for multiple comparisons were also used:
Bonferroni’s post-test, Dunnett’s post-test, Tukey’s post-test, and Sidak’s post-test. All error bars
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indicate standard error of the mean (SEM); if error bars are not visible, then they are shorter than
the height of the symbol. Asterisks indicate statistical significance, with only relevant comparisons
shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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2.6 Figures

Figure 2.1: CHIKV-3ʹ-Cre marks reporter cells in vitro and productively infects muscle
cells and fibroblasts
(A) Schematic of CHIKV-3ʹ-Cre and tdTomato reporter mouse system. (B-C) tdTomato MEFs
were analyzed 2 days after mock infection or infection at an MOI of 10 with CHIKV-WT or CHIKV3ʹ-Cre. (B) Representative images of CHIKV-WT or CHIKV-3ʹ-Cre. Blue shows DAPI staining, and
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red is tdTomato; scale bar represents 250 µm. (C) The percentage of total DAPI+ cells that were
tdTomato+ was quantified by confocal microscopy for tdTomato MEFs that were mock-infected
(mock) or infected at an MOI of 10 with CHIKV-WT (WT), CHIKV-3ʹ-Cre (3ʹ-Cre), CHIKV-3ʹ-Cre
pretreated with ~100 U IFN-b (3ʹ-Cre + IFN-B), CHIKV-3ʹ-Cre cell debris (3ʹ-Cre CD), or CHIKV3ʹ-Cre cell debris that was UV-inactivated (3ʹ-Cre CD + UV) as described in the Methods Section
2.5.5. (D) Growth curves of C2C12 myoblasts or (E) BL/6 MEFs infected with CHIKV-WT (green
circles) or CHIKV-3ʹ-Cre (red triangles) at an MOI of 1. Data for each condition in C were pooled
from 2-3 independent experiments; data in C were statistically analyzed with an ordinary one-way
ANOVA with Tukey’s post-test. Each curve in D and E represents 8 total replicates pooled from
2 independent experiments at each time point; data were then log-transformed and statistically
analyzed with a two-way ANOVA using Sidak's post-test. All error bars indicate mean with
standard error of the mean (SEM); if error bars are not visible, then they are shorter than the
height of the symbol. Asterisks indicate statistical significance, with only relevant comparisons
shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 2.2: CHIKV-3ʹ-Cre retains its pathogenic properties to induce acute arthritis
(A) Swelling curves from the ipsilateral feet of mice infected with 106 PFU of CHIKV-WT (green
circles) or 106 PFU of CHIKV-3ʹ-Cre (red triangles). Data were pooled from two independent
experiments with n=10 for each virus. (B) Levels of infectious virus in the ipsilateral ankle during
acute infection as measured by plaque assay, normalized to gram of tissue. Each time point for
each virus represents 5-7 mice and were pooled from at least 2 independent experiments. (C-D)
Mice were mock-infected (mock, blue diamonds) or infected with 106 PFU CHIKV-WT (WT, green
circles) or 106 PFU CHIKV-3ʹ-Cre (3ʹ-Cre, red triangles), and ipsilateral ankles were taken for H&E
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histology at 7 dpi. (C) Ankles were scored for overall histological damage. (D) Representative
images of the skin, muscle, and synovium. The skin and associated tissue is divided (from left to
right) into muscle (M), hypodermis (H), dermis (D), and epidermis (E). The muscle sections are
divided into tendon (T) and muscle (M). The synovium sections show synovium (S) and bone (B),
with asterisks indicating synovial inflammation and arrows indicating immune infiltrates into the
synovial cavity. Samples were pooled from two independent experiments with five mice for each
condition. The dashed line for B represents limit of detection, and data in B were log-transformed
prior to analysis. Data in A were statistically analyzed with a two-way repeated measures (RM)
ANOVA with Bonferroni’s post-test. Data in B were statistically analyzed with an ordinary two-way
ANOVA with Bonferroni’s post-test. Data in C were statistically analyzed with an ordinary oneway ANOVA with Tukey’s post-test. Scale bars in D represent 100 µm. All error bars indicate
SEM. Asterisks indicate statistical significance, with only relevant comparisons shown (*, P < 0.05;
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 2.3: CHIKV-3ʹ-Cre retains its pathogenic properties to induce chronic disease
(A-B) Mice were mock-infected (mock, blue diamonds) or inoculated with 106 PFU CHIKV-WT
(WT, green circles) or 106 PFU CHIKV-3ʹ-Cre (3ʹ-Cre, red triangles), and ipsilateral ankles were
taken for H&E histology at 28 dpi. (A) Representative images of the skin, muscle, and
synovium. The skin and associated tissue is divided (from left to right) into muscle (M),
hypodermis (H), dermis (D), and epidermis (E). The muscle sections are divided into muscle (M)
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and tendon (T), with black ovals around focal patches of cellular filtrates. The synovium sections
show synovium (S) and bone (B), with asterisks indicating synovial inflammation and
proliferation. (B) Ankles were scored for overall histological damage. Samples were pooled from
two independent experiments with five mice for each condition. (C-D) The ipsilateral ankles of
mice were subjected to RT-qPCR to measure viral E1 RNA copy number, normalized to total µg
of RNA isolated for each sample. (C) Mice were mock-infected (mock) or inoculated with 106
CHIKV-WT (WT), 106 CHIKV-3ʹ-Cre (3ʹ Cre) or UV-inactivated dose of 106 CHIKV-3ʹ-Cre (UV 3ʹCre), and viral E1 RNA levels in the ipsilateral ankles were assayed at 28 dpi. Data were pooled
from at least 2 independent experiments. (D) Viral E1 RNA levels were measured in the
ipsilateral ankles of mice infected with 106 PFU of CHIKV-WT (green circles) or 106 PFU of
CHIKV-3ʹ-Cre (red triangles) at time points ranging from 0 to 112 dpi. (E) The ratio of viral E1
RNA to viral nsP1 RNA in the same samples as D. For D-E, each time point for each virus
represents 5-20 mice and was pooled from at least 2 independent experiments. The dashed line
for C and D represents limit of detection; for E, the dotted line represents an E1: nsP1 ratio of 1.
Data in C and D were log-transformed prior to analysis. Data in B and C were each statistically
analyzed with an ordinary one-way ANOVA using Tukey’s post-test, with only relevant
comparisons shown. Data in D and E were statistically analyzed with an ordinary two-way
ANOVA using Bonferroni’s post-test. All error bars indicate SEM. Asterisks indicate statistical
significance, with only relevant comparisons shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001;
****, P < 0.0001).
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Figure 2.4: Cells are marked by CHIKV-3ʹ-Cre at chronic time points
tdTomato mice were mock-infected (mock, blue circles) or inoculated with 106 PFU CHIKV-WT
(WT, green circles), 106 PFU CHIKV-3ʹ-Cre (3ʹ-Cre, red triangles), or UV-inactivated 106 PFU
CHIKV-3ʹ-Cre (UV 3ʹ-Cre, open red triangles), and ipsilateral ankles were taken for frozen
sections at 28 dpi. (A) A representative image of a whole ankle and foot 28 dpi with CHIKV-3ʹCre. Blue shows DAPI staining, and red is tdTomato; scale bar represents 1000 µm. Higher
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magnification inset images of skin and muscle from mice infected with CHIKV-3ʹ-Cre. Scale bars
represent 100 µm; the skin is divided into dermis (D) and epidermis (E). (B) The total number of
tdTomato+ cells from was quantified at 28 dpi and normalized to ankle area as described in the
Methods Section 2.5.8. (C) Time course of tdTomato mice infected with 3ʹ-Cre from 1 to 112 dpi.
Data from B and C were pooled from at least two independent experiments. B was statistically
analyzed with an ordinary one-way ANOVA using Sidak’s post-test. All error bars indicate SEM.
Asterisks indicate statistical significance, with only relevant comparisons shown (*, P < 0.05; **,
P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 2.5: Immunofluorescence profiling of tdTomato+ cells in the skin and muscle
tdTomato mice were infected with 106 PFU CHIKV-3ʹ-Cre (3ʹ-Cre), and ipsilateral ankles/feet were
taken for frozen sections at 28 dpi. (A) Frozen sections were stained for SAA+ myofibers,
vimentin+ fibroblasts, CD44+ fibroblasts, or CD29+ fibroblasts, with the corresponding isotype
control shown below each co-stain. (B) Frozen sections were stained for CD31+ endothelium,
CD45+ hematopoietic cells, or SMA+ smooth muscle cells, with the corresponding isotype control
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shown below each co-stain. Blue shows DAPI staining, red is tdTomato, and green is the indicated
co-staining marker; scale bars represent 10 or 50 µm. Images are representative of 2-3
experiments with 3-5 mice reviewed for each co-stain.
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Figure 2.6: Mice treated with anti-Mxra8 antibodies exhibit reduced levels of chronic viral
RNA and a reduced number of persistent tdTomato+ cells
tdTomato mice were infected with 106 PFU CHIKV-3ʹ-Cre and treated with anti-Mxra8 mAbs (antiMxra8; red squares) or an isotype control (isotype; green circles). (A) At 28 dpi, mice were
harvested for quantification of CHIKV E1 RNA in the ipsilateral ankle; data represent three
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independent experiments. (B-F) Ipsilateral ankles/feet were harvested for histological analysis at
28 dpi; data represent two independent experiments. (B) Total number of tdTomato+ cells in
ipsilateral ankles/feet. (C) Representative images of ipsilateral feet/ankles, with higher
magnifications of dotted squares inset to the right. Blue shows DAPI staining, and red is tdTomato;
scale bars represent 100 or 500 µm as indicated. (D-F) tdTomato+ cells were quantified by
morphology and co-staining as described in the Methods Section 2.5.9: (D) CD29+ muscle and
skin cells, and (E) SAA+ myofibers. (F) Percentage distribution of cell types for each treatment.
Data in A were normalized to total µg of RNA isolated for each sample and then log-transformed.
Data in A were analyzed with a Mann-Whitney test. Data in B and E were statistically analyzed
with an un-paired t test. Data in D and F were statistically analyzed with a two-way ANOVA using
Sidak’s post-test. All error bars indicate SEM. Asterisks indicate statistical significance, with only
relevant comparisons shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

64

Figure S2.1: CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre mark reporter cells in vitro and grow
productively in muscle cells and fibroblasts
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(A) Genome maps of the three CHIKV clones were used in these studies: CHIKV-WT, CHIKV-3ʹCre, and CHIKV-5ʹ-Cre. (B) tdTomato MEFs plated in 96-well plates (2.5*104 cells/well) were
infected with CHIKV-5ʹ-Cre (purple inverted triangles) or CHIKV-3ʹ-Cre (red triangles) at an MOI
of 0.1, 1.0, or 3.0. (C) tdTomato MEFs plated in 96-well plates (2.5*104 cells/well) and were mockinfected (mock) or infected at an MOI of 3.0 with CHIKV-WT (WT), CHIKV-5ʹ-Cre (5ʹ Cre), CHIKV5ʹ-Cre pretreated with ~100 U IFN-b (5ʹ Cre + IFN-B), CHIKV-5ʹ-Cre cell debris (5ʹ Cre CD), or
CHIKV-5ʹ-Cre cell debris that was UV-inactivated (5ʹ-Cre CD + UV). (D) Growth curves of C2C12
myoblasts or (E) C57BL/6 MEFs infected with CHIKV-WT (green circles), CHIKV-5ʹ-Cre (purple
inverted triangles), or CHIKV-3ʹ-Cre (red triangles) at an MOI of 0.05. The number of tdTomato+
cells per well in B and C were quantified at 2 dpi by eye using a fluorescent microscope. Data in
B were analyzed with a two-way ANOVA using Sidak's post-test. Data in C were statistically
analyzed with an ordinary one-way ANOVA using Sidak’s post-test. Data in D and E were logtransformed and statistically analyzed with a two-way ANOVA using Dunnett’s post-test. All error
bars indicate SEM. Asterisks indicate statistical significance, with only relevant comparisons
shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure S2.2: CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre replicate similarly to CHIKV-WT in a mouse
model, with attenuation in sites of dissemination
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(A) Swelling curves from the ipsilateral footpads of mice infected with 106 PFU of CHIKV-WT
(open green circles; also shown in Figure 2.2A) or 106 PFU of CHIKV-5ʹ-Cre (purple). Data were
pooled from two independent experiments with n=10 for each virus. (B-F) Levels of infectious
virus in mice infected with 106 PFU of CHIKV-WT (solid green circles; or open green circles in
S2B also shown in Figure 2.2B), 106 PFU of CHIKV-5ʹ-Cre (purple inverted triangles), or 106 PFU
of CHIKV-3ʹ-Cre (red triangles) in (B) ipsilateral ankle, (C) serum, (D) ipsilateral quadriceps
muscle, (E) the contralateral ankle, or (F) spleen. For B-F, each time point for each virus and
organ represents 5-7 mice and were pooled from at least 2 independent experiments. Infectious
levels during acute infection was measured by plaque assay, normalized to gram of tissue, and
then log-transformed. The dashed line for B-F represents limit of detection for the plaque assay.
Data in B-F were log-transformed prior to analysis. Data in A were statistically analyzed with a
two-way repeated measures (RM) ANOVA with Bonferroni’s post-test, and data in B-F were
statistically analyzed with an ordinary two-way ANOVA. Sidak's post-test was used for A, and B;
Dunnett's post-test comparing WT as the control column was used for C-F. All error bars indicate
SEM. Asterisks indicate statistical significance, with only relevant comparisons shown (*, P < 0.05;
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure S2.3: CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre retain their pathogenic properties to induce
acute arthritis
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(A) Mice were mock infected or infected with 106 PFU CHIKV-WT (WT) or 106 PFU CHIKV-3ʹ-Cre
(3ʹ-Cre), and ipsilateral ankles were taken for CHIKV ISH at 2 dpi. Paraffin sections were stained
with a probe for E1 CHIKV-LR RNA. Representative images are shown of the skin, muscle, and
synovium. Scale bars represent 100 µm. Represents two independent experiments with 6 mice
per virus and 2 mock-infected mice. (B-C) Mice were mock-infected (mock, blue diamonds) or
infected with 106 PFU CHIKV-WT (WT, green circles) or 106 PFU CHIKV-5ʹ-Cre (5ʹ-Cre, purple
inverted triangles), and ipsilateral ankles were taken for H&E histology at 7 dpi. (B)
Representative images are shown of the skin, muscle, and synovium from CHIKV-5ʹ-Cre samples;
scale bar represents 100 µm. The skin and associated tissue is divided (from left to right) into
muscle (M), hypodermis (H), dermis (D), and epidermis (E). The muscle section is divided into
tendon (T) and muscle (M). The synovium section shows synovium (S) and bone (B), with
asterisks indicating synovial inflammation and arrows indicating immune infiltrates into the
synovial cavity. (C) Ankles from B were scored for overall histological damage, compared to
mock-infected and CHIKV-WT-infected samples. Open symbols for mock and WT indicate that
these data are also shown in the corresponding Figure 2.2C graph. Samples were pooled from
two independent experiments. Data in C were statistically analyzed with a one-way ANOVA with
Tukey's post-test. All error bars indicate SEM. Asterisks indicate statistical significance, with only
relevant comparisons shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure S2.4: CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre retain their pathogenic properties to induce
chronic disease
(A-B) Mice were mock-infected (mock, blue diamonds) or infected with 106 PFU CHIKV-WT (WT,
green circles) or 106 PFU CHIKV-5ʹ-Cre (5ʹ-Cre, purple inverted triangles), and ipsilateral ankles
were taken for H&E histology at 28 dpi. (A) Representative images are shown of the skin, muscle,
and synovium from CHIKV-5ʹ-Cre samples; scale bar represents 100 µm. The skin and associated
tissue is divided (from left to right) into muscle (M), hypodermis (H), dermis (D), and epidermis
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(E). The muscle section is divided into muscle (M) and tendon (T), with black ovals around focal
patches of cellular filtrates. The synovium section shows synovium (S) and bone (B), with
asterisks indicating synovial inflammation and proliferation. (B) Ankles from A were scored for
overall histological damage, compared to mock-infected and CHIKV-WT-infected samples. Open
symbols for mock and WT indicate that these data are also shown in the corresponding Figure
2.3B graph. (C-E) The ipsilateral ankles of mice were subjected to RT-qPCR to measure viral E1,
nsp1, or Cre RNA copy number, normalized to total µg of RNA isolated for each sample and then
log-transformed. (C) Viral E1 RNA levels were measured in the ipsilateral ankles of mice infected
with 106 PFU of CHIKV-WT (open green circles, also shown in Figure 2.3D) or 106 PFU of CHIKV5ʹ-Cre (purple inverted triangles) at time points ranging from 0 to 112 dpi. (D) The ratio of viral E1
RNA to viral nsP1 RNA in the same samples as C (open green circles, also shown in Figure 2.3E).
(E) The ratio of viral Cre RNA to viral nsP1 RNA in mice infected with 106 PFU of CHIKV-5ʹ-Cre
(purple inverted triangles) or 106 PFU of CHIKV-3ʹ-Cre (red triangles). Data in B were statistically
analyzed with a one-way ANOVA with Tukey's post-test. For C-E, each time point for each virus
represents 4-20 mice and was pooled from at least 2 independent experiments. The dashed line
in C represents the limit of detection for the RT-qPCR assay; for D and E, the dotted line
represents a ratio of 1. Data in C were normalized to total µg of RNA isolated for each sample
and then log-transformed. Data in C-E were statistically analyzed with a two-way ANOVA with
Sidak’s post-test. All error bars indicate SEM. Asterisks indicate statistical significance, with only
relevant comparisons shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure S2.5: Cells are marked by CHIKV-5ʹ-Cre or CHIKV-3ʹ-Cre at chronic time points.
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(A) C57BL/6 or (B) tdTomato mice were infected with 106 PFU CHIKV-WT (WT, green circles),
CHIKV-5ʹ-Cre (5ʹ-Cre, purple inverted triangles), or 106 PFU CHIKV-3ʹ-Cre (3ʹ-Cre, red triangles).
Ipsilateral ankles were taken for frozen sections at 28 dpi, and the total number of tdTomato+ cells
was quantified. Open green circles for WT and open red triangles for 3ʹ-Cre indicate that these
data are also shown in the corresponding Figure 2.4B graph. (C) Representative image of a whole
foot/ankle from 5ʹ-Cre at 28 dpi. Blue shows DAPI staining, and red is tdTomato; scale bar
represents 1000 µm. (D) Time course of dtTomato mice infected with CHIKV-5ʹ-Cre (purpled
inverted triangles) or CHIKV-3ʹ-Cre (open red triangles, also shown in Figure 2.4C) from 1 to 112
dpi. Each time point for each virus represents 6-20 mice. (E) Representative images of connective
tissues in the ipsilateral ankle of a mouse infected with CHIKV-3ʹ-Cre. Blue shows DAPI staining,
and red is tdTomato; scale bar represents 1000 µm. In higher magnification inset images scale
bars represent 100 µm; (A) is adipose tissue, (T) is tendon, (B) is bone, (M) is muscle, and (S) is
synovium. Data from A, B and D were pooled from at least two independent experiments. Data
in A and B were statistically analyzed with an ordinary one-way ANOVA using Tukey’s post-test.
Data in D were statistically analyzed with two-way ANOVA using Sidak’s post-est. All error bars
indicate SEM. Asterisks indicate statistical significance, with only relevant comparisons shown (*,
P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure S2.6: Immunofluorescence profiling of tdTomato+ cells in the skin
tdTomato mice were infected with 106 PFU CHIKV-3ʹ-Cre, and ipsilateral ankles were taken for
frozen sections at 28 dpi. Frozen sections were stained for beta III tubulin (nerve fibers) and
CD105 (fibroblasts and endothelial cells), with the corresponding isotype control shown below
each co-stain. Blue shows DAPI staining, red is tdTomato, and green is the indicated co-staining
marker; scale bars represent 10 or 50 µm as indicated.
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Chapter 3:
Modulations of the CHIKV-Cre System
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3.1 Introduction
CHIKV is an arthritogenic alphavirus that causes both acute and chronic musculoskeletal
disease. In Chapter 2, we introduced a CHIKV-Cre reporter mouse system to study the chronic
pathogenesis of CHIKV (Figure 2.1A). We engineered two versions of CHIKV that express Cre
recombinase: CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre (Figure S2.1A). In the process of optimizing this
reporter system, we experimented with varying the viral dose. We ultimately settled on a 106 PFU
dose of CHIKV- 3ʹ-Cre for our detailed analysis of chronic CHIKV pathogenesis, as it exhibited
the highest number of tdTomato+ cells in the ipsilateral foot. However, we observed noticeable
effects on pathogenesis depending on dose.
Our experimentation with varying the dose of CHIKV-Cre was initially driven by published
optimization experiments with other viruses that express Cre. Increasing the dose (ranging from
101 to 105 PFU) of WT Influenza A (IAV) or IAV-Cre correlated with accelerated weight loss and
increased mortality in mice [139]. Similarly, in a paper including a Herpes Simplex Virus 1 (HSV1) expressing Cre, increasing the dose of WT HSV-1 from 103 to 106 PFU corresponded with an
increase in the number of animals infected [140].
Several studies have previously disclosed effects of modulating infection in various
models of CHIKV infection. In vitro cell culture assays have consistently displayed that an
increased CHIKV MOI is associated with increased viral titers in cells including fibroblasts,
macrophages, and HeLa cells [42,58,59,66]. Our data from Chapter 2 with C2C12s or MEFs
infected at a low (0.05) and high MOI (1.0) exhibit a similar trend (Figures 2.1D-E, S2.1D-E). We
have also seen similar results with primary osteoblasts (data not shown).
Varying the CHIKV inoculation dose has also been explored in vivo. In a non-human
primate CHIKV model, macaques were infected with 101 to 108 PFU CHIKV [56]. Increasing the
CHIKV dosage corresponded with an earlier day of peak viremia and a higher maximum viral
RNA load in the serum. Increased CHIKV doses also correlated with more and worsening
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symptoms that closely mimicked human disease, including fever, rash, joint effusion, and edema,
and at the highest dose meningoencephalitis and death [56].
Several published mouse CHIKV models have modulated infection variables with varying
results. Immunocompromised (IFNAR-/- or STAT1-/-) mice exhibited earlier mortality when
inoculated with 106 PFU of CHIKV compared to 102 PFU [58]. In WT mice, it was reported that
mice had to be infected with a dose higher than 1.5x107 PFU of the CHIKV 181/25 vaccine strain
in order to achieve dissemination to distal sites; however, a more detailed analysis of how dose
affected pathogenesis was not disclosed [163]. While not explicitly testing dosage, in a neonatal
mouse model of infection, increasing the age of infection from 6 to 9 to 12-day-old pups decreased
mortality; this effect was associated with type I Interferon expression [124]. The effect of dosage
on pathogenesis in the adult arthritis model of CHIKV infection does not appear to have been
explicitly explored.

3.2 Results
3.2.1 Increasing the dose of CHIKV accelerates acute disease and
clearance in the ipsilateral foot
We first examined the effect of CHIKV dose on swelling in the ipsilateral foot. C57BL/6
mice were inoculated with 102, 104, or 106 PFU of CHIKV-WT, CHIKV-5ʹ-Cre, or CHIKV-3ʹ-Cre
and monitored for ipsilateral foot swelling. The 106 PFU dose of CHIKV-WT exhibited increased
swelling at 1 and 2 dpi, but it exhibited the lowest swelling peaks at 3 and 7 dpi. Strikingly, the 102
PFU dose of CHIKV-WT exhibited the highest swelling peaks at 3 and 7 dpi and took the longest
to resolve swelling (Figure 3.1A). Similar results were seen with varying doses of CHIKV-5ʹ-Cre,
although with lower overall swelling for the 102 PFU dose compared to CHIKV-WT (Figure 3.1B).
With CHIKV-3ʹ-Cre swelling, the first peak of swelling from 1 to 3 dpi was absent, as we have
seen previously. For the second swelling peak for CHIKV-3ʹ-Cre, the 106 PFU dose peaked at 5
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and 6 dpi, the 104 PFU dose peaked at 7 dpi, and the 102 PFU dose peaked at 8 dpi (Figure
3.1C).
We next examined the effect of CHIKV dose on infectious viral titers in the ipsilateral ankle.
C57BL/6 mice were inoculated with 102, 104, or 106 PFU of CHIKV-WT, CHIKV-5ʹ-Cre, or CHIKV3ʹ-Cre, and the ipsilateral ankle was harvested at 1, 3, 5, and 7 dpi for viral quantification by plaque
assay. For all three CHIKV viruses, increasing the viral dose corresponded with an increase in
viral titers at 1 dpi (Figure 3.2A-C). At 3 and 5 dpi, the viral titers were not statistically different
for CHIKV-WT or CHIKV-5ʹ-Cre; however, the 106 PFU dose of CHIKV-3ʹ-Cre was significantly
decreased at 5 dpi compared to the other doses. Intriguingly, increasing the viral dose
corresponded with a decrease in viral titers at 7 dpi for all three viruses.
These acute data thus suggest that increasing the viral dose initially increased swelling
and infectious virus in the ipsilateral foot, but increasing the dose also corresponded with
accelerated clearance of infectious virus.

3.2.2 Increasing the dose of CHIKV-WT increases dissemination and
accelerates clearance at acute time points
We next sought to determine how viral dose affected dissemination outside of the
ipsilateral foot and ankle. C57BL/6 mice were inoculated with 102, 104, or 106 PFU of CHIKV-WT,
CHIKV-5ʹ-Cre, or CHIKV-3ʹ-Cre. Serum, the ipsilateral quadriceps muscle, the contralateral ankle,
and the spleen were harvested at 1, 3, 5, and 7 dpi for viral quantification by plaque assay. At 1
dpi, increasing the viral dose corresponded with an increase in viremia for all three viruses
(Figures 3.3A-C). A similar trend of higher doses correlating with higher viral titers was seen with
infectious CHIKV-WT levels in the ipsilateral quad at 1 dpi (Figure 3.3D), the contralateral ankle
at 1 and 3 dpi (Figure 3.3G), and the spleen at 1 dpi (Figure 3.3J). After 3 dpi, the reverse was
true, and the 102 PFU dose of CHIKV-WT exhibited the highest levels of virus in the serum at 3

79

dpi (Figure 3.3A), in the ipsilateral quad at 3 dpi (Figure 3.3D), the contralateral ankle at 7 dpi
(Figure 3.3G), and the spleen at 5 dpi (Figure 3.3J).
These trends were not as evident for disseminated tissues in mice infected with CHIKV5ʹ-Cre or CHIKV-3ʹ-Cre (Figures 3.3B-C, 3.3E-F, 3.3H-I, 3.3K-L). Overall, dissemination of the
CHIKV-Cre viruses was attenuated compared to CHIKV-WT (see Figures S2.2C-F for direct
comparisons of disseminated viral titers for the 106 PFU dose of the three CHIKV viruses).
Ultimately, increasing the dose of CHIKV-WT did increase early dissemination and clearance, but
increasing the dose of the CHIKV-Cre viruses had less of a pronounced effect on dissemination.

3.2.3 Increasing the dose of CHIKV decreases chronic disease in the
ipsilateral foot
We next sought to examine the effect of viral dose on chronic disease. C57BL/6 mice or
tdTomato reporter mice were infected in the footpad with 102, 104, or 106 PFU of CHIKV-WT,
CHIKV-5ʹ-Cre, or CHIKV-3ʹ-Cre. The ipsilateral ankles were harvested for viral RNA or histological
analysis at 28 dpi. Increasing the dose of CHIKV-WT corresponded with a decrease in persistent
viral RNA levels (Figure 3.4A), and a similar result was seen with CHIKV-5ʹ-Cre (Figure 3.4B).
However, increasing the dose of CHIKV-5ʹ-Cre did not have a significant impact on the number
of tdTomato+ cells in the ipsilateral foot (Figure 3.4C). For CHIKV-3ʹ-Cre, increasing the viral dose
had no significant effect on persistent viral RNA levels (Figure 3.4D) or the number of tdTomato+
cells in the ipsilateral foot (Figure 3.4E). While increasing the dose of CHIKV-WT or CHIKV-5ʹCre corresponded with a decrease in level of persistent viral RNA, these results did not extend to
the number of tdTomato+ cells.

3.2.4 Increasing the dose of CHIKV-Cre has no effect on the number of
tdTomato+ cells at dissemination sites
Since an increased dose of CHIKV-5ʹ-Cre or CHIKV-3ʹ-Cre was associated with increased
early viremia and dissemination to the ipsilateral quad (Figure 3.3B-C, 3.3E-F), we next sought
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to determine if increasing the CHIKV-Cre dose would increase the number of tdTomato+ cells at
sites of dissemination. tdTomato reporter mice were infected in the footpad with 102, 104, or 106
PFU of CHIKV-5ʹ-Cre or CHIKV-3ʹ-Cre, and the contralateral ankle and spleen were harvested
for histological analysis at 28 dpi. Increasing the dose had no significant impact on the number of
tdTomato+ cells in the contralateral ankle or spleen for either virus (Figure 3.5A-B). The majority
of samples had less than 10 tdTomato+ cells per tissue section, which is much lower compared
to the hundreds to thousands of tdTomato+ cells observed in the ipsilateral ankle (Figures 3.4C,
3.4E). A handful of samples exhibited ~50-500 tdTomato+ cells per section; however, this
occurrence was rare and did not appear to exhibit any trends towards dose, virus, or tissue type.

3.3 Discussion
Overall, our preliminary data demonstrate that modulating the dosage of the CHIKV
inoculum can have a significant impact on viral pathogenesis. Increasing the dose of CHIKV (WT,
5ʹ-Cre, and 3ʹ-Cre) was associated with an earlier peak of swelling and infectious titers in the
ipsilateral ankle. Alterations in the swelling curves, especially the second swelling peak, could be
due to alterations in the quantity or quality of cells infiltrating the tissue. Early dissemination was
also increased at higher doses of CHIKV-WT. This initial early replication at higher doses was
also associated with earlier resolution of swelling and faster clearance of infectious virus in the
ipsilateral ankle and distal sites. This accelerated clearance phenotype could explain why levels
of persistent viral RNA tended to be lower in the ipsilateral ankle with increasing initial inoculum.
These results do not necessarily contradict previous studies showing increased CHIKV
dosage correlates with increased pathogenesis in macaques [56]. The mouse system exhibits
fewer observable symptoms than macaques; rash, fever, and death does not occur in WT mice
at the doses used in our studies. Acute and chronic histological damage was not analyzed by
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H&E sections, so it is possible that higher doses exhibit increased acute and or chronic tissue
damage to correlate with increased early swelling and infectious viral titers.
We hypothesize that this increased early replication and accelerated clearance phenotype
at higher virus inoculum is associated with a more vigorous innate immune reaction. A higher
initial dose leads to increased early replication, as has been demonstrated with in vitro cell culture.
Furthermore, a higher MOI is also associated with higher expression of IFN-β, as shown in MEFs,
human foreskin fibroblast (HFF), and lung fibroblast immortalized cell lines [58]. Our preliminary
data in vivo also confirm that increasing the CHIKV inoculum corresponds with an increase in
IFN-β RNA expression at 1 dpi (data not shown). Increased viremia has also been associated
with increased levels of IFN-α in patient sera [58,125]. We predict that such increased expression
of type I IFNs leads to an advanced immune response leading to accelerated clearance of virus
at a higher initial inoculum. In order to further explore this hypothesis, a closer examination of the
immune response is warranted in our system using varying viral doses. For instance, it would be
critical to measure the expression of additional innate immune factors such as ISGs, cytokines,
and chemokines as well as to analyze the numbers and types of immune cells that infiltrate into
the ipsilateral ankle.
A similar hypothesis relating increased early replication, accelerated immune response,
and advanced clearance has been proposed for other viruses, including adenovirus, infectious
bronchitis virus, IAV, and human parainfluenza virus (HPIV) [164–166]. Optimization of the
inoculum dose is of especial importance for vaccines. For instance, a higher initial vaccine
inoculum generally leads to more robust stimulation of the immune system but might worsen side
effects and permit for lower coverage of the population in the event of vaccine shortages.
This association between CHIKV inoculum and replication kinetics could have interesting
implications for human CHIKV disease. Previous studies using human serum samples have
demonstrated an association between increased likelihood of chronic CHIKV with elevated acute
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viremia levels [54,89].

It has also been shown that feeding A. albopictus mosquitos with

increasing amounts of CHIKV resulted in increased dissemination to the salivary glands [167].
Furthermore, the minimum infectious dose from a blood meal of a viremic individual was
estimated to ranges from approximately 104 to 105 PFU/mL for chikungunya virus in A. aegypti
and A. albopictus mosquitoes [168]. However, what remains unknown is how the initial inoculum
dosage from a mosquito correlates with viremia and thus acute and chronic disease in humans.
Based on our results, it could be possible that mosquitos that inject a lower amount of
virus in humans could correlate with prolonged viremia, delayed clearance, and more severe
chronic disease. Such a trend if demonstrated could even be an evolutionary adaptation for
arboviruses overall; perhaps mosquitos only need to transmit a low dose of virus in order to cause
a high enough level of viremia in humans to enable transmission to a new vector. While still
speculative, our results should at least caution researchers that increasing the dose of a virus
such as CHIKV does not always correlate with increased chronic disease and highlights the
complex interplay between host and virus.
Overall, these data highlight the significant impact that viral inoculum can have on the
pathogenesis of CHIKV in mice. For Chapter 2, we decided that a high dose of CHIKV-3ʹ-Cre was
optimal for study of tdTomato+ cells in the ipsilateral ankle. However, using a lower dose of
CHIKV-WT could be optimal for other studies of chronic CHIKV pathogenesis where maximizing
the levels of persistent viral RNA is desired. Whether such results also apply to humans remains
to be seen, though in practice it would be difficult to determine without being able to measure the
exact dose of mosquito bites.
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3.4 Materials and Methods
3.4.1 Viruses
The following viruses were used in these studies: CHIKV-WT, CHIKV-5ʹ-Cre, and CHIKV3ʹ-Cre. Viruses were cloned and produced as described in Section 2.5.1.

3.4.2 Mice
The following strains of mice were obtained from the Jackson Laboratory: C57BL/6 (JAX
Stock No: 000664; C57BL/6J) and tdTomato reporter mice (JAX Stock No: 007914; B6.CgGt(ROSA)26Sortm14(CAG-tdTomato)Hze/J). Mice were maintained as described in Section 2.5.2.

3.4.3 Viral Burden Studies in Animals
Four-week old C57BL/6 mice were inoculated with 102, 104, or 106 PFU of virus. Virus
dilutions were made using a two-step 1:100 dilution series. Viral burden studies were completed
as described in Section 2.5.6.

3.4.4 Quantitative Real-Time PCR
RNA was isolated from tissues E1 and nsP1 levels quantified as described in Section
2.5.7.

3.4.5 Histology Studies
Four-week old tdTomato mice were infected and frozen section histology samples
harvested as described in Section 2.5.8.

3.4.6 Statistical Analysis
All data were analyzed using the Prism software, version 7 (GraphPad), as detailed in the
figure captions. The following statistical tests were used: ordinary one-way analysis of variance
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(ANOVA), ordinary two-way ANOVA, and two-way repeated-measures ANOVA, all with Tukey’s
post-test as a multiple comparisons test. All error bars indicate standard error of the mean (SEM);
if error bars are not visible, then they are shorter than the height of the symbol. Asterisks indicate
statistical significance, with only relevant comparisons shown (*, P < 0.05; **, P < 0.01; ***, P <
0.001; ****, P < 0.0001).
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3.5 Figures

Figure 3.1: Ipsilateral foot swelling at varying CHIKV doses
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C57BL/6 mice were infected in the footpad with 102, 104, or 106 PFU of (A) CHIKV-WT (WT, green
circles), (B) CHIKV-5ʹ-Cre (5ʹ-Cre, purple inverted triangles), or (C) CHIKV-3ʹ-Cre (3ʹ-Cre, red
triangles), and ipsilateral foot swelling was measured. Data are representative of two independent
experiments and represent 3-8 mice per virus and dose. Data were analyzed with a two-way
repeated measures ANOVA with Tukey’s post-test. Error bars indicating SEM. If error bars are
not visible, then they are shorter than the height of the data symbol. The following symbols
indicate statistical significance, with asterisks (*) indicating 102 vs. 104, pound signs (#) indicating
102 vs. 106, and dagger signs (†) indicating 104 vs. 106 (*, #, †, P < 0.05; **, ##, ††, P < 0.01; ***, ###,
†††
, P < 0.001; ****, ####, ††††, P < 0.0001).
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Figure 3.2: Viral titers in the ipsilateral ankle at varying CHIKV doses
C57BL/6 mice were infected in the footpad with 102, 104, or 106 PFU of (A) CHIKV-WT (WT, green
circles), (B) CHIKV-5ʹ-Cre (5ʹ-Cre, purple inverted triangles), or (C) CHIKV-3ʹ-Cre (3ʹ-Cre, red
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triangles). The level of infectious virus in the ipsilateral foot and ankle during acute infection were
measured by plaque assay and normalized to gram of tissue. The data for the 106 PFU dose for
each virus was also shown in the corresponding graph in Figure 2.2B and Figure S2.2B. Each
time point for each virus represents 5-6 mice and were pooled from at least 2 independent
experiments. The dashed line represents limit of detection, and data were log-transformed prior
to analysis. Data were statistically analyzed with an ordinary two-way ANOVA with Tukey’s posttest. All error bars indicate SEM. Asterisks indicate statistical significance (*, P < 0.05; **, P <
0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 3.3: Viral titers in disseminated tissues at varying CHIKV doses
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C57BL/6 mice were infected in the footpad with 102, 104, or 106 PFU of (A, D, G, J) CHIKV-WT
(WT, green circles), (B, E, H, K) CHIKV-5ʹ-Cre (5ʹ-Cre, purple inverted triangles), or (C, F, I, L)
CHIKV-3ʹ-Cre (3ʹ-Cre, red triangles). The level of infectious virus in the serum (A-C), ipsilateral
quadriceps muscle (D-F), contralateral ankle (G-I), and spleen (J-L) during acute infection was
measured by plaque assay and normalized to gram of tissue. Each time point for each virus
represents 5-6 mice and were pooled from at least 2 independent experiments. The data for the
106 PFU dose for each virus and tissue was also shown in the corresponding graph in Figure
S2.2C-F. The dashed line represents limit of detection, and data were log-transformed prior to
analysis. Data were statistically analyzed with an ordinary two-way ANOVA with Tukey’s posttest. All error bars indicate SEM. Asterisks indicate statistical significance (*, P < 0.05; **, P <
0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 3.4: Viral RNA levels and tdTomato+ cells in the ipsilateral ankle at varying CHIKV
doses
C57BL/6 mice or tdTomato reporter mice were infected in the footpad with 102, 104, or 106 PFU
of (A) CHIKV-WT (WT, green circles), (B-C) CHIKV-5ʹ-Cre (5ʹ-Cre, purple inverted triangles), or
(D-E) CHIKV-3ʹ-Cre (3ʹ-Cre, red triangles). Ipsilateral feet and ankles were taken for CHIKV E1
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RNA analysis (A, B, D) or for tdTomato frozen section histological analysis (C, E) at 28 dpi. The
data for the 106 PFU dose for each virus was also shown in the corresponding graph in Figure
2.3C, Figure 2.4B, Figure S2.4C, and Figure S2.5B. The dashed line for A, B, and D represents
limit of detection, and data in A, B, and D were log-transformed prior to analysis. Data were
statistically analyzed with an ordinary one-way ANOVA using Tukey’s post-test. All error bars
indicate SEM. Asterisks indicate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001;
****, P < 0.0001).
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Figure 3.5: tdTomato+ cells in disseminated tissues at varying CHIKV-Cre doses
tdTomato reporter mice were infected in the footpad with 102, 104, or 106 PFU of CHIKV-5ʹ-Cre
(5ʹ-Cre, purple inverted triangles) or CHIKV-3ʹ-Cre (3ʹ-Cre, red triangles). (A) Contralateral
feet/ankles and (B) spleens were taken for tdTomato frozen section histological analysis at 28
dpi. Data were statistically analyzed with an ordinary one-way ANOVA with Tukey’s post-test. All
error bars indicate SEM.
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Chapter 4:
Summary and Future Directions
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4.1 Summary
CHIKV is an arthritogenic alphavirus that causes chronic joint and muscle pain of unknown
etiology in a significant subset of patients. In Chapter 2, we introduced a CHIKV-Cre reporter
mouse system to study the chronic pathogenesis of CHIKV. We showed that these CHIKV-Cre
viruses recapitulate many aspects of acute and chronic disease caused by CHIKV-WT. Using
tdTomato reporter mice, we also showed that the majority of tdTomato+ cells at chronic time points
were myofibers and fibroblasts, and that anti-Mxra8 treatment preferentially reduced the fibroblast
population. In Chapter 3, we experimented with varying doses for our CHIKV-Cre system. A
higher dose of CHIKV was associated with increased early replication and dissemination, but it
also correlated with earlier clearance of the virus and lower persistent RNA levels.
A more detailed analysis of the implications of these results can be found in the Discussion
Sections for Chapters 2 and 3 (Sections 2.4 and 3.3). What follows are some additional, more
speculative or preliminary interpretations of data from the CHIKV-Cre system. Also highlighted
are various future experiments and uses of the CHIKV-Cre system, ranging from single-cell
sequencing and electron microscopy to human studies and clinical applications.

4.1.1 Comparison of CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre
For our studies, we engineered two versions of CHIKV that express Cre recombinase:
CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre (Figure S2.1A). For our more detailed studies, we used CHIKV3ʹ-Cre rather than CHIKV-5ʹ-Cre, as certain aspects of CHIKV-3ʹ-Cre infection more closely
resembled CHIKV-WT infection than CHIKV-5ʹ-Cre. For example, whereas the CHIKV-3ʹ-Cre
E1:nsP1 curve was very similar to CHIKV-WT (Figure 2.3E), the CHIKV-5ʹ-Cre E1:nsP1 curve
was dramatically different during the first seven days of infection (Figure S2.4D). This difference
is likely due to the fact that in CHIKV-5ʹ-Cre the E1 gene is under the replicative influence of two
subgenomic promoters, while the internal genomic structure of CHIKV-3ʹ-Cre is identical to
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CHIKV-WT (Figure S2.1A). In CHIKV-3ʹ-Cre, the Cre gene is downstream of two subgenomic
promoters, which could explain why CHIKV-3ʹ-Cre infection resulted in a higher Cre to nsP1 ratio
compared to CHIKV-5ʹ-Cre (Figure S2.4E). This increased Cre expression could also explain why
CHIKV-3ʹ-Cre infection produced significantly more tdTomato+ cells than CHIKV-5ʹ-Cre in vitro
(Figure S2.1B) as well as in vivo (Figure S2.5B-D).
In addition to the CHIKV-5ʹ-Cre and CHIKV-3ʹ-Cre constructs, it could also be possible to
introduce Cre recombinase into another locus in the CHIKV genome, such as the nsP3 gene as
has been done for mCherry with minimal attenuation in vitro [137]. It is possible that a CHIKVnsP3-Cre virus would produce even less Cre recombinase without the influence of the
subgenomic promoter and be less sensitive in marking tdTomato cells. It is also possible that
CHIKV-nsP3-Cre would be more stable in terms of its expression and mark more cells than
CHIKV-3ʹ-Cre.

4.1.2 Time course kinetics of tdTomato+ cells
We conducted an extensive time course to examine the overall levels of tdTomato+ cells
in the ipsilateral foot from 1 to 112 dpi for both CHIKV-3ʹ-Cre (Figure 2.4C) and CHIKV-5ʹ-Cre
(Figure S2.5D). Intriguingly, substantial numbers of tdTomato+ cells are not apparent until 7-10
dpi; however, the peak of infectious titers in the ipsilateral ankle occurs at 1 dpi (Figures 2.2B,
S2.2B). Our preliminary in vitro infections with tdTomato MEFs have shown that it takes at most
18 hours for detectable levels of tdTomato protein to be produced following infection (data not
shown); however, we have not determined if this tdTomato expression time differs in vivo or in
different cell types. It is thus possible that the majority of cells infected during the early acute stage
of infection (1-5 dpi) lyse and do not persist as tdTomato+ cells. There are much lower levels of
infectious virus during the later stage of acute infection (5-10 dpi), but perhaps cells infected at
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this stage of infection persist as tdTomato+ cells. However, as discussed previously (Section 2.4),
our system does not enable us to determine when a tdTomato+ cell was infected.
After 7-10 dpi, the number of tdTomato+ cells remains relatively constant up to 112 dpi.
There are some variations in the mean number of tdTomato+ cells at chronic timepoints, such as
the gradual increase between 7 and 112 dpi. Indeed, some of the differences reached statistical
significance (Figure 4.1). Such differences could be due to a low number of samples at some
time points. However, such fluctuations could be due to the turnover of tdTomato+ cells or
potentially a low level of infectious virus.

4.1.3 CHIKV RNA copy number per tdTomato+ cell
In addition to a tdTomato+ cell time course, we also conducted a viral RNA time course
using the same time points (Figures 2.3D, S2.4C). Combining such data enables us to
preliminarily calculate the CHIKV RNA copy number per tdTomato+ cell for both CHIKV-5ʹ-Cre
and CHIKV-3ʹ-Cre (Figure 4.2). Interestingly, the RNA copy number per tdTomato+ cell was
higher for CHIKV-5ʹ-Cre compared to CHIKV-3ʹ-Cre; this trend is likely due to the fact that CHIKV5ʹ-Cre had slightly higher levels of viral RNA and significantly lower levels of tdTomato+ cells at
all time points.
From 1 to 10 dpi, both viruses exhibited a steep decrease in viral RNAs per tdTomato+
cell. CHIKV-5ʹ-Cre decreased from a high of 2.1 x 1011 RNAs/cell at 1 dpi to 8.9 x 103 RNAs/cell
at 10 dpi, a ~7.3 log10 decrease. Similarly, CHIKV-3ʹ-Cre decreased from a high of 1.4 x 1010
RNAs/cell at 1 dpi to 5.2 x 102 RNAs/cell at 10 dpi, a ~7.4 log10 decrease. This decrease could
correlate with the majority of infected cells dying, much of the virus being contained by the immune
response, and or a shift from active viral replication to little or no replication.
It is important to note that these calculations represent a mean of viral RNAs per
tdTomato+ cell. The viral RNA may not be evenly distributed between tdTomato+ cells, and some
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viral RNA may be present in tdTomato- cells. However, these results do highlight the possibility
that at chronic time points tdTomato+ cells likely harbor a low number of RNA copies, an average
of ~300 copies per cell from 28 to 112 dpi for CHIKV-3ʹ-Cre. Such a concentration is likely below
the detection limit of RNA ISH for formalin-fixed tissue samples and could explain why detection
of CHIKV RNA+ cells is so rare during chronic time points.

4.1.4 Cell type distribution of chronic tdTomato+ cell population
It is intriguing to consider why skeletal myofibers and fibroblasts are the predominant cell
type to survive acute CHIKV infection when so many cell types are known to be permissive to
CHIKV. Perhaps, myofibers and fibroblasts are the most permissive cell types to CHIKV
infection, as suggested by in vitro growth curves and at the histological level by our ISH staining
(Figure S2.3A); thus, even if similar percentages of all infected cell types die, many more
myofibers and fibroblasts survive infection since a high number were initially infected. Another
possibility is that these cells are somehow immune privileged and more resistant to
programmed cell death pathways normally triggered during an infection. Related to this
hypothesis is the idea that the virus or viral RNA may persist in a protected niche within these
cells but is still able to induce chronic inflammatory pathways. As described in in the next
section, single-cell RNA-seq and electron microscopy could help tease apart these possibilities.

4.2 Future Directions
Chapter 2 introduced our CHIKV-Cre reporter mouse system and its application to
studying chronic pathogenesis and anti-Mxra8 treatment. Many questions remain about chronic
CHIKV pathogenesis, such as the location and status of persistent viral RNA, and our system
could provide valuable insight. For example, single cell or nucleus RNA-seq could help determine
whether persistent viral RNA is concentrated in tdTomato+ cells, the nature of this persistent viral
RNA, and whether the host transcriptome of tdTomato+ cells is altered. Electron microscopy could
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help determine the subcellular location of persistent viral RNA within tdTomato+ cells. CHIKV-Cre
infection of Diphtheria toxin receptor (DTR) mice could allow for depletion of DTR+ cells and
exploration of how these cells contribute to chronic pathogenesis. Additional applications of our
CHIKV-Cre system include chronic experiments using tdTomato MEFs, alternative routes of virus
inoculation, applications to other genotypes and virus strains, and applications to clinical research.

4.2.1 Applications of the In Vivo Reporter System
Many questions remain about chronic CHIKV pathogenesis, such as the location and
status of persistent viral RNA, and our system could provide valuable insight. For instance, is
viral RNA in fact concentrated in tdTomato+ cells? What is the state of this persistent viral RNA?
Is it intact or mutated? Replicating or quiescent? Furthermore, is the transcriptome of tdTomato+
cells altered, and how do these marked cells contribute to chronic CHIKV pathogenesis?
Is viral RNA present in tdTomato+ cells?
Our work with anti-Mxra8 treatment showed a positive correlation between the levels of
chronic viral RNA and the number of tdTomato+ cells (Figure 2.6). However, further work is
needed to determine the exact location of the persistent viral RNA. Currently IFA and ISH are
not sensitive enough to consistently detect viral components in the tissues of WT mice at
chronic time points. In the Influenza system, tdTomato+ cells were sorted out of single cell lung
homogenates, allowing for identification of the cell type that was marked by the IAV-Cre virus
and transcriptional analysis of those cells [139]. A similar analysis in our system has proven to
be more difficult, especially for myofibers and muscle fibroblasts. We have attempted isolation
of tdTomato+ cells through flow cytometry or laser capture microdissection, but we have thus far
been unsuccessful.
Single cell RNA sequencing (RNA-seq) represents a powerful new tool that could help
determine whether viral RNA is present in tdTomato RNA+ cells, potentially acting as a dsRNA
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trigger for chronic inflammation. tdTomato+ fibroblasts could be detected through either singlecell or single-nucleus RNA-seq, but analysis of tdTomato+ myofibers would be limited to singlenucleus RNA-seq due to their large size and fragility [169–171]. Single-nucleus RNA-seq is a
less powerful tool in our system than single-cell RNA-seq as CHIKV RNA is likely present in the
cytoplasm and not the nucleus; thus, single-nucleus RNA-seq would be unable to characterize
CHIKV RNA outside the nucleus in tdTomato+ cells. Therefore, our analysis of single-cell RNAseq may be restricted to the dermal and muscle fibroblasts. Importantly, a BSL3 10x Genomics
machine will soon be available to use for single-cell or single-nucleus RNA-seq, thus avoiding
the need to fix samples.
Is the transcriptome of tdTomato+ cells altered?
If single-cell or single-nucleus RNA-seq is successful, it could help answer many questions
about chronic CHIKV pathogenesis, as was done previously for Influenza using IAV-Cre
[138,139]. Such results could help decipher how CHIKV infection manipulates the transcriptome
of individual infected cells. Previous studies have conducted whole tissue RNAseq or proteomic
analysis on CHIKV-infected tissues or cells, demonstrating an overall upregulation of
inflammatory markers [37,160,161]. Our system could demonstrate whether these inflammatory
markers are specifically upregulated in tdTomato+ cells, and thus whether CHIKV infection results
in a population of pathogenically altered cells. It is also possible that CHIKV infection induces
cellular or viral programs that could abort productive replication, potentially allowing the viral RNA
to persist long-term.
What is the state of the persistent viral RNA?
Sequencing of persistent CHIKV RNA has thus far only been reported in RAG1-/- mice,
which lack an adaptive immune response and fail to clear infectious virus from the serum, joints,
and other tissues. Two groups have deep sequenced viral RNA from RAG1-/- mouse serum, brain,
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and kidney samples at 28, 42, and 100 dpi. Sequence analyses revealed a complete genome
with relatively few and minor fixed mutations [117,151]; they did not indicate the presence of
negative strand genomes or an increased ratio of structural to non-structural gene transcription,
both of which would be indicative of active viral replication. Presumably, deep sequencing of
persistent viral RNA has not yet been reported in WT mice as the level in whole tissue
homogenates would be too low to detect. Assuming persistent viral RNA can be found in
tdTomato+ cells, single cell RNA-seq could offer increased sensitivity compared to whole tissue
sequencing and allow for characterization of the viral RNA in immunocompetent mice. Such data
could help reveal the replication status of the viral RNA through the presence of negative strands
or subgenomes, whether the entire viral genome persists, or the presence of any dominant
mutations.
In addition to single cell RNA-seq, our CHIKV-Cre system could also be applied to
sensitive microscopy techniques. In Chapter 2, we imaged tdTomato+ cells in ankle tissues using
high-power fluorescence microscopy (Figure 2.5). Attempts to co-stain for CHIKV antigen at
chronic time points were unsuccessful (data not shown), and we have not yet attempted to costain with antibody against dsRNA, which has proven useful for detecting other RNA viruses [172].
Higher magnification studies of tdTomato+ cells could be performed using transmission electron
microscopy (TEM). TEM has previously been used to detect CHIKV at acute time points [42], but
detection of viral particles at chronic time points has not been reported. Fluorescence of the
tdTomato protein would not be visible during TEM, but the protein could be labeled using antitdTomato immunogold antibodies. tdTomato+ cells from in vitro or in vivo samples could be
examined for the presence of viral particles or potentially co-stained with anti-CHIKV or antidsRNA antibodies with an alternatively-sized immunogold label. Using TEM, we could potentially
identify the specific subcellular localizations of the virus or viral RNA during chronic stages of the
infection, potentially explaining how it can persist for so long after infection.
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Do cells marked by CHIKV-Cre play a role in chronic pathogenesis?
In order to probe further into chronic CHIKV pathogenesis, we could use our CHIKV-Cre
viruses in Cre-responsive mice other than tdTomato reporter mice. For example, mice that
express the chimpanzee diphtheria toxin receptor (DTR, also called heparin binding EGF like
growth factor, HBEGF) upon Cre-induced removal of a stop cassette (JAX Stock No:007900
C57BL/6-Gt(ROSA) 26Sortm1(HBEGG)Awai/J) can be used to deplete DTR+ cells with diphtheria toxin
(DT) at a desired time point [173]. For example, DT could be administered after infectious virus
is cleared (10-14 dpi), and we could examine whether this depletion has an effect on a chronic
time point (28 dpi). For instance, depletion of DTR+ cells could result in a decrease in the level of
persistent viral RNA, a decrease in chronic myositis and synovitis, and an improvement in the
whole-tissue host transcriptome. Such results would indicate that cells marked by CHIKV-Cre
play a critical role in chronic CHIKV pathogenesis.
We have performed a variety of preliminary experiments involving DTR mice injected
with CHIKV-WT, CHIKV-3ʹ-Cre, or CHIKV-5ʹ-Cre and treated with DT. However, we were unable
to determine a virus dose or DT dosing schedule that resulted in a decrease in persistent viral
RNA levels (data not shown). We were unable to determine if CHIKV-3ʹ-Cre or CHIKV-5ʹ-Cre
infection caused an increase in DTR+ cells compared to CHIKV-WT, as we see in tdTomato
reporter mice. We unsuccessfully attempted IFA to co-stain for DTR protein and RT-qPCR to
detect DTR RNA (data not shown). It is possible that DTR+ cells were produced and that DT
injection did deplete them, but the persistent viral RNA levels did not correspondingly decrease.
In this case, it is possible that the DTR+ cells do not contain viral RNA. It is also possible that
viral RNA is released from the depleted DTR+ cells but then persists in the tissue or is taken up
by other cells. Another issue is that the chronic model currently in use is not robust histologically
(chronic inflammation is mild and not seen in every mouse), so it remains difficult to assess the
impact of DTR+ cells depletion on histopathology.
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Additional studies could also be performed with tdTomato reporter or DTR depletion mice
that express tdTomato or DTR under a tissue-specific promoter, as opposed to the constitutive
Rosa locus. For example, mesenchyme-specific or myofiber-specific promoters could be used to
determine the specific contribution of these cell types to chronic pathogenesis.

4.2.2 Applications of the In Vitro Reporter System
In Chapter 2, we showed that tdTomato+ MEFs can be detected 48 hpi with CHIKV-3ʹ-Cre
or CHIKV-5ʹ-Cre (Figures 2.1B-C, S2.1B-C). Of note, in preliminary experiments, tdTomato+
MEFs could be detected at 28 dpi after infection with CHIKV-5ʹ-Cre, a chronic time point (data not
shown). Fibroblasts represented a large subset of the tdTomato+ cell population, thus tdTomato
MEFs could be a viable in vitro system to begin to test our hypotheses about chronic
pathogenesis. A major question would be to determine if viral components (antigen or RNA) are
specifically enriched in tdTomato+ MEFs compared to tdTomato- MEFs. Assays such as IHC, IFA,
ISH, and RNA-seq could be more sensitive in an in vitro setting, without the high background that
is often found in animal tissue samples. Additional primary cells from tdTomato mice could also
be used such as synovial fibroblasts or myoblasts; however, some of these primary cells may be
unable to survive in culture for several weeks.

4.2.3 Alternative inoculation techniques
Our CHIKV-Cre viruses exhibited low levels of dissemination, as demonstrated by
attenuated viral titers and chronic tdTomato+ cells in the contralateral ankle and spleen (Figure
3.3, 3.5). We sought to determine whether using alternative sites for inoculation could increase
the number of tdTomato+ cells in disseminated tissues.
In a preliminary experiment, tdTomato reporter mice were inoculated normally
(subcutaneously in the footpad) or via intraperitoneal (IP), intravenous (IV), flank, or retro orbital
(RO) routes with 106 PFU of CHIKV-5ʹ-Cre (see Section 4.3.4 of the Methods for more details).
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The feet/ankles and spleen were harvested for histological analysis at 7 and 14 dpi. These
alternative inoculation sites did not increase dissemination to the joints, as few tdTomato+ cells
were observed in either ankle (data not shown). However, RO injection did correspond with an
increased number of tdTomato+ cells in the spleen, especially at 14 dpi (Figure 4.3A). It is unclear
why IV tail vein injections did not produce similar levels of tdTomato+ cells in the spleen to RO
injections since both involve direct injection of virus into the blood.
Such results with the RO route of infection are somewhat surprising. In a macaque model
of CHIKV infection, intravenous (IV) or intradermal (ID) infection did not appear to have a
significant effect on viremia, fever, or blood cell counts [56]; however, viral titers in disseminated
tissues were not explored. RO injection may be a better model of viremia than IV injection. It
would be interesting to see if acute viral titers and persistent viral RNA were correspondingly
increased in the spleen using RO inoculation. While RO injections could be helpful for study of
chronic pathogenesis in the spleen, it is likely not as applicable a model of infection to humans as
subcutaneous inoculation that mimics a mosquito bite.
In addition to the above mentioned alternative inoculation sites, we also experimented with
calf injections of virus. When tdTomato reporter mice were inoculated normally (subcutaneously
in the footpad), the tdTomato+ cells were concentrated in the foot and do not extend past the ankle
into the calf muscle (Figure 2.4A). However, the foot muscles can be difficult to micro-dissect, so
we sought to determine if tdTomato+ cells could be found in the calf muscles using an alternative
inoculation site. In a preliminary experiment, tdTomato reporter mice were inoculated
subcutaneously above the gastrocnemius muscle with 106 PFU of CHIKV-3ʹ-Cre, and the calf
muscles were dissected for histological analysis at 28 dpi. A plethora of tdTomato+ cells were
observed in the calf muscle (Figure 4.3B). It appears by morphological appearance that the
majority of tdTomato+ cells in the calf muscle were myofibers and few cells were fibroblasts;
however, this observation has not yet been confirmed by immunofluorescence analysis.
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Calf injections could be helpful for applications of the CHIKV-Cre system, such as RNAseq, that necessitate taking larger muscle samples than is possible with footpad infections or that
are sensitive to decalcification. However, the muscle population of tdTomato+ cells could be
different between subcutaneous footpad and calf injections, so future experimentation is
warranted.

4.2.4 Applications to Other Genotypes and Virus Strains
In Chapter 2, we used our CHIKV-3ʹ-Cre and tdTomato system to test how treatment with
anti-Mxra8 mAbs affected the number and type of tdTomato+ cells at a chronic time point (Figure
2.6). We have also conducted preliminary studies with other mAb treatments. In one preliminary
study we tested how CHIKV neutralizing antibodies (CHK-152, CHK-166) affected the abundance
of tdTomato+ cells [72,75]. When administered at 3 dpi, treatment with CHK-152 and CHK-166
did decrease the swelling in the ipsilateral foot at 6 dpi (Figure 4.3A). However, there was no
difference in the number of tdTomato+ cells in the ipsilateral or contralateral ankles at 28 dpi
between CHIKV-neutralizing antibody and the isotype control (Figure 4.3B). Such a result is not
entirely surprising as a similar treatment with CHK-152 and CHK-166 at 3 dpi using CHIKV-WT
and C57BL/6 mice did not affect the levels of persistent viral RNA in the ipsilateral ankle (data not
shown). It is possible that treatment with CHIKV neutralizing antibodies prior to infection would
both reduce the number of tdTomato+ cells and the level of persistent viral RNA at 28 dpi.
We have also conducted tests using mAbs against IFN-α or IFN-β [174,175]. Treatment
with a pan anti-IFN-α mAb increased both the number of tdTomato+ cells and the level of
persistent viral RNA in the contralateral ankle at 28 dpi compared to an anti-IFN-β mAb or isotype
control (data not shown). Efforts are underway with IFA co-staining to explore whether the
tdTomato+ cells in the contralateral ankles of anti-IFN-α treated mice show a different cellular
tropism than the tdTomato+ cells in the ipsilateral ankle. Taken together with the results of the
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anti-Mxra8 treatment, these results demonstrate a correlative relationship between the number of
tdTomato+ cells in a tissue and the level of persistent RNA, suggesting that some viral RNA is
indeed found within the tdTomato+ cells. Our system could be thus applied to other host genotypes
through mAb treatment. In the event that a mAb is not available against a specific target, tdTomato
reporter mice could be bred to a knockout mouse or other mouse genotype of interest (assuming
that the gene of interest is not on murine chromosome 6, the location of the tdTomato reporter).
In addition to studying different host genotypes, our system could also be applied to other
viral genotypes. CHIKV-Cre viruses could be constructed from other CHIKV strains or mutant
viruses to further dissect how the viral genetics contribute to tropism and chronic pathogenesis
[66]. For example, one study demonstrated that a virulent IOL CHIKV strain isolated in 2006 from
the La Réunion Island outbreak (LR2006-OPY1) can infiltrate and grow within skeletal muscle
fibers while a pre-epidemic strain cannot [57]. It would be intriguing to generate a Cre virus of the
pre-epidemic CHIKV strain to further explore the tropism differences between these two strains.

4.2.5 Implications for Clinical Studies
The detection of CHIKV antigen or RNA in patient samples from chronic time points has
previously been rare. One study reported detection of CHIKV RNA and antigen in the synovial
macrophages of one patient 18 months after infection [54]. Another study reported detection of
CHIKV antigen in a human quadriceps muscle specimen at least three months after acute
infection [61]. However, another study did not detect chronic CHIKV RNA in patient synovial fluid
[118]. Results from our CHIKV-Cre infections demonstrate that the majority of tdTomato+ cells are
not concentrated in the synovial tissues, but rather in the skeletal muscle and skin (Figure 2.4A).
Previous clinical studies may have thus been looking at suboptimal tissues, and our results could
provide strong enough evidence to collect more invasive tissue samples from chronic CHIKV
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patients, such as skin and muscle biopsies from areas near the chronic joint or muscle pain in
addition to synovial tissue samples.

4.3 Materials and Methods
4.3.1 Viruses
The following viruses were used in these studies: CHIKV-WT, CHIKV-5ʹ-Cre, and CHIKV3ʹ-Cre. Viruses were cloned and produced as described in Section 2.5.1.

4.3.2 Mice
The following strains of mice were obtained from the Jackson Laboratory: C57BL/6 (JAX
Stock No: 000664; C57BL/6J) and tdTomato reporter mice (JAX Stock No: 007914; B6.CgGt(ROSA)26Sortm14(CAG-tdTomato)Hze/J). Mice were maintained as described in Section 2.5.2.
For CHK neutralizing mAb studies, tdTomato reporter mice were infected with CHIKV-3ʹCre as described in Section 2.5.2. The mice were injected intraperitoneally with 500 ug of human
isotype control (WNV E16) or human anti-CHIKV E2 mAbs diluted in PBS [72,75] (250 ug each
of CHK-152 and CHK-166) at 3 dpi. Samples were harvested for histology and frozen section
slide processing and quantification was performed as described in Section 2.5.8.

4.3.3 Quantitative Real-Time PCR
RNA was isolated from tissues and RT-qPCR for CHIKV E1 was performed as described
in Section 2.5.7.

4.3.4 Histology Studies
Four-week old tdTomato mice were infected and histology samples harvested and
processed as described in Section 2.5.8. Alternative inoculation techniques were also used. Foot
pad injection refers to injecting virus subcutaneously into the left (ipsilateral) footpad, between the
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second and third digits. Intraperitoneal (IP) injection refers to injecting virus into the abdomen.
Intravenous (IV) injection refers to injecting virus into the tail vein. Flank injection refers to injecting
virus subcutaneously into skin on the dorsal left side of the mouse, near the relative position of
the spleen. Retroorbital injection refers to injecting virus into the retroorbital sinus, which is
superior and posterior to the eyeball, through the medial canthus. Calf injection refers to injecting
virus subcutaneously above the gastrocnemius muscle.

4.3.5 Calculation of CHIKV E1 copy number per tdTomato+ cell
The total amount of E1 RNA copies for each RT-qPCR sample was calculated by
multiplying each E1/μg (E1 RNA copies per μg of total RNA) value by the total μg of RNA (ng/μL
multiplied by the total μL for each sample divided by 1000). The total amount of tdTomato+ cells
for each histology sample was calculated by estimating the percentage that one 30 μm foot
section represents of the entire foot. A mouse foot is on average 2.8 mm wide horizontally
(averaged from swelling data), and sagittal sections are taken from the foot. Thus one 30 μm
section represents approximately 1/93.33 fraction of the foot, assuming that the foot is closer to
a rectangular prism than a cylinder. The number of tdTomato+ cells per normalized tissue
section was thus multiplied by 93.33 to roughly calculate the total number of tdTomato+ cells per
foot. The total number of E1 copies was then averaged for each time point and virus and then
divided by the average number of tdTomato+ cells for the corresponding time point and virus.
Data were then log-transformed prior to graphing.

4.3.6 Statistical analysis
All data were analyzed using the Prism software, version 7 (GraphPad), as detailed in
the figure captions. The following statistical tests were used: unpaired t test, ordinary one-way
analysis of variance (ANOVA), ordinary two-way ANOVA. The following post-tests for multiple
comparisons were also used: Tukey’s post-test and Sidak’s post-test. All error bars indicate
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standard error of the mean (SEM); if error bars are not visible, then they are shorter than the
height of the symbol. Asterisks indicate statistical significance, with only relevant comparisons
shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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4.4 Figures

Figure 4.1: tdTomato+ cells in the ipsilateral foot during chronic timepoints
tdTomato mice were infected with 106 PFU CHIKV-3ʹ-Cre (red triangles), and ipsilateral feet were
taken for frozen sections at 7-112 dpi. These data are also shown in Figures 2.4C and S2.5C.
The total number of tdTomato+ cells from was quantified for each section and normalized to ankle
area as described in the Methods Section 2.5.8. Data were pooled from at least two independent
experiments, and data were statistically analyzed with an ordinary one-way ANOVA using Tukey’s
post-test. All error bars indicate SEM. Asterisks indicate statistical significance (*, P < 0.05; **, P
< 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 5.2: CHIKV E1 RNA copies per tdTomato+ cells
Preliminary calculation of the number of CHIKV RNA copies per tdTomato+ cell, for 106 PFU
CHIKV-5ʹ-Cre (purple inverted triangles) or 106 PFU CHIKV-3ʹ-Cre (red triangles). C57/BL6 mice
were infected with 106 PFU CHIKV-5ʹ-Cre or 106 PFU CHIKV-3ʹ-Cre, and the ipsilateral ankles
were taken for RNA analysis at 1 to 112 dpi. The level of CHIKV E1 RNA was measured using
RT-qPCR (these data are also shown in Figures 2.3D, S2.4C). The total amount of RNA copies
per ankle was calculated (see the Methods Section 4.3.5). tdTomato mice were also infected with
106 PFU CHIKV-5ʹ-Cre or 106 PFU CHIKV-3ʹ-Cre, and the ipsilateral feet/ankles were taken for
frozen sections at 1-112 dpi (these data are also shown in Figures 2.4C and S2.5C). The total
number of tdTomato+ cells in each sample was calculated (see the Methods Section 4.3.5). The
mean total E1 copy number at each timepoint and virus was then divided by the mean total
tdTomato+ cells at each corresponding timepoint and virus to arrive at a preliminary calculation of
viral copies per tdTomato+ cell. Data were pooled from at least two independent experiments.
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Figure 6.3: Alternative inoculation sites for CHIKV-Cre
(A) tdTomato reporter mice were inoculated retro-orbitally with 106 PFU of CHIKV-5ʹ-Cre, and
spleens were taken for histological analysis at 14 dpi. A representative image from two
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independent experiments is shown, with blue showing DAPI staining and red showing tdTomato;
scale bar represents 100 µm. (B) tdTomato reporter mice were inoculated subcutaneously above
the calf muscle with 106 PFU of CHIKV-3ʹ-Cre, and the ipsilateral calf muscle was taken for
histological analysis at 28 dpi. A representative image from two independent experiments is
shown, with blue showing DAPI staining and red showing tdTomato; scale bar represents 250
µm.
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Figure 7.4: CHIKV neutralizing antibodies given at 3 dpi do not affect the number of
tdTomato+ cells
tdTomato mice were infected with 106 PFU CHIKV-3ʹ-Cre and treated with CHIKV neutralizing
mAbs (CHK-152 & CHK-166; red squares) or an isotype control (isotype; green circles) at 3 dpi.
(A) Ipsilateral foot swelling was measured at 6 dpi. (B) At 28 dpi, the ipsilateral and contralateral
ankles/feet were harvested for histological analysis, the total number of tdTomato+ cells in each
sample was quantified. Data in A were statistically analyzed with an un-paired t test. Data in B
were statistically analyzed with a two-way ANOVA using Sidak’s post-test. All error bars indicate
SEM.

115

References
1.

Robinson MC. An Epidemic of Virus Disease in Southern Province, Tanganyika Territory, in 195253, I. Clinical Features. Trans R Soc Trop Med Hyg. 1955;49(1):28–32.

2.

Lumsden WHR. An Epidemic of Virus Disease in Southern Province, Tanganyika Territory, in
1952-53, II. General Description and Epidemiology. Trans R Soc Trop Med Hyg. 1955;49(1):33–
57.

3.

Ross RW. The Newala Epidemic, III. The Virus: Isolation, Pathogenic Properties and Relationship
to the Epidemic. J Hyg. 1955;54(2):177–91.

4.

Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol
[Internet]. 2010 Jul [cited 2014 Jul 18];8(7):491–500. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20551973

5.

Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of chikungunya and o’nyong-nyong
viruses : evidence for distinct geographical lineages and distant evolutionary relationships. J Gen
Virol. 2000;81:471–9.

6.

Volk SM, Chen R, Tsetsarkin KA, Adams P, Garcia TI, Sall AA, et al. Genome-Scale Phylogenetic
Analyses of Chikungunya Virus Reveal Independent Emergences of Recent Epidemics and
Various Evolutionary Rates Genome-Scale Phylogenetic Analyses of Chikungunya Virus Reveal
Independent Emergences of Recent Epidemics and Various. J Virol. 2010;84(13):6497–504.

7.

Voss A, Ahmedabad I. Chikungunya epidemic in India: a major public-health disaster. Lancet
Infect Dis. 2007;7(May):306–7.

8.

Outbreak and Spread of Chikungunya. Wkly Epidemiol Rec. 2007;82(47):409–16.

9.

Pardigon N. The biology of chikungunya: a brief review of what we still do not know. Pathol Biol
(Paris) [Internet]. 2009 Mar [cited 2014 Nov 19];57(2):127–32. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18456435

10.

Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al. Seroprevalence of
Chikungunya Virus (CHIKV ) Infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg.
2008;78(October 2004):333–7.

11.

Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a reemerging infectious disease. Clin Infect Dis [Internet]. 2009 Sep 15 [cited 2014 Nov 10];49(6):942–
8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19663604

12.

Lemant J, Boisson V, Winer A, Thibault L, André H, Tixier F, et al. Serious acute chikungunya
virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit Care
Med [Internet]. 2008 Sep [cited 2014 Nov 19];36(9):2536–41. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18679124

13.

Ramful D, Carbonnier M, Pasquet M, Bouhmani B, Ghazouani J, Noormahomed T, et al. Motherto-child transmission of Chikungunya virus infection. Pediatr Infect Dis J [Internet]. 2007 Sep [cited
2014 Nov 20];26(9):811–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17721376

14.

Bodenmann P, Genton B. Chikungunya: an epidemic in real time. Lancet. 2006;368:2006.

15.

Aedes albopictus as an epidemic vector of chikungunya virus: another emerging problem ? Lancet

116

Infect Dis. 2006;6:463–4.
16.

Townson H, Nathan MB. Resurgence of chikungunya. Trans R Soc Trop Med Hyg [Internet]. 2008
Apr [cited 2014 Nov 18];102(4):308–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18178232

17.

Tsetsarkin K a, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus
affects vector specificity and epidemic potential. PLoS Pathog [Internet]. 2007 Dec [cited 2014 Jul
10];3(12):e201. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2134949&tool=pmcentrez&rendertype=
abstract

18.

Weaver SC. Arrival of chikungunya virus in the new world: prospects for spread and impact on
public health. PLoS Negl Trop Dis [Internet]. 2014 Jun [cited 2014 Jul 11];8(6):e2921. Available
from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4072586&tool=pmcentrez&rendertype=
abstract

19.

Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani K V. Increased Mortality Rate
Associated with Chikungunya Epidemic, Ahmedabad, India. Emerg Infect Dis. 2008;14(3):412–5.

20.

Bortel W Van, Dorleans F, Rosine J, Blateau A, Rousset D, Matheus S. Chikungunya outbreak in
the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro
Surveill. 2014;19(13).

21.

Chikungunya in the Americas [Internet]. CDC. Available from:
http://www.cdc.gov/chikungunya/geo/americas.html

22.

Nasci RS. Movement of chikungunya virus into the Western hemisphere. Emerg Infect Dis
[Internet]. 2014 Aug;20(8):1394–5. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4111178&tool=pmcentrez&rendertype=
abstract

23.

Halstead S. Chikungunya reappearance, formerly called dengue. Emerg Infect Dis.
2015;21(4):557–61.

24.

Miner JJ, Yeang HXA, Fox JM, Taffner S, Malkova ON, Oh ST, et al. Brief report: Chikungunya
viral arthritis in the United States: A mimic of seronegative rheumatoid arthritis. Arthritis
Rheumatol. 2015;67(5):1214–20.

25.

Centers for Disease Control and Prevention (CDC). Chikungunya virus in the United States
[Internet]. 2018. p. 1–4. Available from: https://www.cdc.gov/chikungunya/geo/united-states.html

26.

Siberia W, Onishi T. Transcontinental Movement of Asian Genotype Chikungunya Virus. Emerg
Infect Dis. 2014;20(8):1400–2.

27.

Lanciotti RS, Lambert AJ. Phylogenetic analysis of Chikungunya virus strains circulating in the
Western Hemisphere. Am J Trop Med Hyg. 2016;94(4):800–3.

28.

Solignat M, Gay B, Higgs S, Briant L, Devaux C. Replication cycle of chikungunya: a re-emerging
arbovirus. Virology [Internet]. 2009 Oct 25 [cited 2014 Nov 11];393(2):183–97. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2915564&tool=pmcentrez&rendertype=
abstract

29.

Assunção-Miranda I, Cruz-Oliveira C, Da Poian AT. Molecular mechanisms involved in the
pathogenesis of alphavirus-induced arthritis. Biomed Res Int [Internet]. 2013 Jan;2013:973516.

117

Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3771267&tool=pmcentrez&rendertype=
abstract
30.

Hyde JL, Chen R, Trobaugh DW, Diamond MS, Weaver SC, Klimstra WB, et al. The 5ʹ and 3ʹ
ends of alphavirus RNAs – non-coding is not non- functional. Virus Res. 2015;206:99–107.

31.

Chen R, Wang E, Tsetsarkin KA, Weaver SC. Chikungunya Virus 3′ Untranslated Region:
Adaptation to Mosquitoes and a Population Bottleneck as Major Evolutionary Forces. PLoS
Pathog. 2013;9(8).

32.

Morley VJ, Noval MG, Chen R, Weaver SC, Vignuzzi M, Stapleford KA, et al. Chikungunya virus
evolution following a large 3′UTR deletion results in host-specific molecular changes in proteincoding regions. Virus Evol [Internet]. 2018;4(1):1–12. Available from:
https://academic.oup.com/ve/article/doi/10.1093/ve/vey012/5032629

33.

Sreejith R, Rana J, Dudha N, Kumar K, Gabrani R, Sharma SK, et al. Mapping interactions of
Chikungunya virus nonstructural proteins. Virus Res [Internet]. 2012 Oct [cited 2014 Dec
2];169(1):231–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22951312

34.

Kumar S, Kumar A, Mamidi P, Tiwari A, Kumar S, Mayavannan A, et al. Chikungunya virus nsP1
interacts directly with nsP2 and modulates its ATPase activity. Sci Rep. 2018;8(1):1–14.

35.

Sharma R, Kesari P, Kumar P, Tomar S. Structure-function insights into chikungunya virus capsid
protein: Small molecules targeting capsid hydrophobic pocket. Virology [Internet].
2018;515(January):223–34. Available from: https://doi.org/10.1016/j.virol.2017.12.020

36.

Kuo S-C, Chen Y-J, Wang Y-M, Tsui P-Y, Kuo M-D, Wu T-Y, et al. Cell-based analysis of
Chikungunya virus E1 protein in membrane fusion. J Biomed Sci [Internet]. 2012 Jan [cited 2014
Aug 26];19(1):44. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3384457&tool=pmcentrez&rendertype=
abstract

37.

Wikan N, Khongwichit S, Phuklia W, Ubol S, Thonsakulprasert T, Thannagith M, et al.
Comprehensive proteomic analysis of white blood cells from chikungunya fever patients of
different severities. J Transl Med [Internet]. 2014 Jan [cited 2014 Sep 4];12(1):96. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4022080&tool=pmcentrez&rendertype=
abstract

38.

Zhang R, Kim AS, Fox JM, Nair S, Basore K, Klimstra WB, et al. Mxra8 is a receptor for multiple
arthritogenic alphaviruses. Nature [Internet]. 2018;1. Available from:
http://www.nature.com/articles/s41586-018-0121-3

39.

Metz SW, Geertsema C, Martina BE, Andrade P, Heldens JG, Van Oers MM, et al. Functional
processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells. Virol J
[Internet]. 2011;8(1):353. Available from: http://www.virologyj.com/content/8/1/353

40.

Silva LA, Dermody TS. Chikungunya virus: Epidemiology, replication, disease mechanisms, and
prospective intervention strategies. J Clin Invest. 2017;127(3):737–49.

41.

Melton J V., Ewart GD, Weir RC, Board PG, Lee E, Gage PW. Alphavirus 6K proteins form ion
channels. J Biol Chem. 2002;277(49):46923–31.

42.

Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, et al.
Characterization of reemerging chikungunya virus. PLoS Pathog [Internet]. 2007 Jun [cited 2014
May 25];3(6):e89. Available from:

118

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1904475&tool=pmcentrez&rendertype=
abstract
43.

Gay B, Bernard E, Solignat M, Chazal N, Devaux C, Briant L. pH-dependent entry of chikungunya
virus into Aedes albopictus cells. Infect Genet Evol [Internet]. 2012 Aug [cited 2014 Dec
2];12(6):1275–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22386853

44.

Bernard E, Solignat M, Gay B, Chazal N, Higgs S, Devaux C, et al. Endocytosis of chikungunya
virus into mammalian cells: role of clathrin and early endosomal compartments. PLoS One
[Internet]. 2010 Jan [cited 2014 Dec 2];5(7):e11479. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2900206&tool=pmcentrez&rendertype=
abstract

45.

Hoornweg TE, van Duijl-Richter MKS, Ayala Nuñez N V., Albulescu IC, van Hemert MJ, Smit JM.
Dynamics of Chikungunya Virus Cell Entry Unraveled by Single-Virus Tracking in Living Cells. J
Virol [Internet]. 2016;90(9):4745–56. Available from:
http://jvi.asm.org/lookup/doi/10.1128/JVI.03184-15

46.

Rupp JC, Sokoloski KJ, Gebhart NN, Hardy RW. Alphavirus RNA synthesis and non-structural
protein functions. J Gen Virol. 2015;96(9):2483–500.

47.

Firth AE, Chung BYW, Fleeton MN, Atkins JF. Discovery of frameshifting in Alphavirus 6K
resolves a 20-year enigma. Virol J. 2008;5:1–19.

48.

Snyder JE, Kulcsar KA, Schultz KLW, Riley CP, Neary JT, Marr S, et al. Functional
Characterization of the Alphavirus TF Protein. J Virol [Internet]. 2013;87(15):8511–23. Available
from: http://jvi.asm.org/cgi/doi/10.1128/JVI.00449-13

49.

Frolova EI, Gorchakov R, Pereboeva L, Atasheva S, Frolov I. Functional Sindbis Virus Replicative
Complexes Are Formed at the Plasma Membrane. J Virol [Internet]. 2010;84(22):11679–95.
Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.01441-10

50.

Soonsawad P, Xing L, Milla E, Espinoza JM, Kawano M, Marko M, et al. Structural Evidence of
Glycoprotein Assembly in Cellular Membrane Compartments prior to Alphavirus Budding. J Virol
[Internet]. 2010;84(21):11145–51. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.00036-10

51.

Alphavirus: Virion [Internet]. Viral Zone. 2010. Available from:
http://viralzone.expasy.org/all_by_species/625.html

52.

Dhanwani R, Khan M, Bhaskar a SB, Singh R, Patro IK, Rao PVL, et al. Characterization of
Chikungunya virus infection in human neuroblastoma SH-SY5Y cells: role of apoptosis in neuronal
cell death. Virus Res [Internet]. 2012 Feb [cited 2014 May 25];163(2):563–72. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22210004

53.

Schmid MA, Glasner DR, Shah S, Michlmayr D, Kramer LD, Harris E, et al. Mosquito Saliva
Increases Endothelial Permeability in the Skin, Immune Cell Migration, and Dengue Pathogenesis
during Antibody-Dependent Enhancement. PLOS Pathog [Internet]. 2016;12(6):e1005676.
Available from: http://dx.plos.org/10.1371/journal.ppat.1005676

54.

Hoarau J-J, Jaffar Bandjee M-C, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, et al.
Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a
robust host immune response. J Immunol [Internet]. 2010 May 15 [cited 2014 May
25];184(10):5914–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20404278

55.

Couderc T, Chrétien F, Schilte C, Disson O, Michault A, Albert ML, et al. Cell and tissue tropisms
of Chikungunya virus and its dissemination to the central nervous system. BMC Proc.

119

2008;2(Suppl 1):S7.
56.

Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, et al. Chikungunya disease
in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest.
2010;120(3):894–906.

57.

Rohatgi A, Corbo JC, Monte K, Higgs S, Vanlandingham DL, Kardon G, et al. Infection of
Myofibers Contributes to Increased Pathogenicity during Infection with an Epidemic Strain of
Chikungunya Virus. J Virol [Internet]. 2014 Mar [cited 2014 Mar 19];88(5):2414–25. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24335291

58.

Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, et al. Type I
IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med [Internet]. 2010
Feb 15 [cited 2014 May 25];207(2):429–42. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2822618&tool=pmcentrez&rendertype=
abstract

59.

Her Z, Malleret B, Chan M, Ong EKS, Wong S-C, Kwek DJC, et al. Active infection of human
blood monocytes by Chikungunya virus triggers an innate immune response. J Immunol [Internet].
2010 May 15 [cited 2014 May 25];184(10):5903–13. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20404274

60.

Kumar S, Jaffar-Bandjee M-C, Giry C, Connen de Kerillis L, Merits A, Gasque P, et al. Mouse
macrophage innate immune response to Chikungunya virus infection. Virol J [Internet]. 2012 Jan
[cited 2014 May 29];9(1):313. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3577478&tool=pmcentrez&rendertype=
abstract

61.

Ozden S, Huerre M, Riviere J-P, Coffey LL, Afonso P V, Mouly V, et al. Human muscle satellite
cells as targets of Chikungunya virus infection. PLoS One [Internet]. 2007 Jan [cited 2014 May
25];2(6):e527. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1885285&tool=pmcentrez&rendertype=
abstract

62.

Ng LFP, Chow A, Sun Y-J, Kwek DJC, Lim P-L, Dimatatac F, et al. IL-1beta, IL-6, and RANTES as
biomarkers of Chikungunya severity. PLoS One [Internet]. 2009 Jan [cited 2014 Aug
28];4(1):e4261. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2625438&tool=pmcentrez&rendertype=
abstract

63.

Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM. The acute phase of
Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell
activation. J Infect Dis [Internet]. 2011 Jul 1 [cited 2014 Nov 11];204(1):115–23. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3307152&tool=pmcentrez&rendertype=
abstract

64.

Morrison TE, Oko L, Montgomery S a, Whitmore AC, Lotstein AR, Gunn BM, et al. A mouse model
of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis,
tenosynovitis, myositis, and persistence. Am J Pathol [Internet]. 2011 Jan [cited 2014 May
29];178(1):32–40. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3069999&tool=pmcentrez&rendertype=
abstract

65.

Priya R, Patro IK, Parida MM. TLR3 mediated innate immune response in mice brain following
infection with Chikungunya virus. Virus Res [Internet]. 2014 Jun 4 [cited 2014 Aug 11];189C:194–
205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24905288

120

66.

Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, et al. Chikungunya virus arthritis in
adult wild-type mice. J Virol [Internet]. 2010 Aug [cited 2014 Dec 2];84(16):8021–32. Available
from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2916516&tool=pmcentrez&rendertype=
abstract

67.

Tharmarajah K, Mahalingam S, Zaid A. Chikungunya: vaccines and therapeutics. F1000Research
[Internet]. 2017;6(0):2114. Available from: https://f1000research.com/articles/6-2114/v1

68.

Delogu I, Pastorino B, Baronti C, Nougairède A, Bonnet E, de Lamballerie X. In vitro antiviral
activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant.
Antiviral Res [Internet]. 2011;90(3):99–107. Available from:
http://dx.doi.org/10.1016/j.antiviral.2011.03.182

69.

Briolant S, Garin D, Scaramozzino N, Jouan A, Crance JM. In vitro inhibition of Chikungunya and
Semliki Forest viruses replication by antiviral compounds: Synergistic effect of interferon-α and
ribavirin combination. Antiviral Res. 2004;61(2):111–7.

70.

Delang L, Guerrero NS, Tas A, Quérat G, Pastorino B, Froeyen M, et al. Mutations in the
chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broadspectrum antiviral. J Antimicrob Chemother. 2014;69(10):2770–84.

71.

Karlas A, Berre S, Couderc T, Varjak M, Braun P, Meyer M, et al. A human genome-wide loss-offunction screen identifies effective chikungunya antiviral drugs. Nat Commun. 2016;7(May).

72.

Scott A. Smith1, 5, 6, Laurie A. Silva2, 4, 6, Julie M. Fox7, Andrew Flyak3, Nurgun Kose5, Gopal
Sapparapu5, Solomiia Khomadiak2, 4, Alison W. Ashbrook2, 3, 4, Kristen M. Kahle5, Rachel H.
Fong5, Sherri Swayne5, Benjamin J. Doranz5, Charles E. McGee6, Mar A, Jr. JEC. Isolation and
characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity
against chikungunya virus. Cell Host Microbe. 2016;23(10):1780–9.

73.

Miner JJ, Cook LE, Hong JP, Smith AM, Richner JM, Shimak RM, et al. Therapy with CTLA4-Ig
and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci Transl Med.
2017;9(375):1–10.

74.

Broeckel R, Fox JM, Haese N, Kreklywich CN, Sukulpovi-petty S, Legasse A, et al. Therapeutic
administration of a recombinant human monoclonal antibody reduces the severity of chikungunya
virus disease in rhesus macaques. PLoS Negl Trop Dis [Internet]. 2017; Available from:
http://dx.doi.org/10.1371/journal.pntd.0005637

75.

Pal P, Dowd K a., Brien JD, Edeling M a., Gorlatov S, Johnson S, et al. Development of a Highly
Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus. PLoS Pathog.
2013;9(4).

76.

Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects
for a vaccine. Expert Rev Vaccines. 2013;11(9):1087–101.

77.

Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL, et al. Attenuation of
Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in
the E2 envelope glycoprotein. J Virol [Internet]. 2012 Jun [cited 2014 Dec 4];86(11):6084–96.
Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3372191&tool=pmcentrez&rendertype=
abstract

78.

Brandler S, Ruffié C, Combredet C, Brault JB, Najburg V, Prevost MC, et al. A recombinant
measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects

121

mice from lethal challenge with chikungunya virus. Vaccine [Internet]. 2013;31(36):3718–25.
Available from: http://dx.doi.org/10.1016/j.vaccine.2013.05.086
79.

Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, et al.
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MVCHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet
[Internet]. 2018;6736(18):1–10. Available from:
https://linkinghub.elsevier.com/retrieve/pii/S0140673618324887

80.

Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and
tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation
trial. Lancet [Internet]. 2014;384(9959):2046–52. Available from: http://dx.doi.org/10.1016/S01406736(14)61185-5

81.

Erasmus JH, Auguste AJ, Kaelber JT, Luo H, Shannan L, Fenton K, et al. A Chikungunya Fever
Vaccine Utilizing an Insect-Specific Virus Platform. Nat Med. 2017;23(2):192–9.

82.

Taylor A, Liu X, Zaid A, H Goh LY, Hobson-Peters J, Hall RA, et al. Mutation of the N-Terminal
Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design. 2017;8(1):1970–86.
Available from: http://mbio.asm.org/

83.

Mehta R, Gerardin P, de Brito CAA, Soares CN, Ferreira MLB, Solomon T. The neurological
complications of chikungunya virus: A systematic review. Rev Med Virol. 2018;28(3).

84.

Johnson BW, Russell BJ, Goodman CH. Laboratory Diagnosis of Chikungunya Virus Infections
and Commercial Sources for Diagnostic Assays. J Infect Dis. 2017;214(July 2015).

85.

Moro ML, Grilli E, Corvetta A, Silvi G, Angelini R, Mascella F, et al. Long-term chikungunya
infection clinical manifestations after an outbreak in Italy: A prognostic cohort study. J Infect
[Internet]. 2012;65(2):165–72. Available from: http://dx.doi.org/10.1016/j.jinf.2012.04.005

86.

Mathew AJ, Goyal V, George E, Thekkemuriyil D V., Jayakumar B, Chopra A. Rheumaticmusculoskeletal pain and disorders in a naïve group of individuals 15 months following a
Chikungunya viral epidemic in south India: A population based observational study. Int J Clin
Pract. 2011;65(12):1306–12.

87.

Rahim AA, Thekkekara RJ, Bina T, Paul BJ. Disability with persistent pain following an epidemic of
chikungunya in rural south India. J Rheumatol. 2016;43(2):440–4.

88.

Taubitz W, Cramer JP, Kapaun A, Pfeffer M, Drosten C, Dobler G, et al. Chikungunya Fever in
Travelers: Clinical Presentation and Course. Clin Infect Dis [Internet]. 2007;45(1):e1–4. Available
from: https://academic.oup.com/cid/article-lookup/doi/10.1086/518701

89.

Chow A, Her Z, Ong EKS, Chen J, Dimatatac F, Kwek DJC, et al. Persistent arthralgia induced by
Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colonystimulating factor. J Infect Dis. 2011;203(2):149–57.

90.

Ramachandran V, Kaur P, Kanagasabai K, Vadivoo S, Murhekar M. Persistent arthralgia among
Chikungunya patients and associated risk factors in Chennai, South India. J Postgrad Med.
2014;60(1):3–6.

91.

Rodríguez-Morales AJ, Calvache-Benavides CE, Giraldo-Gómez J, Hurtado-Hurtado N, YepesEcheverri MC, García-Loaiza CJ, et al. Post-chikungunya chronic arthralgia: Results from a
retrospective follow-up study of 131 cases in Tolima, Colombia. Travel Med Infect Dis.
2016;14(1):58–9.

122

92.

Yaseen HM, Simon F, Deparis X, Marimoutou C. Identification of initial severity determinants to
predict arthritis after chikungunya infection in a cohort of French gendarmes. BMC Musculoskelet
Disord. 2014;15(1):1–8.

93.

Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, et al. Persistent Arthralgia
Associated with Chikungunya Virus: A Study of 88 Adult Patients on Reunion Island. Clin Infect
Dis [Internet]. 2008;47(4):469–75. Available from: https://academic.oup.com/cid/articlelookup/doi/10.1086/590003

94.

Gérardin P, Fianu A, Malvy D, Mussard C, Boussaïd K, Rollot O, et al. Perceived morbidity and
community burden after a Chikungunya outbreak: the TELECHIK survey, a population-based
cohort study. BMC Med [Internet]. 2011;9(5). Available from: http://www.biomedcentral.com/17417015/9/5

95.

Gérardin P, Fianu A, Michault A, Mussard C, Boussaïd K, Rollot O, et al. Predictors of
Chikungunya rheumatism: A prognostic survey ancillary to the TELECHIK cohort study. Arthritis
Res Ther [Internet]. 2013;15(1):R9. Available from: http://arthritis-research.com/content/15/1/R9

96.

Paixão ES, Rodrigues LC, Costa M da CN, Itaparica M, Barreto F, Gérardin P, et al. Chikungunya
chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg [Internet].
2018;(July):1–16. Available from: https://academic.oup.com/trstmh/advancearticle/doi/10.1093/trstmh/try063/5051873

97.

van Aalst M, Nelen CM, Goorhuis A, Stijnis C, Grobusch MP. Long-term sequelae of chikungunya
virus disease: A systematic review. Travel Med Infect Dis. 2017;15:8–22.

98.

Marimoutou C, Vivier E, Oliver M, Boutin JP, Simon F. Morbidity and impaired quality of life 30
months after chikungunya infection: Comparative cohort of infected and uninfected french military
policemen in reunion island. Med (United States). 2012;91(4):212–9.

99.

Bouquillard É, Combe B. A report of 21 cases of rheumatoid arthritis following Chikungunya fever.
A mean follow-up of two years. Jt Bone Spine. 2009;76(6):654–7.

100.

Javelle E, Ribera A, Degasne I, Gaüzère BA, Marimoutou C, Simon F. Specific Management of
Post-Chikungunya Rheumatic Disorders: A Retrospective Study of 159 Cases in Reunion Island
from 2006-2012. PLoS Negl Trop Dis. 2015;9(3):1–18.

101.

Soumahoro MK, Gérardin P, Boëlle PY, Perrau J, Fianu A, Pouchot J, et al. Impact of
Chikungunya virus infection on health status and quality of life: A retrospective cohort study. PLoS
One. 2009;4(11):1–6.

102.

Schilte C, Staikowsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al. Chikungunya Virusassociated Long-term Arthralgia: A 36-month Prospective Longitudinal Study. PLoS Negl Trop Dis.
2013;7(3).

103.

Marimoutou C, Ferraro J, Javelle E, Deparis X, Simon F. Chikungunya infection: Self-reported
rheumatic morbidity and impaired quality of life persist 6 years later. Clin Microbiol Infect [Internet].
2015;21(7):688–93. Available from: http://dx.doi.org/10.1016/j.cmi.2015.02.024

104.

Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, et al. Chikungunya Infection:
An Emerging Rheumatism Among Travelers Returned From Indian Ocean Islands. Report of 47
Cases. Medicine (Baltimore) [Internet]. 2007;86(3):123–37. Available from:
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005792200705000-00001

105.

Ramachandran V, Malaisamy M, Ponnaiah M, Kaliaperuaml K, Vadivoo S, Gupte MD. Impact of

123

Chikungunya on Health Related Quality of Life Chennai, South India. PLoS One. 2012;7(12).
106.

Win MK, Chow A, Dimatatac F, Go CJ, Leo YS. Chikungunya fever in Singapore: Acute clinical
and laboratory features, and factors associated with persistent arthralgia. J Clin Virol.
2010;49(2):111–4.

107.

Huits R, De Kort J, Van Den Berg R, Chong L, Tsoumanis A, Eggermont K, et al. Chikungunya
virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic
polyarthralgia. PLoS One. 2018;13(4):1–21.

108.

Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al. Multidisciplinary
Prospective Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Reunion.
PLoS Med. 2008;5(3):413–23.

109.

Gérardin P, Sampériz S, Ramful D, Boumahni B, Bintner M, Alessandri JL, et al. Neurocognitive
Outcome of Children Exposed to Perinatal Mother-to-Child Chikungunya Virus Infection: The
CHIMERE Cohort Study on Reunion Island. PLoS Negl Trop Dis. 2014;8(7).

110.

Laoprasopwattana K, Suntharasaj T, Petmanee P, Suddeaugrai O, Geater A. Chikungunya and
dengue virus infections during pregnancy: Seroprevalence, seroincidence and maternal-fetal
transmission, southern Thailand, 2009-2010. Epidemiol Infect. 2016;144(2):381–8.

111.

Maek-a-nantawat W, Silachamroon U. Presence of Autoimmune Antibody in Chikungunya
Infection. Case Rep Med [Internet]. 2009;2009:1–4. Available from:
http://www.hindawi.com/journals/crim/2009/840183/

112.

Reddy V, Desai A, Krishna SS, Vasanthapuram R. Molecular Mimicry between Chikungunya Virus
and Host Components: A Possible Mechanism for the Arthritic Manifestations. PLoS Negl Trop
Dis. 2017;11(1):1–20.

113.

Goh LYH, Hobson-Peters J, Prow N a, Gardner J, Bielefeldt-Ohmann H, Suhrbier A, et al.
Monoclonal antibodies specific for the capsid protein of chikungunya virus suitable for multiple
applications. J Gen Virol [Internet]. 2014;(May):507–12. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25480927

114.

Her Z, Teng T, Tan JJL, Teo T, Kam Y, Lum F, et al. Loss of TLR3 aggravates CHIKV replication
and pathology due to an altered virus-specific neutralizing antibody response. EMBO Mol Med.
2015;7(1):24–41.

115.

Teo T-H, Lum F-M, Claser C, Lulla V, Lulla A, Merits A, et al. A pathogenic role for CD4+ T cells
during Chikungunya virus infection in mice. J Immunol [Internet]. 2013;190(1):259–69. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/23209328

116.

Teo TH, Lum FM, Ghaffar K, Chan YH, Amrun SN, Tan JJL, et al. Plasmodium co-infection
protects against chikungunya virus-induced pathologies. Nat Commun [Internet]. 2018;9(1).
Available from: http://dx.doi.org/10.1038/s41467-018-06227-9

117.

Poo YS, Rudd P a., Gardner J, Wilson J a C, Larcher T, Colle MA, et al. Multiple Immune Factors
Are Involved in Controlling Acute and Chronic Chikungunya Virus Infection. PLoS Negl Trop Dis.
2014;8(12).

118.

Chang AY, Martins KAO, Encinales L, Reid SP, Acuña M, Encinales C, et al. Chikungunya
Arthritis Mechanisms in the Americas: A Cross-Sectional Analysis of Chikungunya Arthritis
Patients Twenty-Two Months After Infection Demonstrating No Detectable Viral Persistence in
Synovial Fluid. Arthritis Rheumatol. 2018;70(4):585–93.

124

119.

Mccarthy MK, Morrison TE. Persistent RNA virus infections: Do PAMPS drive chronic disease ?
Curr Opin Virol [Internet]. 2017;23:8–15. Available from:
http://dx.doi.org/10.1016/j.coviro.2017.01.003

120.

Hawman DW, Stoermer K a., Montgomery S a., Pal P, Oko L, Diamond MS, et al. Chronic Joint
Disease Caused by Persistent Chikungunya Virus Infection Is Controlled by the Adaptive Immune
Response. J Virol [Internet]. 2013;87(24):13878–88. Available from:
http://jvi.asm.org/cgi/doi/10.1128/JVI.02666-13

121.

Zare F, Bokarewa M, Nenonen N, Bergstrom T, Alexopoulou L, Flavell RA, et al. Arthritogenic
Properties of Double-Stranded (Viral) RNA. J Immunol [Internet]. 2004;172(9):5656–63. Available
from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.172.9.5656

122.

Magnusson M, Zare F, Tarkowski A. Requirement of type I interferon signaling for arthritis
triggered by double-stranded RNA. Arthritis Rheum. 2006;54(1):148–57.

123.

Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE, Streblow DN. Animal models of
chikungunya virus infection and disease. J Infect Dis. 2016;214(Suppl 5):S482–7.

124.

Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, et al. A mouse
model for Chikungunya: Young age and inefficient type-I interferon signaling are risk factors for
severe disease. PLoS Pathog. 2008;4(2).

125.

Werneke SW, Schilte C, Rohatgi A, Monte KJ, Michault A, Arenzana-Seisdedos F, et al. ISG15 is
critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation.
PLoS Pathog [Internet]. 2011 Oct [cited 2014 Sep 2];7(10):e1002322. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3197620&tool=pmcentrez&rendertype=
abstract

126.

Schilte C, Buckwalter MR, Laird ME, Diamond MS, Schwartz O, Albert ML. Cutting edge:
independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host
response to Chikungunya infection. J Immunol [Internet]. 2012 Apr 1 [cited 2014 Oct
17];188(7):2967–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22371392

127.

Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, et al. Interferon Response Factors 3
and 7 Protect against Chikungunya Virus Hemorrhagic Fever and Shock. J Virol [Internet].
2012;86(18):9888–98. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.00956-12

128.

Fox JM, Diamond MS. Immune-Mediated Protection and Pathogenesis of Chikungunya Virus. J
Immunol [Internet]. 2016;197(11):4210–8. Available from:
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1601426

129.

Chan Y-H, Lum F-M, Ng L. Limitations of Current in Vivo Mouse Models for the Study of
Chikungunya Virus Pathogenesis. Med Sci [Internet]. 2015;3(3):64–77. Available from:
http://www.mdpi.com/2076-3271/3/3/64/

130.

Binn LN, Harrison VR, Randall R. Patterns of viremia and antibody observed in rhesus monkeys
inoculated with chikungunya and other serologically related group A arboviruses. Am J Trop Med
Hyg. 1967;16(6):782–5.

131.

Messaoudi I, Vomaske J, Totonchy T, Kreklywich CN, Haberthur K, Springgay L, et al.
Chikungunya Virus Infection Results in Higher and Persistent Viral Replication in Aged Rhesus
Macaques Due to Defects in Anti-Viral Immunity. PLoS Negl Trop Dis. 2013;7(7).

132.

Akahata W, Yang1 Z, Andersen H, Sun S, Holdaway HA, Kong W-P, et al. A VLP vaccine for
epidemic Chikungunya virus protects non-human primates against infection. Nat Med [Internet].

125

2010;16(3):334–8. Available from: http://www.sciencemag.org/content/306/5703/1895.short
133.

Chen CI, Clark DC, Pesavento P, Lerche NW, Luciw P a., Reisen WK, et al. Comparative
pathogenesis of epidemic and enzootic Chikungunya viruses in a pregnant Rhesus macaque
model. Am J Trop Med Hyg. 2010;83(6):1249–58.

134.

Pal P, Fox JM, Hawman DW, Huang Y-JS, Messaoudi I, Kreklywich C, et al. Chikungunya Viruses
That Escape Monoclonal Antibody Therapy Are Clinically Attenuated, Stable, and Not Purified in
Mosquitoes. J Virol [Internet]. 2014;88(15):8213–26. Available from:
http://jvi.asm.org/cgi/doi/10.1128/JVI.01032-14

135.

Tsetsarkin K, Higgs S, McGee CE, De Lamballerie X, Charrel RN, Vanlandingham DL. Infectious
Clones of Chikungunya Virus (La Reunion Isolate) for Vector Competence Studies. Vector-Borne
Zoonotic Dis. 2006;6(4).

136.

Vanlandingham DL, Tsetsarkin K, Hong C, Klingler K, McElroy KL, Lehane MJ, et al. Development
and characterization of a double subgenomic chikungunya virus infectious clone to express
heterologous genes in Aedes aegypti mosqutioes. Insect Biochem Mol Biol. 2005;35(10):1162–70.

137.

Kümmerer BM, Grywna K, Gläsker S, Wieseler J, Drosten C. Construction of an infectious
Chikungunya virus cDNA clone and stable insertion of mCherry reporter genes at two different
sites. J Gen Virol [Internet]. 2012 Sep [cited 2014 Dec 8];93(Pt 9):1991–5. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22673932

138.

Hamilton JR, Sachs D, Lim JK, Langlois RA, Palese P, Heaton NS. Club cells surviving influenza
A virus infection induce temporary nonspecific antiviral immunity. Proc Natl Acad Sci U S A
[Internet]. 2016;(13):2–7. Available from: http://dx.doi.org/10.1073/pnas.1522376113 VN readcube.com

139.

Heaton NS, Langlois R a., Sachs D, Lim JK, Palese P, TenOever BR. Long-term survival of
influenza virus infected club cells drives immunopathology. J Exp Med [Internet].
2014;211(9):jem.20140488-. Available from:
http://jem.rupress.org/content/early/2014/08/12/jem.20140488.abstract

140.

Shivkumar M, Milho R, May JS, Nicoll MP, Efstathiou S, Stevenson PG. Herpes simplex virus 1
targets the murine olfactory neuroepithelium for host entry. J Virol [Internet]. 2013;87(19):10477–
88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23903843

141.

Ma JZ, Russell TA, Spelman T, Carbone FR, Tscharke DC. Lytic Gene Expression Is Frequent in
HSV-1 Latent Infection and Correlates with the Engagement of a Cell-Intrinsic Transcriptional
Response. PLoS Pathog. 2014;10(7).

142.

Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney M-C, et al. Genome
microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med [Internet].
2006 Jul [cited 2014 Aug 8];3(7):e263. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1463904&tool=pmcentrez&rendertype=
abstract

143.

Centers for Disease Control and Prevention (CDC). Countries and territories where chikungunya
cases have been reported (as of May 29, 2018) [Internet]. Cdc. 2018. p. 1. Available from:
http://www.cdc.gov/chikungunya/geo/index.html

144.

Alphavirus [Internet]. Viral Zone. 2018. Available from:
https://viralzone.expasy.org/625?outline=all_by_species

145.

Yaseen HM, Simon F, Deparis X, Marimoutou C. Estimation of Lasting Impact of a Chikungunya

126

Outbreak in Reunion Island. Epidemiology [Internet]. 2012;S2(003):1–6. Available from: accessed
on Dec.2015
146.

Javelle E, Gautret P, Ribéra A, Gaüzère BA, Cabié A, Corail PR, et al. The challenge of chronic
chikungunya. Travel Med Infect Dis. 2017;15:3–4.

147.

Chaaitanya IK, Muruganandam N, Sundaram SG, Kawalekar O, Sugunan AP, Manimunda SP, et
al. Role of Proinflammatory Cytokines and Chemokines in Chronic Arthropathy in CHIKV Infection.
Viral Immunol. 2011;24(4):265–71.

148.

Kelvin A a, Banner D, Silvi G, Moro ML, Spataro N, Gaibani P, et al. Inflammatory cytokine
expression is associated with chikungunya virus resolution and symptom severity. PLoS Negl Trop
Dis [Internet]. 2011 Aug [cited 2014 Sep 2];5(8):e1279. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3156690&tool=pmcentrez&rendertype=
abstract

149.

Chirathaworn C, Rianthavorn P, Wuttirattanakowit N, Poovorawan Y. Serum IL-18 and IL-18BP
levels in patients with Chikungunya virus infection. Viral Immunol [Internet]. 2010 Feb;23(1):113–7.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20121409

150.

Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, et al. Pathogenic
Chikungunya Virus Evades B cell Responses to Establish Persistence. Cell Rep.
2016;16(5):1326–38.

151.

Seymour RL, Adams AP, Leal G, Alcorn MDH, Weaver SC. A Rodent Model of Chikungunya Virus
Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation. PLoS Negl
Trop Dis [Internet]. 2015;9(6):e0003800. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4482609&tool=pmcentrez&rendertype=
abstract

152.

Heath CJ, Lowther J, Noël TP, Mark-George I, Boothroyd DB, Mitchell G, et al. The identification
of risk factors for chronic chikungunya arthralgia in Grenada, West Indies: A cross-sectional cohort
study. Open Forum Infect Dis. 2018;5(1).

153.

Hoffman PN, Lopata MA, Watson DF, Luduenafl RF. Axonal Transport of Class II and III Betatubulin: Evidence that the Slow Component Wave Represents the Movements of Only a Small
Fraction of the Tubulin in Mature Motor Axons. J Cell Biol. 1992;119(3):595–604.

154.

Rieske P, Krynska B, Azizi SA. Human fibroblast-derived cell lines have characteristics of
embryonic stem cells and cells of neuro-ectodermal origin. Differentiation [Internet]. 2005;73(9–
10):474–83. Available from: http://dx.doi.org/10.1111/j.1432-0436.2005.00050.x

155.

Yusuf B, Gopurappilly R, Dadheech N, Gupta S, Bhonde R, Pal R. Embryonic fibroblasts
represent a connecting link between mesenchymal and embryonic stem cells. Dev Growth Differ.
2013;55(3):330–40.

156.

Couderc T, Lecuit M. Focus on Chikungunya pathophysiology in human and animal models.
Microbes Infect. 2009;11(14–15):1197–205.

157.

Noret M, Herrero L, Rulli N, Rolph M, Smith PN, Li RW, et al. Interleukin 6, RANKL, and
Osteoprotegerin Expression by Chikungunya Virus - Infected Human Osteoblasts. J Infect Dis.
2012;206(3):455–459.

158.

Chen W, Foo S-S, Taylor A, Lulla A, Merits A, Hueston L, et al. Bindarit, an Inhibitor of Monocyte
Chemotactic Protein Synthesis, Protects against Bone Loss Induced by Chikungunya Virus
Infection. J Virol [Internet]. 2015 Jan 1 [cited 2015 Jan 12];89(1):581–93. Available from:

127

http://www.ncbi.nlm.nih.gov/pubmed/25339772
159.

Miner JJ, Cook LE, Hong JP, Smith AM, Richner JM, Shimak RM, et al. Therapy with CTLA4-Ig
and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci Transl Med.
2017;9(375):1–10.

160.

Wilson JAC, Prow NA, Schroder WA, Ellis JJ, Cumming HE, Gearing LJ, et al. RNA-Seq analysis
of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic
inflammation. Vol. 13, PLoS Pathogens. 2017. 1-32 p.

161.

Nakaya HI, Gardner J, Poo YS, Major L, Pulendran B, Suhrbier A. Gene profiling of chikungunya
virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis
Rheum. 2012;64(11):3553–63.

162.

National Research Council. Guide for the care and use of laboratory animals [Internet]. Vol. 8th
Ed. Washington, DC: National Academies Press, Washington, DC; 2011. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21595115

163.

Mahauad-Fernandez WD, Jones PH, Okeoma CM. Critical role for BST-2 in acute Chikungunya
virus infection. J Gen Virol [Internet]. 2014 Jul 22 [cited 2014 Aug 26];319–35. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25053563

164.

Li Y, Handel A. Modeling inoculum dose dependent patterns of acute virus infections. J Theor Biol
[Internet]. 2014;347(1):63–73. Available from: http://dx.doi.org/10.1016/j.jtbi.2014.01.008

165.

Society R, Only FR. Exploring the impact of inoculum dose on host immunity and morbidity to
inform model-based vaccine design. 2017;1–18.

166.

Marois I, Cloutier A, Garneau E, Richter M V. Initial infectious dose dictates the innate, adaptive,
and memory responses to influenza in the respiratory tract. J Leukoc Biol [Internet].
2012;92(1):107–21. Available from: http://www.jleukbio.org/cgi/doi/10.1189/jlb.1011490

167.

Vazeille M, Moutailler S, Coudrier D, Rousseaux C, Khun H, Huerre M, et al. Two Chikungunya
isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in
the mosquito, Aedes albopictus. PLoS One. 2007;2(11).

168.

Ledermann JP, Borland EM, Powers AM. Minimum infectious dose for chikungunya virus in Aedes
aegypti and Ae. albopictus mosquitoes. Rev Panam Salud Publica [Internet]. 2017;41:e65.
Available from: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S102049892017000100410&lng=en&nrm=iso&tlng=en%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/289022
78

169.

Habib N, Avraham-Davidi I, Basu A, Burks T, Shekhar K, Hofree M, et al. Massively parallel
single-nucleus RNA-seq with DroNc-seq. Nat Methods. 2017;14(10):955–8.

170.

Zeng W, Jiang S, Kong X, El-Ali N, Ball AR, Ma CIH, et al. Single-nucleus RNA-seq of
differentiating human myoblasts reveals the extent of fate heterogeneity. Nucleic Acids Res.
2016;44(21):1–13.

171.

Bergmann O, Jovinge S. Isolation of Cardiomyocyte Nuclei from Post-mortem Tissue. J Vis Exp
[Internet]. 2012;(65):1–6. Available from: http://www.jove.com/video/4205/

172.

Son K-N, Liang Z, Lipton HL. Double-Stranded RNA Is Detected by Immunofluorescence Analysis
in RNA and DNA Virus Infections, Including Those by Negative-Stranded RNA Viruses. J Virol
[Internet]. 2015;89(18):9383–92. Available from: http://jvi.asm.org/lookup/doi/10.1128/JVI.0129915

128

173.

Buch T, Heppner FL, Tertilt C, Heinen TJ a J, Kremer M, Wunderlich FT, et al. A Cre-inducible
diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods.
2005;2(6):419–26.

174.

Sheehan KCF, Lazear HM, Diamond MS, Schreiber RD. Selective blockade of Interferon-α and -β
reveals their non-redundant functions in a mouse model of West Nile virus infection. PLoS One.
2015;10(5):1–19.

175.

Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, et al. Blockade of Interferon Beta, but
Not Interferon Alpha, Signaling Controls Persistent Viral Infection. Cell Host Microbe [Internet].
2015;17(5):653–61. Available from:
http://www.sciencedirect.com/science/article/pii/S1931312815001638

129

